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Abstract 
Autism is a neurodevelopment disorder characterised by problems in communication and 
social interaction skills. In addition to psychological comorbidities, autistic individuals 
might suffer of GI problems that have been previously associated with gut bacteria, 
altered dietary intake and barrier function problems. In order to improve these aspects, 
exclusion diets, such as gluten and casein free diets (GFCF), and/or use of food 
supplements have been suggested in ASD, but little is known about their impact on gut 
microbiota composition and metabolic activity, especially for prebiotics. The aim of this 
work was to investigate the effect of a prebiotic B-GOS on different aspects of autism, in 
in vitro and in in vivo. B-GOS (65%GOS content) was tested in dose response batch 
culture experiments inoculated with faecal samples from healthy donors, compared to the 
commercial B-GOS (50%GOS content). It showed an increase in bifidobacteria and 
modulation of SCFAs production. 65% B-GOS was then tested on faecal samples from 
autistic and non-autistic children using a three-stage continuous fermentation system that 
mimicked various anatomical regions of the colon. Results showed that B-GOS 
administration significantly increased bifidobacterial populations in the models 
inoculated with both autistic and non-autistic samples and influences changes in other 
bacterial groups, such as Clostridium, Roseburia, Bacteroides, Atopobium, 
Faecalibacterium prausnitzii, Sutterella spp. and Veillonellaceae. In addition, B-GOS 
modulated SCFA production in both groups, and increased ethanol and lactate inocula 
from autistic children. Next, a parallel, double blind, randomised study was designed in 
order to confirm these results in in vivo. Baseline samples from 30 autistic children aged 
4-11 years old, were analysed to understand the effect of the exclusion diets on the gut 
microbiota and metabolome. In addition, parents were asked to fill in GI symptoms and 
food diaries. Results showed ASD children following GFCF diet had significant 
reduction in abdominal pain and bowel movement, compared to the un-restricted dietary 
group, and reduced abundance of Bifidobacterium spp. and Veillonellaceae family, with 
increased F. prausnitzii and Bacteroides spp. In both groups, no significant differences 
were found in urine metabolome, but significant correlations were found between 
bacterial populations and amino acids in faeces. After 6 weeks B-GOS intervention, no 
effect was reported on GI issues, but there were improvements in sleep habits and anti-
social behaviour. B-GOS significantly modulated bifidobacteria and Lachnospiraceae 
family, as well as the metabolome in children whose diet was not restricted. Butyrate and 
valerate were the main SFCAs produced and reduced amino acid excretion was detected 
in faecal samples of the intervention group. Urine samples were dominated by citrate, 
creatine, creatinine, DMA (dimethylamine), DMG (dimethylglycine), malonate, 
carnitine, TMAO (trimethylamine-N-oxide), and α-hydroxybutyrate, comparing to the 
control group, where PAG (phenylacetiyglycine), phenylalanine and β-hydroxybutyrate 
were detected. Overall, the results presented in this study demonstrated, for the first time, 
that a prebiotic B-GOS is able to modulate different aspects of autism and be considered 
as potential dietary therapeutic approach for ASD individuals. 
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 1 
CHAPTER 1 
 
1.1 Gut microbiota 
1.1.1 Health and disease 
The human gut is an extremely complex ecosystem whereby microbiota, nutrients, and 
host cells interact. The relationship between microorganisms and the host involves important 
aspects such as metabolism, barrier effect, and trophic functions. Consequently, dysbiosis, or 
bacterial imbalance, can be considered a cause or consequence of several gastrointestinal 
disorders (Butel et al. 2014). Microorganisms colonise the gastrointestinal tract from the 
mouth to the large intestine, where they reach a maximum estimated concentration of 10
12 
bacteria per gram of gut contents (Sender et al. 2016). Therein, fermentative metabolism of 
undigested food and host-derived products creates a microbial metabolome that impacts on 
the host. The major end products of carbohydrate fermentation are short chain fatty acids 
(SCFAs) such as acetate, propionate and butyrate (Cummings 1981). They are produced in 
particular via glycolytic and pentose phosphate pathways that are briefly summarised in Figure 
1.1. 
 
 
Figure 1.1. Diagram of non-digestible carbohydrate breakdown in the colon 
and main pathways. PEP: posphonenolpyruvate (adapted from Macfarlane & 
Macfarlane 2003). 
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SCFAs are sources of energy for the host tissues but may also have anti-apoptotic and anti-
inflammatory effects. In addition, it seems that they may have effects on lipogenesis and their 
interaction with host receptors seems linked to the regulation of hormones affecting the satiety. 
In addition, SCFAs have an important role in keeping the gut environment stable, influencing 
pH, gut transit, nutrient uptake and microbial composition (Macfarlane and Macfarlane 2011) 
(Table 1.1). 
 
Table1.1: Role of SCFAs in gut environment (Saulnier et al. 2009) 
End Product Bacterial group involved Metabolic Fate 
Acetate bacteroides, bifidobacteria, lactobacilli, clostridia, 
ruminococci, peptococci, veillonella, 
peptostreptococci, fusobacteria, butyrivibrio 
 
Metabolised in muscle, kidney, 
heart and brain 
Propionate bacteroides, propionibacteria, veillonella Cleared by the liver, possible 
gluconeogenesis precursor, 
suppresses cholesterol synthesis 
 
Butyrate clostridia, fusobacteria, bityrivibrio, eubacteria, 
peptostreptococci 
Metabolised by the colonic 
ephitelium, regulator of cell 
growth and differentiation 
 
Ethanol, 
succinate, 
lactate, pyruvate 
bateroides, bifidobacteria, lactobacilli, eubacteria, 
peptostreptococci, clostridia, ruminococci, 
actinomycetes, enterococci, fusobacteria 
 
Absorbed, electron sink products, 
further fermented to SCFA 
Hydrogen clostridia, ruminococci, fusobacteria Partially excreted in breath, 
metabolised by hydrogenotrophic 
bacteria 
 
SCFAs are transported from the large intestine to the blood stream via three main transporters: 
MCTs, monocarboxylate transporters; mOATs, multispecific organic anion transporters; and 
SLC5A8, a sodium-coupled monocarboxylate transporter. 
The most well–studied trasporter is SLC5A8, expressed in the apical membranes of 
the colon, which leads to SCFA absoption in association with increased Na+ intake (ratio 1:3). 
The other two transporters are considered as potential candidates. MCT1 is associated with 
lactate and butyrate absoption, but there is still conflicting evidence in the literature so its role 
needs to be fully elucidated (Natarajan et al. 2014). 
Recent studies have shown how G protein-coupled receptors (GPCRs) may play a role 
in microbial communication with the host. Four SCFAs receptors have been identified: Gpr41, 
Gpr43, Gpr109a and Olfr78. Gpr41 and Gpr43 mainly respond to propionate but they can be 
stimulated also by formate, acetate, butyrate, iso-butyrate and acetate, butyrate, respectively. 
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Gpr41 is expressed in different tissues and cell types and it seems to be involved in inhibition 
of cell proliferation and apoptosis via the activation of p53 and MAPK. Gpr43 is expressed on 
lymphocytes, neurotrophils, monocytes and peripheral blood mononuclear cells, and its 
functionally regulates inflammatory responses, activating cytokines and chemokines (Brown 
et al. 2003; Samuel et al. 2008). Gpr109a responds only to butyrate and it is located on 
epithelial cells. Its activation has been associated with carcinogenesis suppression (Singh et 
al. 2014). Olfr78 (human ortholog OR51E2) responds to propionate and acetate and is located 
on enteroendocrine cells in the murine colon, but not in small intestine, and it seems to be 
involved in the regulation of PYY hormone (Fleischer et al. 2015).  
Composition of the human gut microbiota is very complex and studies using 16S RNA 
sequencing have shown Firmicutes, Bacteroidetes and Actinobacteria as dominant phyla in 
healthy adult, with Bacteroides, Faecalibacterium, Bifidobacterium, Roseburia, Alistipes, 
Collinsella, Ruminococcus, Prevotella and Akkermansia as main genera (Arumugam et al. 
2011). In addition, Arumugam and colleagues were able to identify three main enterotypes, 
persistent in all samples from European individuals, based on variations in genus level and 
activity, such as Bacteroides (carbohydrates and proteins fermenters); Prevotella and 
Desulfovibrio (respectively mucin-degraders and involved in mucin desulphation); 
Ruminococcus and Akkermansia (able to degrade mucin and sugars; Arumugam et al. 2011). 
Beneficial bacteria in the human gut include bifidobateria and lactobacilli. They are 
therefore main targets for the modulation of the gut microbiota through diet. Bifidobacteria 
have several positive effects such as inhibition of pathogens (Tejero-Sariñena et al. 2012), 
modulation of the immune system (Dong et al. 2010) and restoration of the intestinal 
microflora after antibiotic therapy (Madden et al. 2005). Beneficial effects of lactobacilli 
involve in particular the production of antimicrobial compounds that help in controlling 
proliferation of potential harmful microorganisms (Saulnier et al. 2009). An imbalance in 
composition of the gut microbiota can lead to changes in interactions between the intestinal 
microflora and host, which are related to different gastrointestinal diseases such as infectious 
and non-infectious disorders.  
Infectious disorders include pathogens such as Salmonella or Escherichia coli, 
principal microorganisms responsible for Traveller’s diarrhoea and Clostridium difficile that 
can lead to complications associated with mortality. The success of recent protocols for faecal 
transpantation as potential therapy for C. difficile infection have shown an important role of 
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the gut microbiota (Fischer et al. 2015). 
Non-infectious disorders may be caused by factors such as genetics, environment and 
lifestyle and they involve obesity, Inflammatory Bowel Disease (IBD) or Irritable Bowel 
Syndrome (IBS). Obesity is a physiological state in which the ratio between the two main 
dominant phyla in the gut seems to be shifted in favour of Firmicutes instead of Bacteroidetes. 
The microbiota, may regulate appetite, producing hormones like PYY and GPL-1 that 
stimulate satiety, reduce permeability of the gastrointestinal trait and reduce inflammatory 
markers (Rastall and Gibson 2015). Inflammatory Bowel Diseases such as Crohn’s Disease, 
Ulcerative colitis and pouchitis are a range of recurrent inflammatory disorders of the colon 
with a complex undefined aetiology. Environmental factors may play a role and genetically 
susceptible hosts seem to be more affected, but the possibility that microbes could be involved 
has been suggested. In CD patients, there is an increase in Proteobacteria and Bacteroidetes, 
in comparison to UC patients who no displayed significant differences compared to healthy 
volunteers (Gophna et al. 2006). This similarity could be explained by the fact that the cause 
of UC symptoms may be an increase of bacterial activity, especially Desulfovibrio spp. 
Metabolomic studies, indeed, confirm this hypothesis showing different production of 
metabolic compounds between remission and active phase of disease pathology 
(Balasubramanian et al. 2009, Bjerrum et al. 2010).  
IBS is a disorder that affects 10-20% of the population in developed countries and it is 
characterised by abdominal pain, bloating and changes in stool frequency and consistency. 
The pathogenesis is multifactorial and includes the intestinal microbiota, with a higher risk of 
gastroenteritis and gas production (Blatchford et al. 2013).  
 
1.1.2 Infant microbiota 
Colonisation of the gastrointestinal (GI) tract starts immediately following delivery 
(natural or caesarean birth). Several research groups have recently started questioning this 
dogma focusing on the hyphothesis that gut microbial colonisation might initiate in utero.  
Collado and collegues analysed amniotic fluid, placenta, colostrum, maternal and 
infant faeces and they showed unique microbial communities characterised by low abundance, 
low richness and low diversity (Collado et al. 2016). Proteobacteria was the most predominant 
phylum in amniotic fluid and placenta with Enterobacter, E. coli and Shigella as main types 
also in colostrum, meconium and infant faeces, but in lower numbers. The second predominant 
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genus was Propionibacterium, found in placenta parenchyma during the second trimester of 
pregnancy and meconium, confirming data previously published (Onderdonk 2008). Since 
meconium is formed during foetal life, their findings support the hypothesis that meconium 
and colostrum microbiota share a common maternal source and that the foetus might not be 
sterile but colonised by microbes in the placenta and amniotic fluid (Collado 2016). These 
results match findings from two pioneer studies by Ardissone et al.  (2014) and Jimenez et al. 
(2008) who showed, respectively, correlation between bacterial populations in meconium and 
amniotic fluid in a human study (Ardissone 2014) and in a mouse trial (Jimenez 2008). 
Labelling Enterococcus faecium and orally inoculating pregnant mice, this strain was detected 
in the meconium of inoculated mice but not in the control group (Jimenez 2008). 
After birth, several factors might alter bacterial composition, such as mode of delivery, 
diet, environment, genetics and antibiotic treatment from early life to adulthood (Figure 1.2).  
 
 
Figure 1.2: Factors influence gut microbiota during early life (Tamburini 2016). 
 
Vaginally delivered infants are initially enriched in Lactobacillus spp. which resembles the 
maternal vaginal microbiota. In contrast children delivered by C-section were instead 
colonised by common skin and environmental microbes, such as Staphylococcus, 
Streptococcus or Propionibacterium spp. (Tamburini 2016). 
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Due to its unique composition, human milk modulates the gut bacterial population of 
breast fed infants by promoting the growth of beneficial bacterial, such as bifidobacteria and 
lactobacilli. Rich in oligosaccharides (human milk oligosaccharides, HMO), other nutrients 
and characterised by a specific microbial ecosystem, human milk has a strong impact on the 
immune system and gut function (Gomez-Gallego 2016). Breast and formula-fed infants have 
different gut microbiota composition with the latter one characterised by high diversity and 
dominated by Clostridium spp., Bacteroides and E. coli (Hascoet et al. 2011). 
Antibiotic treatments in early life are another important factor with a strong impact on 
diversity and stability. Recent studies have shown that their effects are more pronounced 
during the first year of life, causing delays in gut microbiota maturation and gene resistance 
(Bokulich 2016, Yassour 2016). Alterations of gut microbial ecology may have a long-term 
impact on adult phenotype, modulating susceptibility to allergy, infection, obesity or diabetes 
(Kirjavainen 2002, Sjögren 2009, Abrahamsson 2012).  
The infant GI microbiota is more variable in composition and less stable over time, 
compared to the adult one. The first 3 years of life are the most critical in terms of dietary 
intervention and introduction of solid food, but between 3 and 5 years of age, the microbiota 
of infants resembles that of the adult. 
 
1.2 Gut-Brain axis 
 In the last 20 years, the gut microbiota and its interaction with neurological disorders 
has had a raised profile. The field of microbial endocrinology is expressly devoted to 
understanding the mechanisms by which the microbiota (bacteria within the microbiome) 
interact with the host. Microbial endocrinology was founded by Lyte in 1993 who focused on 
neuro-active compounds produced by the microbiota that can modulate the brain and 
behaviour within the microbiota-gut-brain axis (Lyte 1993). 
Psychobiotics is a new definition of gut bacteria involved in the production of active 
compounds associated with mammalian neurotransmission. They have been defined by Dinan 
et al. 2013 as an “emerging class of probiotics that, when ingested in adequate amounts, 
produces a health benefit in patients suffering from psychiatric illness” (Dinan 2013).  
It is well-known that certain bacteria are able to produce molecules that may act as 
neurotransmitters and directly affect the brain. Wall and colleagues reported some of the main 
neurochemicals that have been isolated from gut bacteria and the impact that they have on the 
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central nervous system, brain function and behaviour (Wall 2014) (Table 1.2). 
 
Table 1.2. List of neurochemicals isolated from gut bacteria. BBB=blood-brain barrier (adapted from Wall 2014) 
Bacterial genus Neurochemicals Functions 
Lactobacillus, Bifidobacterium GABA Inhibitor of different physiological and 
psychological processes 
Streptococcus, Escherichia, 
Enterococcus, Lactococcus, 
Lactobacillus 
Serotonin Metabolite from tryptophan and it has an 
important role in mood regulation 
Escherichia, Bacillus Norepinephrine Major neurotransmitters that mediate 
motor control, cognition, memory 
processing, emotion and endocrine 
regulation 
Streptococcus, Escherichia, 
Bacillus, Lactococcus, 
Lactobacillus 
Dopamine 
Lactobacillus, Bacillus Acetylcholine Neurotransmitter important in memory 
and learning 
Lactobacillus, Lactococcus, 
Streptococcus, Enterococcus 
Histamine Important role in the maintenance of 
wakefulness 
Gut microbiota SCFAs They can cross BBB and work as energy 
source during early brain development; 
play a role in cell signaling and 
neurotransmitter synthesis and release 
 
Interaction between intestinal microbiota and the brain includes the central nervous 
system (CNS), neuroendocrine and neuroimmune systems, sympathetic and parasympathetic 
arms of the autonomic nervous system (ANS) and enteric nervous system (ENS). The vagus 
nerve is the major nerve of ANS and mouse studies showed the impact of probiotics such as 
L. rhamnosus and Bifidobacterium spp. on stress, depression and anxiety via this path and 
alteration in GABA receptors (Bercik 2011, Bravo 2011).  
In addition to SCFAs and neurotransmitter production, other routes where the gut 
microbiota is involved include tryptophan metabolism and kynurenine pathway, previously 
shown to be altered in autism (Boccuto 2013), the hypothalamic-pituitary-adrenal axis (HPA) 
and cytokine production.  
Tryptophan is an essential amino acid and once in the bloodstream, it can cross the 
blood-brain barrier (BBB) and participate in serotonin synthesis in the CNS. However, 
serotonin, mainly located in the gut, is synthesised from tryptophan in enterochromaffin cells 
(ECs) of the gastrointestinal tract and from certain bacterial strains that produce indole from 
tryptophan (O’Mahony 2015). Yano and colleagues showed that spore-forming bacteria had 
an effect on serotonin in mice, by producing metabolites directly involved in signalling 
between gut microbiota and ECs (Yano 2015).  
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The HPA is a major neuroendocrine system that regulates different processes, 
including stress response. Cortisol is an important biomarker of stress and both excessive and 
deficient cortisol responses have been associated with dysregulation of the HPA axis. Acute 
stress seems to be involved in mast cell activation and can cause increases in GI barrier 
permeability allowing gut bacterial metabolites, toxins and lipopolysaccharides (LPS) to enter 
the bloodstream and reach the CNS (Santos 2001). Mouse experiments showed how 
Bacteroides spp. and Clostridium spp. respectively decrease and increase after chronic stress 
exposure, and this led to immune system activation (Bailey 2011). 
There is bi-directional communication between the HPA axis and the immune system. 
A number of cytokines, such as IL-1, IL-6, IL-10 and TNF-α can activate the HPA axis. During 
an immune response, pro-inflammatory cytokines are released into the peripheral circulation 
system and can pass through the BBB where they can interact with the brain and activate the 
HPA axis. Interactions between pro-inflammatory cytokines and the brain can alter the 
metabolic activity of neurotransmitters and cause symptoms such as fatigue, depression, and 
mood changes (Padgett and Glaser 2003). 
Interaction with gut bacterial populations has a strong impact in health and well being 
of the host from early life, including brain development and function. Changes in early life 
nutrition influence gut microbiota composition and metabolism, resulting in depressive-like 
behaviour and metabolic phenotype in non-weaned rats (Farshim 2016).  
Psychiatric co-morbidities, such as anxiety and depression are common in patients 
with chronic bowel disorders, including IBS and IBD. Typical symptoms in IBS such as sleep 
difficulties, anxiety, depression, headache, fatigue, in particular abdominal pain, seem to get 
worse during periods of stress (Lacker 2010). Stress has a big impact on the gastrointestinal 
tract, altering intestinal motility, barrier function, and mucosal transport (Hyland 2014). 
Consequently, behavioural changes have been noticed in relation to modification of gut 
microbiota composition and it has been postulated that stress might have a long-term effect on 
gut bacterial populations (Collins 2012).  
The GI symptoms associated with IBS seem to be similar to those of autism spectrum 
disorders (ASD) and to date there are no biological biomarkers for both conditions. Based on 
this, it may be relevant to note the potential therapeutic effects of pre- and probiotics in the 
treatment of certain neurological conditions (O’Mahony 2005, Whorwell 2006). Recent rodent 
studies have also shown increased expression of neurotransmitters and neuromodulators in the 
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hippocampus, after FOS and GOS supplementation (Savignac 2016, De Vadder 2014, 
Williams 2016). 
 
1.2.1 Autism spectrum disorders (ASD) 
“Autism typically develops early in childhood, and is considered as a systemic 
spectrum disorder with multiple development trajectories with an incidence four times higher 
in males than in females” (Grossi 2014).  
Around 700,000 people may be autistic, or more than 1 in 100 of the population. The 
latest prevalence studies of autism indicate that 1.1% of the population in the UK may have 
autism. This prevalence rate is based on two relatively recent studies, one on children in the 
South Thames area (Baird 2006) and the other on adults (Brugha 2011). 
Autism is currently diagnosed using behavioural criteria from the Diagnostic and 
Statistical Manual of Mental Disorders (DSM). ASDs is a term used to include and replace all 
subtypes of autism, including autistic disorder, Aspergers syndrome, childhood disintegrative 
disorder, and pervasive developmental disorder (not otherwise specified). The DSM-V (fifth 
edition), published in May 2013, eliminated the four sub-types listed above, by dissolving 
them into one diagnosis called Autism Spectrum Disorders (American Phychiatric Association 
2013). 
In this new edition ASD is defined as: 
1. Persistent deficits in social communication and social interaction across contexts, not 
accounted for by general developmental delays 
2. Restricted, repetitive patterns of behavior, interests, or activities 
3. Symptoms must be present in early childhood (but may not become fully manifest until 
social demands exceed limited capacities) 
4. Symptoms together limit and impair everyday functioning. 
 
Autism was first considered as a distinct clinical disorder by Kanner (1943) but its exact cause 
is still unknown. It is a complex condition and may occur as a result of genetic predisposition 
and/or environmental factors. 
There is clearly a genetic component and this has been established through twin and 
family studies (Ronald and Hoekstra 2011, Robinson 2016). Genetic aspects have involved 
parental age, male sex (gender bias with a ratio of 4:1), autism in the family, deficiency in 
 10 
gene transcription and it is known that autism disorder is commonly found in genetic 
syndromes such as Fragile X and tuberous sclerosis (Liu 2001). 
Despite evidence of a genetic component, genetics does not explain the whole picture. 
Environmental factors, such as dysbiosis in gut microbiota, diet or antibiotic therapy in early 
age, seem to have a huge impact on several aspects of autism. Correlation between medical 
history, GI symptoms and antibiotic treatments in 99 children with and without ASD has been 
investigated (Niehus and Lord 2006). ASD children seem to have significantly more ear 
infections than typically developing children, with consequently signficant higher use of 
antibiotics before the age of 2 years. As mention above, early life history of antibiotic use have 
a big impact on gut microbiota composition and dysbiosis seen in ASD might be due to such 
therapy (Niehus and Lord 2006). 
 
1.2.2 Gut microbiota in ASD 
Apart from the cognitive aspects, a significant majority of ASD sufferers also have 
associated GI issues. A recent detailed survey compared children with ASD to their non-ASD 
siblings and ASD was associated with diarrhoea, constipation, smelling stools, gaseousness, 
abdominal bloating and discomfort and food regurgitation. Moreover, 76% of children with 
ASD had at least one GI symptom compared to only 30% of a non-ASD siblings (Horvath 
2002); with most children with ASD having two or more GI symptoms (64%). Several studies 
reported a prevalence of GI symptoms as high as 70% in children with ASD, although it was 
recently suggested that prospective studies be performed to determine the actual prevalence 
of GI disorders in ASD and their biological basis (Buie 2010). 
Bolte hypothesized that autistic symptoms may be based on colonisation of 
Clostridium tetani. It was thought that the toxin produced from this spore-forming species, 
tetanus neurotoxin (TeNT), could impact on autistic symptomatology in different ways. In 
fact, autistic children do not show typical effects of tetanus infection, such as spasms, due to 
the presence of proteolytic enzymes in the human digestive tract. Basically these enzymes 
break down the toxin in fragments, reducing its effect but, unfortunately, they can still exert 
an influence (Bolte 1998). 
To date, more recent studies have confirmed the role of Clostridium spp. in the gut of 
autistic children and how antimicrobial and antifungal therapies could help in relieving the 
symptoms. Finegold et al. (2002) found nine unique species of clostridia in autistic children 
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compared to healthy controls (Finegold 2002). Song et al. (2004), using qPCR analysis, found 
higher levels of C. boltea and Clostridium cluster I and XI (Song 2004). Furthermore, Parracho 
and co-authors, using FISH analysis, found greater number of those species derived from the 
Clostridium histolyticum group (Clostridium clusters I and II) (Parracho 2005). Comparing 
the microbiota of autistic and non-autistic children, Kang and colleagues, using recent 
pyrosequencing techniques, demonstrated that autistic children suffering GI problems have a 
distinct and less diverse gut bacterial population, characterised by lower levels of Prevotella, 
Coprococcus, and unclassified Veillonellaceae; and higher presence of Akkermansia genus 
(Kang 2013).  
The genus Sutterella has been identified in intestinal biopsy and faecal samples from 
individuals with gastrointestinal disorders such as Crohn’s disease and ulcerative colitis. On 
this basis, Williams and colleagues investigated its presence in biopsy samples from autistic 
children with gastrointestinal problems and non-autistic controls with only gastrointestinal 
dysfunction. In these results, they showed higher presence of this bacterial group only in 
autistic individuals but not in the control (Williams 2012). These data were confirmed by 
Wang et al. who analysed faecal samples of autistic children and showed increase number of 
Sutterella spp. and Ruminococcus torque (Wang 2013). 
Shaw et al. found high levels of tartaric acid in the urine of two autistic siblings which 
was suggested to be due to overgrowth of Candida albicans. Potential toxins released may 
cause an effect on the central nervous system and subsequently affect behaviour (Shaw 1995). 
Antifungal treatments seem to be a potential strategy to reduce presence of the yeast (Shaw 
2000). In another study, antibiotic Vancomycin therapy, in an uncontrolled trial (n=11) with 
regressive autistic children, showed a short-term improvement in behavioural parameters, 
which waned following discontinuation of antibiotic treatment (Sandler 2000). 
Another interesting aspect of the effect of Clostridium spp. involves tryptophan 
metabolism. Normally, this amino acid is catabolised with indole pyruvate and indole acetate 
being detected in the urine of healthy people as well the end product of their metabolic 
pathway, IAG (indolyl-acryuloyl-glycine). IAG seems to be a detoxified version of an acidic 
precursor that affects permeability of membranes. It has been shown that in autistic children, 
higher amounts of indole derivates are present in the blood and higher levels of IAG have been 
identified in urine. Increased numbers in Clostridium spp. can be, again, an explanation. 
Clostridium can metabolise tryptophan and contribute to an abnormal metabolic state 
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(Bingham 2003). 
Recently, a model of the autism pathology has been proposed based on three main 
pathways: oxidative stress, gut bacterial dysbiosis and “leaky gut” syndrome. Taking into 
account different studies on autism pathogenesis, Heberling and colleagues suggested that 
overgrowth of some bacterial populations, in particular Clostridium spp. and Desulfovibrio 
spp., can lead to an inflammatory state that might cause increased gut permeability. This can 
cause inappropriate passage of molecules to the bloodstream and BBB affecting the central 
nervous system (Heberling 2013). Gram-negative bacteria, that possess LPS on the cell wall 
surface, may be involved in ASD. LPS activates the innate immune system (Trent 2006), is 
involved in tissue damage and it has been suggested to induce the nitric oxide (iNOS) gene, 
causing release of nitric oxide, which is a neurotransmitter (Berdeaux 1993). It also damages 
the BBB, making it porous and allowing LPS to cross (Gaillard 2001, Xaio 2001). Moreover, 
LPS seems to work with other toxins, notably heavy metal ions, to increase the extent of 
cellular damage (Rumbeiha 2000). In addition, oxidative stress seems to have an impact on 
sulphate metabolism in cysteine and methionine pathways and consequences related to that, 
alteration in DNA, RNA, protein, lipids methylation and gene expression (Heberling 2013). 
James et al. in an in vivo human intervention study, involving 20 ASD children and 33 
controls, showed imbalances in the methionine cycle mainly due to a “bottle-neck” at S-
adenosylhomocysteine (SAH) and adenosine. Supplement of folinic acid, betaine and 
methylcobalamin have shown stabilisation in metabolite concentrations within the methionine 
cycle into the normal range (James 2004). 
Based on Heberling hypothesis and taking into account the main bacterial populations 
involved in autism dysbiosis, Weston and his research group developed a model which 
simulates direct and indirect effects of the interaction between bifidobacteria, clostridia and 
Desulfovibrio spp. (Figure 1.3) (Weston 2015).  
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                        Figure 1.3: Model of bifidobacteria, clostridia and Desulfovibrio interaction. Arrows 
represent positive interaction; Flat head negative interaction (adapted from Weston et al. 
2015). 
  
In addition the authors proposed a new quantitative measure in order to valuate the risk to 
develop autism based on bacterial shift from a steady state:  
Gut Bacteria Index (GBI) = (B / Bss) / [(C + D) / (Css + Dss)] -1 
where B, C and D are bifidobacteria, clostridia and desulfovibrio respectively and SS is the 
steady state, before any treatments. If GBI is 0, this means that gut bacteria are similar to the 
control, if it is positive or negative it means that there is lower or higher risk to develop autism, 
respectively. Basically in their computational model, the authors introduced step-by-step 
variables that have been seen in previous studies to affect gut bacterial populations and 
improvement of ASD symptoms, in order to see how GBI changes. Variables involve use of 
pre- or probiotics, since they can enhance bifidobacterial growth; or use of antibiotics as 
treatments for ear infection; or use of lysozyme since it is present in breast milk (Weston 
2015). Even though it is an intriguing model, the Gut Bacteria Index has not been validated 
and it has limitations. Autism is a wide spectrum disorder and three variables are not enough 
to explain the all picture. 
Autism is a wide-ranging disorder and complex pathogenesis, involving both 
environmental and genetic factors. Differences in data between studies suggest that there may 
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be more than one possible cause. Potential treatments may need to be personalised according 
to individual needs and, perhaps, a combination of treatments would result in a greater 
improvement of symptoms. 
 
1.2.3 Potential treatments and their influence on gut microbiota activity 
Symptoms reported in ASD people can be considered individual and heterogeneous, 
but many research groups are looking at dietary intervention as potential therapy for GI issues 
in autism in order to modulate the intestinal microbiota and alleviate gut symptoms.   
The term nutraceuticals is defined ‘‘any substance that is food or a part of food and 
provides medical or health benefits, including the prevention and treatment of disease’’ and 
was introduced for the first time in 1989 by the US Foundation for Innovation in Medicine 
(FIS) (Alanazi 2013). This approach is interesting and promising in autistic disorders since 
food selectivity is a common characteristic in children with ASD (Schreck and Williams 2006) 
and might be associated with nutrient inadequacies (Bandini 2010) (Cermak 2010).  Kral et 
al. in recent review paper reported some of the main studies involving food supplements and 
their impact on different aspects of autism. Omega-3, multivitamins, minerals, L-carnitine, 
ascorbic acid, vitamin B12 and B6, folinic acid, dietary fatty acid, folate, creatine and 
probiotics are some examples of nutraceticals that have been investigated so far, with 
interesting results in improving ASD behavioural symptoms and gut dysfunction, but there are 
still limitations in the trial designs and lack of strong evidence to support efficacy (Kral 2013). 
Gluten and casein-free (GFCF) diets are common as individuals with ASD have been 
shown to have an impaired epithelial barrier function. Gliadin (glycoprotein present in wheat) 
activates zonulin signalling, a protein that modulates the permeability of tight junctions 
between cells wall of the digestive tract, leading to increased intestinal permeability to 
macromolecules (Fasano 2011, Lammers 2008). Opioid peptides released from gluten and 
casein can pass through the BBB and have an impact on the CNS (Lázaro 2016). Studies have 
been conducted to evaluate the efficacy of gluten and casein-free diets (Mulloy 2010). Some 
results suggested positive effects on behaviour and GI symptoms (Pennesi and Klein 2012, 
Harris and Card 2012); other findings did not show any improvement in the intervention group 
(Hyman 2015, Elder et al. 2006), suggesting that more studies are required in order to assess 
efficacy of the GFCF diet.  
Unfortunately none of those studies took into account the impact of these particular 
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diets on gut microbiota composition and its correlation with potential amelioration in GI 
problems. A recent metagenomic study aimed to compare the gut bacterial populations of 
samples from healthy adults after 4 weeks gluten-free diet (GFD) to those collected during 
normal diet. They noticed, in GFD, significant changes in alpha diversity and reduction of 
Veillonellaceae family, Ruminococcus bromii and Roseburia faecis. While families 
Victivallaceae, Clostridiaceae and Coriobacteriaceae, and genus Slackia significant increase 
in abundance. No significant modifications have been seen in normal dietary groups (Bonder 
2016). Veillonellaceae is considered to be a pro-inflammatory family of bacteria and its high 
abundance was consistently found in IBD or IBS (Gevers 2014, Shukla 2015). Decrease in 
this bacterial family might be correlated to the beneficial effects of GF diets observed in 
patients with gluten-related disorders, including potentially autism. 
Prebiotics and probiotics have been widely investigated and have been shown to 
modulate the intestinal microflora. Therefore, they could be a useful novel therapeutic 
approach in order to potentially ameliorate behavioural symptoms and GI discomforts 
associated with some children with ASD (Critchfield 2011). 
A recent survey conducted on ASD children taking Delpro® (Lactobacillus 
acidophilus, Lactobacillus casei, Lactobacillus delbruecki, Bifidobacterium longum and 
Bifidobacterium bifidum) for 6 months, showed improvements in GI symptoms (diarrhoea or 
constipation), stool frequency and ASD symptoms. These data, even lacking of a controlled 
clinical trial, suggest that probiotics have an impact on GI distress and ATEC signs and 
symptoms among autistic population (West 2013). 
Parracho et al. reported in children with ASD a significant behavioural improvement 
when administered Lactobacillus plantarum WCSF1 compared to ASD treated with placebo 
(Parracho 2010). Adams et al. compared gut microbiota composition and inflammatory 
markers from stool samples of 58 children with ASD and 39 healthy typical children of similar 
ages, and found reduced levels of total SCFAs in the ASD group with a higher difference in 
children with autism taking probiotics. In addition, they showed a strong correlation between 
GI symptoms and severity of autism (Adams 2011). Kaluzna-Czaplinska administered oral 
supplementation of Lactobacillus acidophilus twice a day for 2 months to a group of ASD 
children and found significant modifications in the level of D-arabinitol (DA) and the ratio of 
D-/L-arabinitol (DA/LA), and an improvement in the ability to carry out instructions and 
concentration (Kaluzna-Czaplińska 2012). Recently, Tomova and colleagues confirmed the 
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results from Adams et al., revealing a strong positive correlation of autism severity with 
severity of GI dysfunction. In their study, 4 months of probiotic mixture diet supplementation 
normalised gut bacterial populations of ASD children. However, no behavioural traits were 
investigated (Tomova 2015). Furthermore, probiotic supplement has been demonstrated to 
reduce the concentration of myeloperoxidase, a marker for inflammation and oxidation, in 
autistic children compared to non-autistic controls (Russo 2015). 
Considering previous study limitations, Santocchi and colleagues suggested a protocol 
in order to improve probiotic study outcomes. A six month parallel, randomised, probiotic 
feeding study will aim to assess changes GI symptoms, autism severity, affective and 
behavioural comorbid symptoms, plasmatic, urinary and faecal biomarkers related to 
abnormal intestinal function and neurophysiological patterns. However, potential limitations 
might include the length of the study and kind of samples requested (blood, urine and faecal 
samples) and lack of control group (non-ASD children) in order to compare biomarkers levels 
(Santocchi 2016).  
Little is known about prebiotic supplementation and its impact on autism. The 
prebiotic FOS (fructo-oligosaccharides) has been tested in order to determine effects on end 
products of trytophan metabolism, known to be altered in ASD individuals, from gut 
microbiota using a mixed bacterial population from the large intestines of pigs. The results 
showed indole-3 acetic acid (a microbial precursor of IAG) decreased with the addition of 
FOS (Xu 2002).  
The positive effects of pre- and probiotics on wellbeing of the host are known and 
confirmed in healthy people and different clinical conditions.  Even if the causes of the GI 
symptoms in the autism are still unknown, further studies are necessary to better understand 
correlation with dysbiosis in the gut microbiota and the potential of pre- and probiotics in this 
neurological disorder. 
 
1.3 Probiotics 
One definition of probiotic has been proposed by the World Health Organization as 
“live microorganisms which, when administrated in adequate amounts, confer a health benefit 
to the host” (FAO/WHO 2002). They are usually strains of lactic acid producing bacteria 
(LAB), in particular members of Lactobacillus and Bifidobacterium genera. Probiotic bacteria, 
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in order to exert their activity, have to survive the gastrointestinal transit (Gibson 2005). Their 
positive effects on the human health may include: 
1) Improvement of tolerance to lactose, thanks to the presence of enzymatic lactase 
activity 
2) Competition with pathogens for colonisation and nutrients 
3) Vitamin synthesis and improvement of mineral absorption 
4) Stimulation of the immune system 
5) Improvement digestion and gut function 
To be known as a probiotic, a candidate microorganism has to be regarded as GRAS 
(Generally Recognized As Safe). This means it should not be pathogenic and should not be 
able to transfer antibiotic resistance genes, as well as be able to maintain genetic stability.  
  Although the beneficial effect of probiotics have been widely tested, these food 
supplements do have limitations. In order to be effective, probiotics must remain viable and 
stable along the gastrointestinal tract, and the host should gain beneficial impacts. However, 
such live microorganisms may reach the lower gut in a compromised state due to bile and 
stomach acid secretions. For the microorganisms to be fully effective, they will then have to 
compete with an established colonic microbiota for nutritional sources (Walton 2013).  
 
1.4 Prebiotics 
Prebiotics are defined as “substrates that are selectively utilized by host micro- 
organisms conferring a health benefit” (Gibson 2017). 
All prebiotics are dietary carbohydrates but not all of them can be considered prebiotics. In 
order to be classified as prebiotic, there are certain criteria: 
1) Resistance to the low gastric pH, hydrolysis by intestinal enzymes and gastrointestinal 
absorption 
2) Be selective substrates for certain bacteria 
3) Stimulate the growth and the activity of the beneficial bacteria that contribute to the well 
being of the host 
Gibson et al. (2004) in a review paper revisited the concept of prebiotic and updated the list 
of the candidate prebiotic according to criteria mentioned above (Gibson 2004). 
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Inulin and Fructo-oligosaccharides (FOS), are non-digestible oligosaccharides present 
in plants, fruits and vegetables such as bananas, onions, chicory root, garlic, asparagus, 
artichoke, and leeks. FOS can be obtained by partial enzymatic hydrolysis of inulin using an 
endo-inulinase, and by enzymatic synthesis using E-fructosidase from Aspergillus niger, but 
the end products have different degree of polymerisation (DP). Orafti NV, have developed an 
inulin, known as Synergy1, which consists of 1:1 inulin and oligosaccharide. The chicory-
derived inulin has a DP of 10 to 60 (average DP of 25). The oligofructose is produced by 
partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 
(average DP of 4; Gibson 2004). 
Several in vitro and in vivo studies have been carried out using both inulin and FOS. 
Kaplan and Hutkins demonstrated the selectivity properties of FOS for bifidobacteria and 
lactobacilli. Studying 28 strains, their results showed L. acidophilus, L. casei, L. plantarum, 
B. adolescentis, B. infantis, B. breve and B. longum as FOS-fermentors and L. lactis, L. 
bulgaricus, L. rhamnosus GG, Streptococcus thermophilus and B. bifidum as non FOS-
fermentors (Hutkins 2000). Batch fermentation experiments, inoculated with human faecal 
samples, showed fructans were consumed accordingly to their DP and that different gut 
bacteria were also able to grow on these carbon sources. In particular, Rossi and colleagues 
demonstrated that bifidobacteria grew by cross-feeding on mono- and oligosaccharides 
produced by primary inulin intestinal degraders (Rossi 2005). According to the different 
human intervention studies reported by Kolida & Gibson, 5–8 g/d of inulin intake is an 
adequate dose in order to modulate the gut microbiota. One potential side effect is gas 
production that might be explained by bacteria other than the target organisms being involved 
in the fermentation, since bifidobacteria and lactobacilli do not produce gas, or high doses of 
prebiotic (Kolida and Gibson 2007). 
These criteria have been fulfilled also for lactulose. It is produced by isomerisation of 
lactose to generate the disaccharide galactosyl E-(1-4) fructose and different human studies 
show how it can be selective fermented by bifidobacteria and lactobacilli and reduce the 
growth of potential harmful bacteria (Tuohy 2002, Bouhnik 2004). 
Galacto-oligosaccharides (GOS) are defined as “a mixture of those substances 
produced from lactose which comprise between two and eight saccharide units, with one of 
these units being a terminal glucose and the remaining saccharide units being galactose, and 
disaccharides comprising two units of galactose” (Tzortzis 2011) (Table 1.3). 
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Table 1.3: Different definitions of GOS (Roberfroid 2010) 
GALACTANS  
Mixture of β(1-6); β(1-3); β(1-4) galactosyl-galactose 
GOS 
Galn-Gal and/or Galn-Glc; DP 2-8 
Galacto-oligosaccharides, 
trans-galacto-oligosaccharides 
(enzymatic transgalactosylsation of lactose) 
 
The structural size of GOS plays a role in targeting the bifidobacterial genus, however this 
relationship has not been extensively determined at species level (Matsuki 2004, Rodriguez-
Colinas 2013). 
Differently from FOS, GOS is not a food component but it is a synthetic product and 
to date, the main companies involved in the GOS market include Yakult Honsha (Oligomate 
55N and 55NP and TOS-100), Nissin Sugar Manufacturing (Cup-Oligo P and H-70) and 
Purimmune from Japan; Floraid GOS from the United States; Friesland Food Domo (Vivinal 
GOS), Nestle GOS and Clasado (B-GOS) from Europe. They produce usually GOS in syrup 
or powder format that, in both cases, contain oligosaccharides of different DP, non-reacted 
lactose, glucose and galactose. Table 1.4 summarises characteristics of commercially GOS 
available (Torres et al. 2010). 
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Table 1.4: Characteristics of commercially GOS (adapted from Torres et al. 2010) 
                                                     GOS   
 Glucose Galactose Lactose DP2 DP3 DP4 DP>4 Total GOS 
content 
Enzyme source 
CUP-oligo  25 to 30  - - - - 70 Cryptococcus laurentii 
Oligomate55 18 to 39 10 to 22 15 to 17 18 to 24 10 to 16 2 to 5.4 50 to 60 A.oryzae and S. 
thermophilus 
TOS-100 0 0 to 1 0 55 33 to 35 12 to 14 99 to 100 Bacillus circulans 
Vivinal GOS 19 to 22 0.8 to 1.3 10 to 23 19 to 27 22 to 23 11 6 to 7.6 57 to 59 Bacillus circulans 
B-GOS 18 12 22 25 to 29 12 to 14 6.7 to 7.7 3.8 to 4.4 48 to 55 Bifidobacterium bifidum 
Purimune 
 
0 to 1 0 to 0.5 7 to 10 16 to 21 38 to 51 25 to 29 90 to 92 Bacillus circulans 
 
Floraid GOS 21 8.5 18 - - - - 20-28 A.oryzae 
 
Nestle GOS 10 5 20 to 40 - - - - 46 A.oryzae 
DP: degree of polymerisation;  
DP and total GOS content expressed in %;  
- :  data not available 
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1.4.1 Galacto-oligosaccharides as prebiotics   
GOS is thought to remain largely undigested through the human gut making it is a  
prebiotic. Not only is it suitable for administration, its functional properties enable it to be easily 
manufactured. A low pH tolerance enables GOS to withstand acidic conditions in the stomach 
but also offers potential for use in fruit juices (Sangwan 2011). At present, GOS has been 
associated with numerous health benefits. In fact, the two main mechanisms by which this is 
achieved are through the production of SCFAs from its fermentation and the selective 
enhancement of beneficial gut organisms, thus modulating the microbiota (Sangwan 2011).  
Acetate, butyrate and propionate are the most common SCFA in the colon. SCFAs 
reduce the luminal pH increasing mineral absorption, suppressing the growth of pathogens and 
influencing intestinal motility. In addition, they may be absorbed by the colonic mucosa and 
provide an energy supply (mainly butyrate). Acetate can be metabolised in human muscle, 
kidney, heart and brain. Propionate is metabolised by the liver and as a glucogenic substrate 
affects the hepatic control of lipids, cholesterol production and adipose tissue deposition. 
Butyrate is an energy substrate for cell growth and differentiation, it also reduces the risk of 
colon cancer stimulating apoptosis (Roberfroid 2010). There has been a range of studies 
demonstrating the efficacy of GOS. It should be noted that bifidobacteria mainly generate 
acetate and lactate, but not propionate or butyrate. 
Another important factor could be the ability of prebiotics to act as anti-adhesive agents 
against pathogens. Studies have revealed that GOS was more effective than inulin and FOS at 
preventing the attachment of EPEC to gut a cell line in vitro (Tzortzis 2005, Shoaf 2006). GOS 
has also been seen to reduce the severity of pathogen infection and prevent colonization in mice 
e.g. of S. typhimurium (Searle 2009).  
In most cases, GOS has been proven to elicit a bifidogenic effect increasing levels of these 
potentially beneficial organisms. This positive ability is supported by the presence of specific 
membrane mechanisms of transport like diffusion, cation symport and proton symport, and the 
presence of extracellular β-galactosidases that hydrolyse GOS, internalise the products and 
degrade them in the cell, avoiding competition with other bacteria (Boehm 2005, Fanaro 2009). 
Recently, GOS and inulin has become a standard component in infant formulae, attempting to 
generate similar compositions of the gut microbiota between breast fed infants and 
supplemented formula fed infants i.e. higher concentrations of bifidobacteria (Scholtens 2008, 
Ben 2008). 
Another important factor is immune-modulatory activities related to the GALT system (Gut 
Associated Lymphoid Tissue) that contain 60% of lymphocytes and sIgA that play a role 
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against pathogenic invasion. These effects are due to direct interaction with the immune, 
mucosal and epithelial cells or indirect by selective modulation of the microbiota.  
 
1.4.2 B-GOS 
B-GOS as manufactured by Clasado Biosciences Ltd., is synthesised from food grade 
lactose using the transgalactosidic activity of a microbial derived β-galactosidase enzyme 
preparation which catalyses lactose to form a mixture of β-linked disaccharide, trisaccharide, 
tetrasaccharide and pentasaccharide chains in configurations depicted in Table 1.5.  
 
Table 1.5: Dimeric and oligomeric saccharides present in B-GOS. Gal= Galactose; Glc = 
glucose. (Clasado Inc.) 
 
 
The β-galactosidase activity of Bifidobacterium bifidum NCIMB 41171 has been used to 
produce the B-GOS mixture (Table 1.6): 
 
Table 1.6: B-GOS composition-in dry matter. DP, degree of 
polymerisation (Tzortzis 2009) 
Ingredient g/100 g 
Monosaccharide <15.3 
Lactose <28 
GOS <50 
DP2 52% 
DP3 26% 
DP4 14% 
DP5 8% 
Minerals <5 
Protein <1 
Fat 0.5 
 
 
Tzortzis et al. (2005) showed that B. bifidum, isolated from faecal samples of a healthy human 
volunteer could convert 55% of lactose to a novel mixture of GOS at the optimum activity 
condition (pH: 6.9 and temperature: 40°C). The bifidogenic activity of B-GOS was higher than 
inulin and a GOS mixture generated from enzymes of a Bacillus strain. The prebiotic potential 
of this mixture has been tested also in vivo in a pig-feeding trial  (Tzortzis 2005b). Four β-
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galactosidase enzymes, three β- and one α-galactosidase, involved in the reaction have been 
cloned, sequenced and characterised by Goulas et al. to better understand their physiological 
and biotechnological properties, including selectivity, interaction with pathogens and immune 
system (Goulas 2009). 
B-GOS has been tested further in human studies. Depeint et al. showed the bifidogenic 
effects of B-GOS in healthy volunteers comparing to a GOS mixture produced by an industrial 
β-galactosidase from Bacillus circulans ATCC 4516 (V-GOS). Using a B-GOS mixture in three 
different doses (0 g, 3.6 g, 7 g), each for 7 days, with an equivalent washout period between 
each treatment, there was a positive effect in a dose-response relation in terms of increasing 
Bifidobacterium group. There was a significant increase in B. bifidum and B. longum compared 
to V-GOS (Depeint 2008).  
Furthermore, the positive effects of B-GOS have been also assessed by Vulevic et al., 
in elderly healthy volunteers. To date, several studies have shown negative modifications of 
elderly intestinal microflora composition compared to younger persons. One possible 
explanation is related to the aging process that is associated with a reduced activity of the 
immune system and an increase of pro-inflammatory cytokines. Forty-four volunteers were 
randomly assigned into 2 groups: one consuming placebo and B-GOS (both powder form, 5.5g) 
for 2 treatment periods of 10 weeks each, separating by a 4 weeks washout period. The results 
showed how, after 5 weeks, the microbiota was similar to younger counterparts, reducing the 
presence of putrefactive bacteria. The study highlighted significant changes, enhanced at 10 
weeks, in production of IL-10, reduced production of pro-inflammatory cytokines like IL-1 β, 
TNF-α and IL-6 and increased NK cell activity. This is a key point that shows how B-GOS can 
influence immune senescence, decline of immune functions, which promotes hypo 
responsiveness to vaccination and predisposition to infectious and non-infectious diseases 
(Vulevic 2008). These potential immune modulatory properties of B-GOS have been shown 
also in vitro by Dubert-Ferrandon et al. (2008) using adult human colonic NCM 460 cells 
showing a positive effect on TNF-α mediated inflammation in human intestinal epithelial cells. 
Another interesting area, in which the B-GOS mixture has been tested, was related to 
functional GI disorders, in particular IBS. Silk et al. investigated the efficacy of B-GOS in 
changing the colonic microflora and improving symptoms in IBS sufferers. In this clinical trial, 
patients were randomised to receive either 3.5 g⁄d B-GOS, 7 g⁄d B-GOS or 7 g⁄d equivalent 
placebo. Both doses were well tolerated and no adverse side effects were reported by any of the 
patients. Moreover, this study highlighted that B-GOS has potential as a therapeutic agent 
effective in alleviating symptoms and in increasing bifidobacteria numbers (Silk 2009). 
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The efficacy of B-GOS against pathogens has been shown by Searle et al. using in vitro 
and in vivo models where 2mM of B-GOS significantly reduced colonisation and pathology 
associated with Salmonella enterica typhimurium, but the mechanism of action is still to be 
elucidated (Searle 2009). Drakoularakou et al. focused on the severity and/or incidence of 
travellers’ diarrhoea, in healthy volunteers who travel and stay in a high-risk destination (Asia, 
Middle East, Africa, Mexico, Central and South America). The volunteers were consuming B-
GOS (5.5g/d) for 1 week before the holiday and for the 2 weeks holiday. Results showed 
reduced diarrhoeal episodes and decreased symptoms such as abdominal pain, vomiting, fever, 
anorexia, headache and dizziness (Drakoularakou 2009). 
Another study on the potential activity of B-GOS focused on its effect in reducing risk 
factors of metabolic syndrome. Two groups of volunteers started the treatment respectively 
with placebo and B-GOS (powder 5.5g/d) for 12 weeks, followed by 4 weeks washout before 
swapping the treatment for other 12 weeks. The results showed that B-GOS had a significant 
prebiotic effect on aspects of insulin resistance (Vulevic 2013).  
B-GOS was also shown to reduce cortisol secretion and anxiety in healthy volunteers. 
Schmidt and colleagues, in their human intervention study, showed that B-GOS 
supplementation lowered cortisol reactivity and modulate attention to emotional stimuli 
compared to a placebo group and FOS (Schmidt 2015). 
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Aims and Objectives 
 To date, studies focussing on the interactions between gut microbiota dysbiosis and 
ASD show common and consistent results. Some bacterial groups, such as Clostridium spp., 
Desulfovibrio spp. and Sutterella spp. seem to be present in higher numbers in autistic children 
compared to non-autistic ones, and beneficial bacteria such as bifidobacteria and lactobacilli 
have been found to be in lower amounts in ASD individuals. In addition, strong alterations in 
some metabolic pathways have also been seen. Modifications in gut microbiota composition 
might be associated to GI discomforts observed in ASD and have an impact on CNS and 
consequently on mood and behaviour. Therefore, dietary intervention therapies have been 
postulated to improve these aspects. The potential of prebiotics to alleviate gut symptoms and 
modulate the GI microbiota has been widely investigated in healthy individuals and different 
bowel disorders but there is a lack of knowledge about their impact on autism and gut-brain 
axis. 
The aims and objectives of this research project were therefore (Figure 1.4): 
• To investigate the impact of a purified prebiotic B-GOS (65%GOS content) on overall 
diversity of the anaerobic faecal bacterial population using in vitro batch culture 
fermentation systems; 
• To determine the effect of B-GOS (65%GOS content) on the gut microbiota composition 
and metabolites production using a three-stage continuous system models inoculated with 
faecal samples from autistic and non-autistic children; 
• To design and perform a human intervention study investigating the effects of B-GOS 
(83%GOS content) on different aspects of autism: 
➢ The first aim was to investigate the effect of a 6-weeks prebiotic supplementation on 
gut microbiota and its metabolic by-products in children with ASD.  
➢ The second aim was to assess the impact of this treatment period on GI symptoms 
(including adequate relief of symptoms, severity and incidence of symptoms, stool 
consistency and frequency), sleep, mood and behaviour. 
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Figure 1.4: Summary of the research strategies used to achive principal aims of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gut microbiota and bacterial metabolism 
Autism Spectrum 
Disorders (ASDs) 
Prebiotics as 
Potential treatment 
In vitro batch culture system: 
Testing the prebiotic effect of purified B-GOS 
(65%GOS) on faecal bacterial and metabolic 
composition in healthy volunteers  
In vitro gut model system: 
Understanding the prebiotic potential of 
B-GOS (65%GOS) on faecal gut 
microbiota and metabolites production in 
ASD and non-ASD children  
Human intervention study: 
Double-blind, parallel, randomised, placebo-
controlled study in order to assess the impact of 
B-GOS (83%GOS) supplementation on different 
aspect of autism  
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Abstract 
Prebiotic oligosaccharides have the ability to generate important changes in the gut 
microbiota composition that may confer health benefits to the host. Reducing impurities 
in prebiotic mixtures could expand their application in food industries and improve 
selectivity and prebiotic effects on potential beneficial bacteria such as bifidobacteria and 
lactobacilli. This study aimed to determine the in vitro potential fermentation properties 
of a 65 % galacto-oligosaccharide (GOS) content, Bimuno® GOS (B-GOS), on gut 
microbiota composition and metabolites. Fermentation of 65 % B-GOS was compared 
with 52 % B-GOS in pH- and volume-controlled dose–response anaerobic batch culture 
experiments. In total, three different doses (1, 0·5 and 0·33 g equivalent to 0·1, 0·05 and 
0·033 active GOS g/l) were tested. Changes in the gut microbiota during a time course 
were identified by fluorescence in situ hybridisation, whereas small molecular weight 
metabolomics profiles and SCFA were determined by 1H-NMR analysis and GC, 
respectively. The 65% B-GOS showed positive modulation of the microbiota 
composition during the first 8 h of fermentation with all doses. Administration of the 
specific doses of B-GOS induced a significant increase in acetate as the major SCFA 
synthesised compared with propionate and butyrate concentrations, but there were no 
significant differences between substrates. The 65% B-GOS in syrup format seems to 
have, in all the analysis, an efficient prebiotic effect. However, the applicability of such 
changes remains to be shown in an in vivo trial. 
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2.1 Introduction 
In vitro and in vivo studies involving prebiotic oligosaccharides have been carried 
out using inulin and its fructo-oligosaccharide (FOS) derivatives, as well as various 
galacto-oligosaccharides (GOS). It has been shown that these food ingredients have the 
ability to selectively improve the growth of bifidobacteria, and consequently lead to 
important changes in the gut microbiota composition that may confer health benefits to 
the host. To date, GOS has been associated with numerous health benefits such as low 
energy content, insulin-independent metabolism and stimulation of growth and 
metabolism of specific colonic microbiota. The two main mechanisms by which this is 
achieved are through the production of SCFA from its fermentation and selective 
enhancement of beneficial gut microorganisms (Sangwan 2011).  
GOS can be defined as a mixture of the end products of lactose breakdown by β-
galactosidases, containing two to eight saccharide units, with a terminal glucose unit 
(Tzortzis 2009). These mixtures can be complex and their structures are often 
imperfectly characterised. They tend to be mixtures of β-1,3, β-1,4 and β-1,6 linkages 
with degrees of polymerisation ranging from two to five. A characteristic of GOS is that 
the set of structures present depends on source of the enzyme used to bring about 
synthesis. Structural and functional relationships of GOS play a role in targeting the 
Bifidobacterium genus (Matsuki 2004). Another important aspect is the presence of 
impurities such as monosaccharides, disaccharides or metabolic products from 
purification steps. Removing these compounds can lead to a mixture with a GOS content 
as high as possible that can be better used to study fermentation and structural properties 
of novel prebiotics in in vitro experiments.  
In addition, purified Bimuno® GOS (B-GOS) mixture might have significantly 
increased interest in production and application in various food and pharmaceutical 
processes, especially if the prebiotic is incorporated directly into food such as diabetic or 
low-energy foods. Reducing monosaccharides and disaccharides such as glucose, 
galactose and lactose from the mixture might help minimise their impact on consumers, 
particularly by taking into account lactose intolerance. Several techniques have been 
suggested in order to obtain high recovery of GOS, but all of them have some limitations 
(Hernandez 2009). B-GOS (Bimuno® 52% GOS content; Clasado Biosciences Ltd) 
refers to prebiotic GOS compounds that have multiple biological health activities within 
the colonic environment. It is produced from the activity of galactosidase enzymes 
isolated from Bifidobacterium bifidum NCIMB 41171 (Tzortzis 2009). The method for 
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B-GOS purification has been studied by Goulas et al. (2007) in order to reduce the 
amount of free glucose and galactose produced during its synthesis, and it led to the 
removal of 92% of glucose by fermentation with Saccharomyces cerevisiae.  
The bifidogenic properties of B-GOS have been investigated in vitro and in vivo. 
Tzortzis et al. (2005) showed in vitro and in a pig trial the prebiotic potential of GOS. In 
this study, it was established that B-GOS prebiotic activity was relevant in terms of 
increase in bifidobacteria numbers, SCFA production and decreased pH, compared with 
other prebiotics such as inulin and other GOS types (Tzortzis 2005). B-GOS has also 
been tested in healthy volunteers, clinical conditions that have a purported microbial 
aetiology such as Irritable Bowel Syndrome, traveller’s diarrhoea and obesity, and on 
cognitive functions (Schmidt 2015; Depeint 2008; Drakoularakou 2009; Silk 2009; 
Vulevic 2008; Vulevic 2013).  
This study aimed to determine the potential prebiotic activity of a purified 65% 
GOS content B-GOS, compared with 52% GOS content B-GOS, used as positive control 
in in vitro dose–response batch cultures. 
 
2.2 Methods 
2.2.1 Substrates 
The two B-GOS products, supplied by Clasado BioSciences Ltd, used in this 
study were produced from the activity of galactosyltransferases from B. bifidum NCIMB 
41171 on lactose (Tzortzis 2005). Both were used in syrup form. The B-GOS mixtures 
consisted of (w/w) 52 % GOS, 8 % lactose, 22 % glucose, 16·5 % galactose; and 65% 
GOS, 10·1% lactose, 22% glucose, 1·8% galactose, respectively. 
 
2.2.2 Faecal inoculation 
Experiments were carried out using fresh faecal samples from three healthy 
donors (one female aged 26 years and two males aged 25 and 31 years, respectively) who 
were free of any metabolic and gastrointestinal diseases, were not taking probiotic or 
prebiotic supplements and had not taken antibiotics for 6 months before faecal sample 
donation. All donors then provided written informed consent, and filled in a standard 
questionnaire to collect information regarding health status, drug use, clinical anamnesis 
and lifestyle factors. This study was approved by The University of Reading Research 
Ethics Committee (UREC 15/20). Faecal samples were placed in an anaerobic jar 
(AnaeroJarTM 2.5L; Oxoid Ltd) including a gas- generating kit (AnaeroGenTM; Oxoid). 
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Samples were diluted 1/10 w/w in anaerobic PBS (0·1 mol/l phosphate buffer solution, 
pH 7·4) and homogenised (Stomacher 400; Seward) for 2min at 240 paddle beats/min. 
Samples were added to anaerobic fermenters within 15 min of voiding. 
 
2.2.3 In vitro batch culture fermentation 
This method was previously described by Rodriguez-Colinas et al. (2013). B-
GOS were added at concentrations shown in Table 2.1 before adding faecal slurry.  
 
Table 2.1: Doses of the B-GOS syrups tested (equivalent to 0.1, 0.05 and 0.033 g/L) in 100mL working 
volume vessels during 24 hours fermentation in pH and volume controlled batch fermentation experiments.  
Vessel 
 
Treatment Syrup (g) DM (g)  GOS (g) in 
100mL 
1 B-GOS (52% GOS content) 2.66 2  1 
2 B-GOS (52% GOS content) 1.33 1  0.5 
3 B-GOS (52% GOS content) 0.88 0.66  0.33 
4 B-GOS (65% GOS content) 2.05 1.54  1 
5 B-GOS (65% GOS content) 1.02 0.77  0.5 
6 B-GOS (65% GOS content) 0.68 0.51  0.33 
7 Negative control (only 
faeces) 
    
DM: dry matter. 
 
An extra vessel with no added carbohydrate source was also included as a negative 
control. Culture pH was maintained in the range of 6·7–6·9 via automatic controllers 
(Fermac 260; Electrolab) and adjusted by adding 0·5mM-NaOH and HCl to the vessels 
when required. The pH and temperature mimicked the conditions of the distal region of 
the human large intestine. Batch culture fermentations were run for 24 h, and samples 
(3·5 ml from each vessel) were collected at 0, 4, 8 and 24 h for analysis of bacterial 
populations and metabolite production. Fermentation experiments were performed in 
triplicate. 
 
2.2.4 Bacterial enumerations by fluorescence in situ hybridisation 
Differences in bacterial populations were assessed by fluorescence in situ 
hybridisation (FISH) with oligonucleotide probes designed to target specific diagnostic 
regions of 16S rRNA, as previously described (Costabile 2010). The probes were 
commercially synthesised and labelled at the 5′ end with the fluorescent dye Cy3 
(Sigma-Aldrich) as reported in Table 2.2 (Langendijk 1995; Manz 1996; Harmsen 1999; 
Franks 1998; Daims 1999; Walker 2005).  
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Table 2.2: Oligonucleotide probes used in the study for FISH analysis of bacterial populations 
Probe name and Sequence (5’ to 3’) Target species Hybridization-
Washing 
Temperature (C) 
References 
Bif164  
CATCCGGCATTACCACCC 
Most Bifidobacterium spp. and Parascardovia denticolens 50-50 Langendijk 
1995 
Bac303  
CCAATGTGGGGGACCTT 
Most Bacteroides sensu stricto and Prevotella spp.; all 
Parabacteroides;Barnesiella viscericola and Odoribacter splanchnicus 
46-48 Manz 1996 
Lab158 
GGTATTAGCAYCTGTTTCCA 
Most Lactobacillus, Leuconostoc and Weissella spp.; Lactococcus lactis; 
all Vagococcus, Enterococcus, Melisococcus, Tetragenococcus, 
Catellicoccus, Pediococcus and Paralactobacillus spp. 
50-50 Harmsen 
1999 
Chris150 
TTATGCGGTATTAATCTYCCTTT 
Most members of Clostridium cluster I; all members of Clostridium 
cluster II;Clostridium tyrobutyricum; Adhaeribacter aquaticus and 
Flexibactercanadensis (family Flexibacteriaceae); [Eubacterium] 
combesii (family Propionibacteriaceae) 
50-50 Franks 
1998 
Erec 482 
GCTTCTTAGTCARGTACCG 
Most members of Clostridium cluster XIVa; Syntrophococcus 
sucromutans, [Bacteroides] galacturonicus and [Bacteroides] 
xylanolyticus, Lachnospira pectinschiza and Clostridium saccharolyticum 
50-50 Franks 
1998 
EUB338 I 
GCTGCCTCCCGTAGGAGT 
Total bacteria 46-48 Daims 
1999 
EUB338 II 
GCAGCCACCCGTAGGTGT 
Total bacteria 46-48 Daims 
1999 
EUB338 III 
GCTGCCACCCGTAGGTGT 
Total bacteria 46-48 Daims 
1999 
Rrec584 
TCAGACTTGCCGYACCGC 
Roseburia - Eubacterium rectale (a component of cluster XIVa) 50-50 Walker 
2005 
Prop853 
ATTGCGTTAACTCCGGCAC 
Clostridium cluster IX 50-50 Walker 
2005 
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Numbers of specific and total bacteria were determined using the following equation: 
DF×ACC×6732·42×50×DF sample, where DF is the dilution factor (300/375 = 0·8), 
ACC is the average cell count of fifteen fields of view and DF sample refers to the 
dilution of sample used with a particular probe or stain. The figure 6732·42 refers to the 
area of the well divided by the area of the field of view and the factor 50 takes the cell 
count back to per millilitre of sample. 
 
2.2.5 SCFA analysis 
Production of SCFA was determined using GC as previously described (Massot-
Cladera 2015). Peaks were integrated using Agilent ChemStation software (Agilent 
Technologies), and SCFA content was quantified by single-point internal standard 
method. Peak identity and internal response factors were determined using a 20 mM 
calibration cocktail including acetic, propionic, iso-butyric, butyric, iso-valeric, valeric, 
caproic and caprylic acids. 
 
2.2.6 Metabolite analysis by 1H-NMR 
Fermentation supernatants from all time points were defrosted, vortexed and 
centrifuged at 599 xg for 5 min. Supernatants were filtered using 0·22-μm low protein 
binding durapore polyvinylidene fluoride membrane (Millex; EMD Millipore) and 400μl 
was transferred into fresh eppendorf tubes. Filtered samples were then combined with 
200 μl of phosphate buffer (0·2M (pH 7·4) in D2O plus 0·001% (w/v) trimethylsilyl 
propionate (TSP)). The mixture was vortexed and centrifuged at 1136 x g for 10 min and 
then 550 μl was transferred into 5-mm NMR tubes for analysis. All NMR spectra were 
acquired on Bruker Avance DRX 500MHz NMR Spectrometer (Bruker BioSpin) 
operating at 500 MHz. They were acquired using a standard 1-dimensional (1D) pulse 
sequence (recycle delay (RD)−90°−t1−90°−tm− 90°−acquire free induction decay (FID)) 
with water suppression applied during RD of 2 s, a mixing time tm of 100 ms and a 90 
pulse set at 7·70 μs. For each spectrum, a total of 128 scans were accumulated into 64 k 
data points with a spectral width of 12·001 parts per million. The FID were multiplied by 
an exponential function corresponding to 0·3 Hz line broadening. All spectra were 
manually phased, baseline corrected and calibrated to the chemical shift of TSP (δ 0·00). 
Spectra were digitised using an in-house MATLAB (version R2014a; The Mathworks 
Inc.) script. The spectral region containing the water resonance was removed to minimise 
distortions in the baseline arising from imperfect water saturation. Principal component 
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analysis (PCA) was performed with Pareto scaling using scripts provided by Korrigan 
Sciences Ltd. 
 
2.2.7 Statistical analysis 
All statistical tests were performed using GraphPad Prism (version 5.0; Graph-
Pad Software). A two-way ANOVA test was used to compare dose, substrates and time-
dependent effects. When there was no significant effect, one-way ANOVA tests and 
paired T-tests, including post hoc tests appropriate for the individual data sets 
(Bonferroni post-test with significance set at P<0·05), were used for bacterial counts and 
organic acid concentrations. 
 
2.3 Results 
2.3.1 SCFA analysis 
Results showed acetate as the dominant SCFA produced for both substrates with 
significant differences between 4 and 8 h of fermentation using 65 % B-GOS at 0·033 g/l 
(P<0·01) (Table 2.3). In particular, there was a clear dose–response effect during the first 
4h of fermentation. However, no significant differences were observed between the two 
substrates at the same dose. The dose–response effect was also confirmed by 1H-NMR 
data. PCA revealed a clear trajectory over time, showing a clear separation between 0 
and 4 h with acetate as main component influencing variation through time (Figure 2.1). 
Significant decreases in propionate concentration throughout fermentation were 
observed, mainly between 8 and 24h of fermentation (P<0·01). None of the substrates 
generated major changes in butyrate production (Table 2.3). Two-way ANOVA data 
analyses did not show significant differences on SCFA production between the two 
substrates. 
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Table 2.3: SCFAs production measured by Gas Chromatography (GC) in the pH controlled and volume controlled batch cultures at 0, 4, 8 and 24 hour fermentation. 
Results reported as average (AV) of the data expressed in millimolar (mM) ± standard deviation (SD). Branched SCFAs: Iso-butyric acid and iso-valeric acid. 
SUBSTATE Time ACETATE PROPIONATE BUTYRATE BRANCHED TOTAL  
  [h] [AV (mM) ± SD] [AV (mM) ± SD] [AV (mM) ± SD] [AV (mM) ± SD] [AV (mM) ± SD] 
 
0 26.77 ± 22.13 6.50 ± 7.25 4.63 ± 5.11 15.60 ± 17.26 53.49 ± 51.53 
52%B-GOS 1g 4 30.96 ± 18.64 6.43 ± 8.32 4.44 ± 6.92 16.08 ± 11.36 57.92 ± 56.63 
 
8 28.39 ± 6.91 2.59  ± 0.76 0.95 ± 0.47 3.13 ± 1.42 35.06 ± 6.89 
  24 17.14 ± 0.1 1.06± 0.1 0.55± 0.1 0.22± 0.1 18.98± 0.1 
 
0 17.27 ± 8.37 3.63 ± 3.42 2.57 ± 2.61 8.81 ± 9.28 32.28 ± 23.49 
52%B-GOS 0.5g 4 28.33 ± 19.27 4.67 ± 6.09 2.29 ± 3.41 7.71 ± 11.36 43.01 ± 40.13 
 
8 31.25 ± 15.30 2.11 ± 1.65 0.80 ± 0.51 1.37 ± 0.98 35.52 ± 18.34 
  24 20.3 ± 0.1 0.91± 0.1 0.39± 0.1 0.23± 0.1 21.84± 0.1 
 
0 11.41 ± 8.94 2.26 ± 1.92 1.63 ± 1.52 5.74 ± 5.89 21.04 ± 16.22 
52%B-GOS 0.33g 4 17.43 ± 19.16 4.56 ± 6.62 1.75 ± 2. 63 4.62 ± 7.01 28.36 ± 35.33 
 
8 26.54 ± 26.11 4.47 ± 5.63 1.24 ± 1.57 1.13 ± 0.92 33.37 ± 35.22 
  24 26.24± 0.1 0.75± 0.1 0.24± 0.1 0.17± 0.1 27.39± 0.1 
 
0 18.29 ± 10.59 2.33 ± 2.31 1.32 ± 1.39 4.69 ± 4.87 26.63 ± 19.12 
65%B-GOS 1g 4 38.42 ± 2217 4.65 ± 4.45 1.42 ± 1.91 4.47 ± 5.65 48.97 ± 34.11 
 
8 43.37 ± 28.55 6.81 ± 5.19 1.21 ± 0.99 1.47 ± 1.15 52.82 ± 33.81 
  24 6.78± 0.1 0.73± 0.1** 0.4± 0.1 0.39± 0.1 8.31± 0.1 
 
0 17.94 ± 7.95 2.01 ± 1.94 0.92 ± 0.97 3.42 ± 3.61 24.29 ± 14.33 
65%B-GOS 0.5g 4 30.61 ± 20.92 3.97 ± 3.69 1.27 ± 1.59 3.19 ± 3.95 39.03 ± 30.10 
 
8 24.43 ± 11.06 3.32 ± 2.47 0.72 ± 0.56 1.18 ± 0.81 29.65 ± 13.96 
  24 21.51± 0.1 0.61± 0.1** 0.50± 0.1 0.28± 0.1 22.89± 0.1 
 
0 12.29 ± 5.37 1.33 ± 1.14 0.58 ± 0.6 2.1 ± 2.31 16.3 ± 9.21 
65%B-GOS 0.33g 4 24.68 ± 15.65 3.39 ± 3.19 0.84 ± 1.03 2.14 ± 2.65 31.05 ± 22.49 
 
8 27.18 ± 12.41** 3.98 ± 2.72 0.71 ± 0.48 1.25 ± 1.02 33.12 ± 15.48 
  24 20.88± 0.1 1.18± 0.1* 0.97± 0.1 0.77± 0.1 23.79± 0.1 
 
0 5.28 ± 5.69 0.71 ± 0.51 0.36 ± 0.32 1.15 ± 1.25 7.5 ± 5.34 
NEG.CONTROL 4 8.68 ± 5.25 1.68 ± 0.97 0.61 ± 0.47 1.3 ± 1.66 12.31 ± 8.28 
 
8 18.82 ± 8.74 2.71 ± 1.47 0.67± 0.12 0.97 ± 0.84 23.17 ± 10.64 
  24 18.43± 0.1 2.37± 0.1 1.47± 0.1 0.49± 0.1 22.76± 0.1 
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Figure 2.1: 1H-NMR data analysis. (A-C) PCA score plot B-GOS 65% - T4 and PCA score plot B-GOS 
52% - T4, respectively, show a clear separation during the first 4 hours fermentation due to dose response 
effect.  (B-D) PCA score plot B-GOS 65% - T8 and PCA score plot B-GOS 52% - T8, respectively, show 
how dose effect is lost after for 4 h fermentation. (E) Colour plot illustrates the main compound, acetate, 
influencing the separation. The 65%B-GOS and 52%B-GOS were tested at 1g, 0.5g and 0.33 g equivalent 
to 0.1g/L, 0.05 g/L and 0.033 g/L.  
 
 
2.3.2 Changes in bacterial populations 
A significant increase in bifidobacteria was observed with 52 %B-GOS 0·5 and 
0·33 g (equivalent to 0·05 and 0·033 g/l) at same time 0 and 24 h and with 65 % B-GOS 
doses at all time points tested (P < 0·05; Table 2.4). Lactobacilli significantly increased 
after addition of 52 % B-GOS and 65 % B-GOS 1 and 0·33 g (equivalent to 0·1 and 
0·033 g/l) (P < 0·01) and 52 % B-GOS 0·5 g (equivalent to 0·05 g/l) (P < 0·05) between 
8 and 24 h. An overall decrease in the Bacteroides–Provotella group with 52% B-GOS at 
doses of 1 and 0·33 g (equivalent to 0·1 and 0·033 g/l) was observed between 0 and 24h 
(P<0·05). With 65% B-GOS at 1 and 0·5g (equivalent to 0·1 and 0·05 g/l), there was a 
significant decrease between 4 and 24 and 0 and 4 h, respectively (P < 0·05). Two- way 
ANOVA data analyses did not show significant differences in microbiota composition 
between the two substrates. 
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Table 2.4: Bacterial groups detected by FISH in the pH controlled and volume controlled batch cultures at 0, 4, 8 and 24 hours fermentation Results are reported as mean of the data of three 
experiments (n=3) and expressed as Log10 cells/mL ± standard deviation (SD). The 65%B-GOS and 52%B-GOS were tested at 1g, 0.5g and 0.33 g (equivalent to 0.1g/L, 0.05 g/L and 0.033 g/L). a Significant 
difference from 0 h with P<0.05; b Significant difference from 4 h with P<0.05; c Significant difference from 8 h with P<0.05; In italics type: significant differences with P<0.01; In bold type: significant 
differences with P<0.001  (T-test). 
Probes Time point (h) Bacterial population (log10 cells/ml) 
   52%B-GOS 1g 52%B-GOS 0.5g 52%B-GOS 0.33g 65%B-GOS 1g 65%B-GOS 0.5g 65%B-GOS 0.33g NC 
Eub338 I-II-III 0 9.24 ± 0.09 9.13 ± 0.11 9.22± 0.11 9.24 ±0.11 9.27 ±0.12 9.23 ±0.1 9.19 ±0.08 
 4 9.11 ± 0.17 9.15 ± 0.18 9.14 ± 0.44 9.39 ±0.14 8.9 ± 0.14 9.35 ±0.07 9.04 ±0.31 
 8 9.16 ± 0.13 9.49 ± 0.23 9.05 ± 0.41 9.52 ± 0.1 8.92 ± 0.1 9.46 ±0.04 9.2 ± 0.59 
 24 9.14 ± 0.01 9.33 ± 0.03 9.1 ± 0.05 8.94 ±0.07a,c 9.21 ±0.01 9.56 ±0.04a 8.95 ±0.02a 
Lab158 0 7.63 ± 0.09 7.48 ± 0.11 7.55 ± 0.05 7.52 ±0.07 7.54 ±0.15 7.47 ±0.06 7.48 ±0.06 
 4 7.57 ± 0.05 7.64 ± 0.16 7.77 ± 0.27 7.78 ±0.14 7.73 ±0.12 7.31 ±0.29 7.54 ± 0.2 
 8 7.74 ± 0.1 8.05 ± 0.11 7.6 ± 0.36 7.98 ±0.27 8.21 ±0.56 7.66 ±0.12 7.55 ± 0.4 
 24 8.39 ±0.02a,b,c 7.7 ± 0.01c 7.94 ± 0.07a 7.94 ±0.09a 7.68 ±0.06 7.85 ±0.05a 7.29±0.08a 
Bif164 0 8.61 ± 0.28 8.7 ± 0.17 8.58 ± 0.26 8.45 ±0.35 8.63 ±0.21 8.47 ± 0.3 8.68 ±0.21 
 4 8.73 ± 0.33 9.1 ± 0.22 8.79 ± 0.67 8.86 ± 0.2b 8.75 ±0.19 8.47 ± 0.4 8.45 ±0.31 
 8 8.93 ± 0.29 8.87 ± 0.61 8.95 ± 0.63 9.12 ±0.21 9.25 ±0.04a,b 9.31 ± 0.1a,b 8.53 ±0.13 
 24 9.2 ± 0.06 9.31 ± 0.03a 9.19 ± 0.08a 9.12 ±0.21 9.2 ± 0.07a,b 9.24 ±0.04a 8.25 ±0.07 
Bac303 0 8.26 ± 0.16 8.23 ± 0.35 8.27 ± 0.33 8.33 ±0.25 8.33 ± 0.3 8.2 ± 0.19 8.26 ±0.29 
 4 8.07 ± 0.55 8.41 ± 0.53 8.09 ± 0.86 8.49 ±0.15 7.94 ±0.26a 8.39 ±0.12 7.75 ±0.83 
 8 7.33 ± 064 7.83 ± 0.82 8.11 ± 0.66 8.31 ±0.46 7.88 ±0.32 8.63 ±0.19 6.71 ±0.37a 
 24 7.78 ± 0.05a 8.39 ± 0.15 7.06 ± 0.2a 7.94 ±0.03b 8.41 ±0.06 8.29 ±0.04 8.39±0.2a,c 
Erec482 0 8.35 ± 0.16 8.34 ± 0.13 8.42 ± 0.03 8.34 ±0.06 8.38 ±0.09 8.3 ± 0.04 8.32 ±0.05 
 4 8.29 ± 0.12 8.39 ± 0.15 8.17 ± 0.31 8.4 ± 0.21 8.36 ± 0.2 8.24 ±0.34 8.08 ±0.43 
 8 7.85 ± 1.21 7.92 ± 1.42 7.88 ± 1.22 7.91 ±1.36 8.45 ±0.08 8.38 ±0.38 7.98 ±0.76 
 24 8.85 ± 0.37a,b 8.65 ± 0.06a 7.94 ± 0.04a 8.58 ±0.01a 8.59 ±0.01a 8.56 ±0.04a 8.06±0.05a 
Rrec584 0 8.34 ± 0.25 8.24 ± 0.08 8.06 ± 0.54 8.15 ± 0.3 8.17 ±0.17 8.28 ±0.09 8.34 ±0.04 
 4 7.54 ± 1.04 8.13 ± 0.3 7.85 ± 0.59 8.2 ± 0.41 7.29 ±0.86 7.77 ±0.62 7.78 ±0.69 
 8 7.06 ± 0.87 7.47 ± 0.74 7.37 ± 0.78a 7.71 ±0.98 7.21 ±0.78 7.6 ± 0. 56 7.66±0.21a 
 24 7.2 ± 0.02 7.14 ± 0.05a,b 6.92 ± 0.01 7.78 ±0.14 7.23 ±0.06a 8.51 ±0.03a 7.54 ± 0.2a 
Chis150 0 5.83 ± 0.2 5.73 ± 1.1 5,83 ± 0.2 5,73 ± 1.1 5.93 ± 0.3 5.73 ± 1.1 5.73 ± 1.1 
 4 5.86 ±0.04 6.34 ± 0.5 5.79 ± 0.1 6.56 ± 0.6 6.11± 0.2 6.2 ± 0.3 5.9 ± 0.1 
 8 6.03 ± 0.1 6.74 ± 1 6.53 ± 1 6.80 ± 1.1 6.92 ± 1.3 7.24 ± 0.8 5.87 ± 0.2 
 24 5.73 ± 0.02 5.73 ± 0.05 7.45 ± 0.01 5.73 ± 0.2 6.43 ± 0.03 5.73 ± 0.01 5.73 ±0.01 
Prop853 0 7.98 ± 0.18 7.97 ± 0.27 8.05 ± 0.22 8.18 ±0.26 8.16 ±0.22 8.08 ±0.22 8.04 ±0.06 
 4 8.04 ± 0.28 7.97 ± 0.02 7.81 ± 0.47 8.02 ±0.09 8.02 ±0.05 8.11 ±0.09 7.99 ±0.19 
 8 7.84 ± 0.37 7.74 ± 0.48 7.83 ± 0.37 7.85 ±0.68a 7.67 ±1.03a 8.16 ± 0.3a 7.76±0.08a 
 24 8.19 ± 0.01b,c 7.99 ± 0.01 7.95 ± 0.04a,b 6.53 ± 0.02b 6.15 ± 0.06b 8.72 ± 0.01b, c 8.1 ±0.07c 
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2.4 Discussion 
The present study was carried out in order to evaluate the in vitro fermentation 
properties of B-GOS (65 % GOS content) in pH- and volume-controlled batch culture 
fermentation. The fermentability and selectivity of GOS have been previously evaluated 
in vitro by several comparative studies. Rycroft et al. (2001) compared the efficacy of 
different prebiotics including FOS and GOS in 24-h batch culture experiments, and the 
results showed how GOS induced the largest significant increases in bifidobacteria, 
lactobacilli and total bacterial numbers during fermentation (Rycroft 2001). In our study, 
administration of B-GOS showed the same trend, especially considering bifidobacteria 
and lactobacilli populations. There was also a significant decrease in Bacteroidetes 
numbers, except for 52 % B-GOS at 0·05 g/l and 65 % B-GOS at 0·033 g/l. The 65 % B-
GOS also had a strong influence in the production of SCFA, compared with B-GOS that 
is commercially available (52% GOS content). Our results showed a double increase in 
acetate production at all doses using 65 % B-GOS, but were not significant, except for 65 
% B-GOS at 0·033 g/l, probably due to the high standard deviation. 
The fermentation of all different doses induced the production of acetate, which 
correlated with an increase in Bifidobacterium populations (Macfarlane 2008). Palframan 
et al. (2002) in a study comparing the effect of the pH and dose on batch culture 
fermentation of five commercial prebiotics have shown similar results. FISH analysis 
showed how highest bacterial numbers were obtained with GOS at pH 6 and 1% (w/v) 
(Palframan 2002). The global effect on the bacterial population of 52% B-GOS has been 
tested in a previous fermentation study where the commercial B-GOS mixture was 
compared with different purified GOS. Using Selectivity Index (SI) as an estimate for the 
growth of beneficial bacteria, Rodriguez-Colinas et al. (2013) have shown that 52 % B-
GOS had the highest SI, and consequently a strong degree of selectivity for 
Bifidobacterium population. 
Our results highlighted that 65 % GOS had an effective prebiotic activity, in 
terms of increasing numbers of bifidobacteria and metabolite production. This was 
especially seen for acetate, probably due to the lower content of monosaccharides and 
disaccharides in the mixture that might have affected in vitro fermentation experiments 
overall. However, a previous study of Costabile et al. (2014) demonstrated that the 
carbohydrates that remained following in vitro pre-digestion processes did not have any 
selective properties to invoke a bifidogenic effect, which perhaps would not persist in 
vivo (Costabile 2015). 
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In our study, major changes in other bacterial populations were seen, which might be due 
to the presence of these sugars. Different concentrations of SCFA have been identified at 
time 0, but it may be explained by the high inter-individual variability among each 
individual. Significant differences were observed between the time points in all analyses 
but not between the two substrates. 
The effects of B-GOS 52 % as a potential modulator of the gut microflora and the 
immune system have been extensively investigated in several human intervention 
studies. The 65% B-GOS has shown a significant modulation of health-promoting 
beneficial bacteria, and our findings proved that reducing impurities in the prebiotic 
mixture might improve the selectivity of prebiotics in in vitro experiments. However, the 
comparison between the effect of 65 % B-GOS and 52 % B-GOS has shown similar 
bifidogenic effects (data not published). The applicability of such changes remains to be 
investigated in in vivo human intervention studies. 
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Abstract 
Children with autism spectrum disorders (ASD) often suffer gastrointestinal problems 
consistent with imbalances in the gut microbial population. Treatment with antibiotics or 
pro/prebiotics has been postulated to regulate microbiota and improve gut symptoms, but 
there is a lack of evidence for such approaches, especially for prebiotics. This study assessed 
the influence of a prebiotic galactooligosaccharide (B-GOS) on gut microbial ecology and 
metabolic function using faecal samples from autistic and non-autistic children in an in vitro 
gut model system. Bacteriology was analysed using flow cytometry combined with 
fluorescence in situ hybridisation and metabolic activity by HPLC and 1H-NMR. Consistent 
with previous studies, the microbiota of ASD children contained a higher number of 
Clostridium spp. and a lower number of bifidobacteria compared to non-autistic children. B-
GOS administration significantly increased bifidobacterial populations in each compartment 
of the models, both with autistic and non-autistic derived samples, and lactobacilli in the 
final vessel of non-autistic models. In addition, changes in other bacteria were seen in 
particular for Clostridium, Roseburia, Bacteroides, Atopobium, F. prausnitzii, Sutterella spp. 
and Veillonellaceae. Furthermore, the addition of B-GOS to the models significantly altered 
short chain fatty acid production in both groups, and increased ethanol and lactate in autistic 
children inocula. 
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3.1 Introduction 
Autism typically develops in childhood, and is considered as “a systemic spectrum 
disorder with multiple development trajectories with an incidence four times higher in males 
than in females” (Grossi 2014). In addition to behavioural traits, GI abnormalities such as 
diarrhoea, constipation, bloating, and abdominal pain are common in autism and they seem 
to contribute to, and exacerbate, overall behaviour of children (irritability, sleeplessness, 
posturing) (Van De Sande 2014). A cross talk exists between the gut microbiota and central 
nervous system (CNS) mediated via a range of different chemical, immunological and 
signalling interactions that form part of the gut-brain axis. Several studies have demonstrated 
the role of the gut microbiota in neurodevelopment and mental health (Foster 2013) and 
there is increasing evidence associating gut microbial dysbiosis with GI problems that might 
affect autistic children.  
Bacteria such as Clostridium spp., Desulfovibrio spp. and Streptococcus spp. are 
dominant in the guts of ASD children. Finegold et al. found nine unique species of clostridia 
in autistic children compared to controls (Finegold 2002). Song et al., using qPCR analysis, 
found higher levels of C. boltea and Clostridium cluster I and XI (Song 2004). Furthermore, 
Parracho and co-authors, using FISH analysis, found greater number of species derived from 
the C. histolyticum group (Clostridium clusters I and II) (Parracho 2005). Desulfovibrio 
group was found to be ten times higher in the gut microbiota of autistic children compared to 
controls (Finegold 2010; Finegold 2011).  
High-throughput sequencing has been used in more recent studies to determine 
bacterial composition of faecal samples from autistic children. The genera Prevotella, 
Coprococcus, and unclassified Veillonellaceae have been found in lower abundance in 
autistic individuals (Kang 2013) with high genus Sutterella spp. (Wang 2013; William 
2012). In addition, Bifidobacterium species decreased in ASD, comparing to non-autistic 
control (De Angelis 2013).  
 Metabolic associations have also been identified with ASD and may be attributed to 
gut dysbiosis in autistic individuals. Abnormalities have been reported in tryptophan 
metabolism where higher amount of indole derivates in the blood and higher levels of IAG 
(indolyl-acryuloyl-glycine) in the urine of autistic children have been identified. Increased 
abundance of Clostridium spp. in the ASD-associated microbiota may contribute to these 
metabolic alterations as these microorganisms can metabolise tryptophan (Bingham 2003). 
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Metabonomic studies also identified alterations in nicotinic acid metabolism (Yap 2010) and 
amino acid deficiencies in autism with restricted diets, modified gut microbial population 
and GI symptoms being suggested as potential contributors (Ming 2012).  
Modulation of the gut microbiota is an interesting potential strategy to reduce the 
presence of harmful microorganisms and their metabolites that might be involved in negative 
stimulation of CNS and affect behaviour (Shaw 1995; Sandler 2000 ). Treating GI disorders 
in ASD with antibiotics or pro/prebiotics has been postulated to regulate microbiota and 
improve gut symptoms, but the evidence is scarce, especially for prebiotics.  
The bifidogenic properties of B-GOS (Bimuno®, Clasado Biosciences Ltd., 
Buckinghamshire, UK) have been investigated in vitro and in human intervention studies 
involving healthy volunteers, and conditions that have a purported microbial input such as 
IBS, travellers’ diarrhoea and obesity (Tzortzis 2005;  Depeint 2008;  Vulevic 2008; Silk 
2009;  Drakoularakou 2009;  Vulevic 2013). Recently, B-GOS was also shown to reduce 
cortisol secretion and anxiety in healthy volunteers (Schmidt 2015). Cortisol is a reliable 
marker of stress and hypothalamic pituitary adrenal (HPA) axis activity. B-GOS 
supplementation lowered cortisol reactivity and modulated attention to emotional stimuli 
compared to a placebo group, supporting the hypothesis that the gut microbiota might have a 
role in behavioural traits (Schmidt 2015). 
Our study aimed to assess the effects of B-GOS (65% GOS content) on gut microbial 
ecology and metabolic end products of microbial fermentation. We used in vitro, three-stage, 
continuous gut model systems, inoculated with faecal samples of autistic and non-autistic 
children, that simulated different physicochemical characteristics of the proximal, transverse 
and distal colons.  
 
3.2 Materials and methods 
3.2.1 Substrate 
The B-GOS product was supplied by Clasado Biosciences Ltd. The mixture was in 
syrup format consisting of 65% (w/v) GOS, 10.1% (w/v) lactose, 22% (w/v) glucose, 1.8% 
(w/v) galactose.  
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3.2.2 Faecal inoculation 
Faecal samples were obtained from three non-autistic children and three autistic child 
donors (male, aged 5-10 years-old) who were free of any metabolic and gastrointestinal 
diseases, were not taking probiotic or prebiotic supplements, and had not taken antibiotics 6 
months before faecal sample donation. Autistic children had formal diagnosis of mild 
autism. None of the children followed any specific or restricted diet. 
All parents then provided written informed consent for use of their children’s faeces in the 
study. This study was approved by The University of Reading research Ethics Committee 
(UREC 15/20). Faecal samples were placed in an anaerobic jar (AnaeroJarTM 2.5 L, Oxoid 
Ltd) including a gas-generating kit (AnaeroGenTM, Oxoid). Aliquots of 20 g of samples 
were diluted in 100 ml anaerobic PBS (0.1 mol/L phosphate buffer solution, pH 7.4, w/w) 
and homogenised (Stomacher 400, Seward, West Sussex, UK) for 2 minutes at 240 paddle 
beats per minute. Samples were added to anaerobic fermenters within 15 minutes of voiding. 
 
3.2.3 Three stage continuous culture gut model system 
Physicochemical conditions in the colon were replicated in a continuous culture 
system, comprised of a cascade of three glass fermenters of increasing working volume 
connected in series. A small scale version of the validated system described by Macfarlane et 
al. (1998) was used in this study, with vessels (V) representing the proximal (V1, 80ml, 
pH=5.5), transverse (V2, 100ml, pH=6.2), and distal colon (V3, 120ml, pH=6.8). The 
systems were inoculated with 20% (w/v) faecal homogenate from either non-autistic and 
autistic children volunteers in a growth medium (Macfarlane 1998). Following inoculation, 
the colonic model was run as a batch culture for 24 h in order to stabilise bacterial 
populations prior to the initiation of medium flow. After 24 h (T0), the medium flow was 
initiated and the system ran for at least 8 full volume turnovers to allow for steady state to be 
achieved (SS1). SCFA profiles (+/-5%) were assessed before starting B-GOS administration. 
Taking into account the operating volume (300 mL) and retention time (48 h, flow rate 6.25 
mL/h) of the colonic model system, a syrup containing GOS (2g/daily, equivalent to 1g of 
GOS) was added daily into V1. The syrup was added to the system for at least a further 8 
volume turnovers upon which steady state 2 (SS2) was achieved. Aliquots of 4.5 mL were 
removed at SS1 and SS2. 
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3.2.4 Short chain fatty acids (SCFAs) analysis by HPLC 
The production of SCFAs in the fermentations was determined by HPLC (Merck, 
NJ) as previously described by Rodriguez-Colina et al. 2013. Twenty µL of each sample was 
injected with a run time of 45 min. Peaks were integrated using Atlas Lab managing 
software (Thermo Lab Systems, Mainz, Germany). Quantification of the samples was 
obtained through calibration curves of lactic, acetic, propionic, butyric and formic acids in 
concentrations of 12.5, 25, 50, 75 and 100 mM. 
 
3.2.5 In vitro enumeration of bacterial population by FISH-FCM 
Bacterial composition in the gut models was analysed for using fluorescence in situ 
hybridisation combined with flow cytometry (FISH-FCM). 750 µl of samples were 
centrifuged at 1136 x g for 5 min. Pellets were re-suspended in 375 µL of filtered PBS 
(using a 0.22 µm PVDF membrane) and fixed in 1125 µL of 4% (v/v) paraformaldehyde. 
After 4 hours incubation at 4 °C, samples were washed twice using 1 mL of PBS, re-
suspended in 600 µL PBS-ethanol (1:1, v/v) and stored at -20 °C. Permeabilisation steps 
were performed using 30 µL of the fixed samples added to 500 µL PBS and centrifuged at 
1136 x g for 3 min. Pellets were re-suspended using 100 µL of filtered TE-FISH (Tris/HCl 1 
M pH 8, EDTA 0.5 M pH 8, distilled H2O, 0.22 µm PVDF membrane) containing lysozyme 
(1 mg/mL of 50,000 U/mg protein) and incubated for 10 min at room temperature. Solutions 
containing the samples were then vortexed and centrifuged at 1136 x g for 3 min. Pellets 
were washed with 500 µL PBS and centrifuged (1136 x g, 3 min). Hybridisations were 
performed by re-suspending the pellets in 150 µL of hybridisation buffer (5M NaCl, 1M 
Tris/HCl pH8, 30% formamide, ddH2O, 10% SDS), vortexed and centrifuged (1136 x g, 3 
min). Pellets were then re-suspended in 1 mL of hybridisation buffer and 50 µL aliquoted 
into Eppendorf tubes. The probes used (Sigma Aldrich Ltd., Poole, Dorset, UK) are reported 
in Table 3.1 (Wallner 1993;  Daims 1999;  Langendijk 1995;  Harmsen 1999;  Manz 1996;  
Franks 1998;  Walker 2005;  Harmsen 2000;  Hold 2003;  Devereux 1992;  Poulsen 1995;  
Harmsen 2002;  Lay 2005; Stoffels 1998; Kong 2012). NON EUB338 and EUB338 I-II-III 
linked at their 5’ end either to Alexa488 and Alexa647. Group specific probes were linked 
with Alexa647 at their 5’ end. 4µL of each probe and 4 µL of Eub338 I-II-III (linked to 
Alexa488) were added to the working solution and incubated overnight at 35°C in a heating 
block. After 12 hours incubation, an aliquot of 150 µL hybridisation buffer was added to the 
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working solution, vortexed and centrifuged (1136 x g, 3 min). 150 µL of supernatant was 
removed from each sample and the remaining volume centrifuged (1136 x g, 3 min).  The 
pellets were washed with 200 µL of washing buffer (5M NaCl, 1M Tris/HCl pH8, 0.5 M 
EDTA pH8, ddH2O, 10% SDS), homogenised by vortexing and incubated for 20 min at 37 
°C in a heating block. Afterwards the samples were centrifuged (1136 x g, 3 min) and 
supernatants removed. Negative control samples (no probes added) were screened by flow 
cytometry to detect background before the probe samples were re-suspended in an 
appropriate amount of PBS. Samples were stored at 4 °C until determinations. Numbers of 
specific and total bacteria were determined taking into account dilution factor (DF), calculate 
from different volumes used in samples preparation steps, and events/µl obtained from NON 
EUB338 and EUB338 I-II-III probes analysed by flow cytomotry. 
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Table 3.1. Oligonucleotide probes used in this study for FISH-FCM analysis of bacterial populations. +: These probes are used together in equimolar concetration of 
50 ng/μl. 
PROBE NAME SEQUENCE (5’ TO 3’) TARGET GROUP REFERENCE 
Non Eub ACTCCTACGGGAGGCAGC  Wallner 1993 
Eub338 I + GCT GCC TCC CGT AGG AGT Most Bacteria Daims 1999 
Eub338 II + GCA GCC ACC CGT AGG TGT Planctomycetales Daims 1999 
Eub338 III + GCT GCC ACC CGT AGG TGT Verrucomicrobiales Daims 1999 
Bif164 CAT CCG GCA TTA CCA CCC Most Bifidobacterium spp. and Parascardovia denticolens Langendijk 
1995 
Lab158 GGTATTAGCAYCTGTTTCCA Most Lactobacillus, Leuconostoc and Weissella spp.; Lactococcus lactis; all Vagococcus, 
Enterococcus, Melisococcus, Tetragenococcus, Catellicoccus, Pediococcus and Paralactobacillus 
spp 
Harmsen 1999 
Bac303 CCA ATG TGG GGG ACC TT Most Bacteroidaceae and Prevotellaceae, some Porphyromonadaceae Manz 1996 
Clit135 GTTATCCGTGTGTACAGGG  Some of the Clostridium lituseburense group (Clostridium cluster XI) Manz 1996 
Erec482 GCT TCT TAG TCA RGT ACCG Most of the Clostridium coccoides-Eubacterium rectale group 
(Clostridium cluster XIVa and XIVb) 
Manz 1996 
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium histolyticum group (Clostridium cluster I and II) Franks 1998 
Rrec584 TCA GAC TTG CCG YAC CGC Roseburia sub cluster Franks 1998 
Prop853 ATT GCG TTA ACT CCG GCAC Clostridial Cluster IX Walker 2005 
Ato291 GGT CGG TCT CTC AAC CC Atopobium, Colinsella, Olsenella and Eggerthella spp.; Cryptobacterium curtum; Mycoplasma 
equigenitalium and Mycoplasma elephantis 
Harmsen 2000 
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii and related sequences Hold 2003 
DSV687 TAC GGA TTT CAC TCC T Most Desulfovibrionales (excluding Lawsonia) and many Desulfuromonales Devereux 1992 
EC1531 CACCGTAGTGCCTCGTCATCA  Escherichia coli BJ4 Poulsen 1995 
Rbro730 + TAAAGCCCAGYAGGCCGC  Clostridium sporosphaeroides, Ruminococcus bromii, Clostridium leptum Harmsen 2002;  
Lay 2005 
Rfla729 + AAA GCC CAG TAA GCC GCC Ruminococcus albus, R. flavefaciens Harmsen 2002;  
Lay 2005 
SUBU1237 CCC TCT GTT CCG ACC ATT Burkholderia spp., Sutterella spp. Stoffels 1998 
Vei723 ACA CAG TCC AGA AAG GCG Veillonellaceae Kong 2012 
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3.2.6 Metabolic analysis by 1H-NMR 
Three consecutive days of the three biological replicates for each group (autistic and 
non-autistic) of all time points (before and after treatment) were analysed by 1H-NMR 
(n=27, each group). Fermentation supernatants were defrosted, vortexed and centrifuged at 
599 x g for 5 minutes. The supernatants were filtered using 0.22µm low protein binding 
Durapore polyvianylidene fluoride (PVDF) membranes (Millex; EMD Millipore, Billerica, 
MA, USA) and 400 µL transferred into fresh Eppendorf tubes. Filtered samples were 
combined with 200 µL of phosphate buffer (0.2 M (pH 7.4) in D2O plus 0.001% TSP), 
mixed by vortexing, centrifuged at 1136 x g for 10 minutes and then 550 µL was transferred 
into 5 mm NMR tubes for analysis. All NMR spectra were acquired on a Bruker Avance 
DRX 500 MHz NMR spectrometer (Bruker Biopsin, Rheinstetten, Germany) operating at 
500 MHz. They were acquired using a standard one-dimensional (1D) pulse sequence 
[recycle delay (RD)-90°-t1-90°-tm-90°-acquire free induction decay (FID)] with water 
suppression applied during RD of 2 s, a mixing time Tm of 100 ms and a 90 pulse set at 7.70 
μs. For each spectrum, a total of 128 scans were accumulated into 64 k data points with a 
spectral width of 12.001 ppm. The FIDs were multiplied by an exponential function 
corresponding to 0.3 Hz line broadening.  
 
3.2.7 Data Preprocessing and Analysis 
All spectra were manually phased, baseline corrected and calibrated to the chemical 
shift of TSP (3-(trimethylsilyl)-[2,2,3,3,-2H4]-propionic acid, δ 0.00). Spectra were digitised 
using an in-house MATLAB (version R2014a, The Mathworks, Inc.; Natwick, MA) script. 
The spectral region containing the water resonance was removed to minimise distortions in 
the baseline arising from imperfect water saturation. Median fold normalisation was 
performed for both groups, non-autistic and autistic children. Before and after administration 
of B-GOS, principal components analysis (PCA) using mean-centred data was applied. 
Orthogonal projection to latent structure discriminant analysis (OPLS-DA) models were 
constructed using unit variance scaling for pairwise comparisons of the different 
experimental groups and time points. Correlation coefficients plots were generated from the 
model outputs by back-scaling transformation to display the contribution of each variable 
(metabolites) to sample classification (e.g. before and after treatment). Colour represents the 
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significance of correlation (R2) for each metabolite to class membership. Predictive strength 
(Q2Y) of the models was obtained using a seven-fold cross validation method and these were 
validated using permutation testing (number of permutations=10,000). 
 
3.2.8 Statistical analysis 
Data from HPLC and FMC-FISH analyses were analysed using paired T-test in order 
to assess significance of results, comparing the two time points SS1 and SS2, before and 
after treatment respectively. Statistical significance was at P<0.05 for all analyses. Analyses 
were performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). 
 
3.3 Results 
3.3.1 Bacterial enumeration 
  Changes in bacterial compositions in gut model systems are reported in Figure 3.1. 
The data showed lower numbers of bifidobacteria in ASD models compared to non-autistic. 
Significant increases in Bifidobacterium spp, following addition of B-GOS to models 
containing both autistic and non-autistic samples were seen. In autistic models, a significant 
increase of bifidobacteria occurred from 5.32 to 7.27 log10 cells/ml (P<0.01), from 4.81 to 
6.79 log10 CFU/ml (P<0.001) and from 5.57 to 6.83 log log10 cells/ml (P<0.05), in V1, V2 
and V3 respectively. A slight but significant increase in Clostridium cluster XI in V2 for 
autistic children was also found, as well as significant decrease in V2 in Veillonellaceae 
group from 6.06 to 5 log10 CFU/ml (P<0.05). In non- autistic models, there was a significant 
increase in numbers of bifidobacteria in V1, from 5.83 to 7.16 log log10 cells/ml (P<0.01), 
and in V3, from 4.97 to 6.73 log10 cells/ml (P<0.001) and in lactic acid bacteria (Lab158) in 
V3 from 5.13 to 6.01 log10 cells/ml (P<0.05). Additionally, B-GOS slightly increased 
Roseburia spp. in V1 and 3 (P<0.05) and reduced Atopobium spp. from 6.06 to 5.28 log10 
cells/ml and F. prausnitzii from 6.78 to 5.27 log10 cells/ml (P<0.05 for both) in the second 
vessel, while increasing Atopobium spp. from 5 to 5.92 log10 cells/ml (P<0.05) in the third 
vessel of non-autistic models. In these models, numbers of Clostridium coccoides - 
Eubacterium rectale were also increased from 6.76 to 7.08 log10 cells/ml (P<0.01) in V1 and 
Sutterella spp. significantly decreased in V1 from 7.05 to 6.49 (P<0.01) and V2 from 7.02 to 
6.37 log10 CFU/ml (P<0.05) after B-GOS administration. There was a general trend to 
increase all other bacterial groups analysed in all vessels but this was not significant. 
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Exceptions were seen for Bacteroides (V1), Clostridial Cluster IX (V1), F. prausnitzii (V1), 
E. coli (V3), Ruminococcus spp., Clostridium leptum (V2), Sutterella spp. and 
Veillonellaceae (all vessels) in autistic models, and for Clostridium coccoides - Eubacterium 
rectale (V2), Atopobium spp. (V1), Clostridial Cluster IX (V2), Clostridium cluster XI (V1, 
V2), E. coli (V2), Sutterella spp. and Veillonellaceae (all vessels) in non-autistic models that 
slightly decreased.  
 
3.3.2 Short chain fatty acids production 
SCFAs concentrations are presented in Figure 3.2. Data show a lower concentration 
of butyrate and propionate in autistic models, compared to non-autistic models, but no 
differences in acetate before adding B-GOS into the system. After administration of B-GOS, 
acetate and butyrate were the main end products of microbial fermentation. Supplementation 
of B-GOS to gut models inoculated with faecal samples from autistic children, led to a 
significant increase of acetate and butyrate in V1 and V2, simulating the proximal and 
transverse colons (P<0.05) respectively, while concentration of propionate was decreased 
(P<0.05) in V3 mimicking distal colon. In models simulating the colon of non-autistic 
children, fermentation of B-GOS mediated significant production of acetate (P<0.05) and 
butyrate (P<0.001) in V2 and V3, simulating the transverse and distal colons respectively. 
There was no effect on propionate.  
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Figure 3.1: Bacterial groups detected by FISH-FCM (Log10 CFU/ml) in culture broth recovered from each vessel (V1, V2 
and V3) of a colonic model before (SS1) and after (SS2) the daily administration of B-GOS (2g/d, equivalent to 1g GOS). 
Significant difference after the treatment: * P<0.05; **P<0.01; ***P<0.001. Probes: Total bacteria (Eub338I-II-III), 
Bifidobacterium spp. (Bif164), Lactobacillus spp. (Lab158), Most Bacteroidaceae and Prevotellaceae (Bac303), 
Clostridium coccoides-Eubacterium rectale group (Erec482), Roseburia sub cluster (Rrec584), F. prausnitzii (Fprau655), 
Atopobium spp. (Ato291), Clostridium cluster XI (Clit135), Sutterella spp. (SUBU1237), Veillonellaceae (VEI732). (A) 
autistic children; (B) non-autistic children. 
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Figure 3.2: HPLC analysis. Acetate, propionate and butyrate concentrations in culture broths 
recovered from vessels (V1, V2 and V3) of in vitro gut model systems before (SS1) and after 
(SS2) administration of B-GOS (1g/daily GOS). Results are reported as means (mM) of the data 
(n=3): A) autistic children and B) non-autistic children. Significant difference after the treatment: 
* P<0.05; ***P<0.001. 
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3.3.3 1H-NMR Spectroscopic Profiles 
PCA analysis was performed on mean-centred data to summarise variance with the 
dataset. The scores plot (PC1 versus PC2) shown in Figure 3.3A, showed separation between 
autistic and non-autistic models after treatment, indicating that B-GOS supplementation 
contributed to the largest source of variance in the metabolic data. Comparison of the spectra 
profiles from gut models before and after treatment identified that a number of metabolites 
changed following B-GOS supplementation to characterise the metabolic variation 
associated with ASD, B-GOS supplementation and differences in microbial response to B-
GOS between the ASD and non-ASD microbiota. The results of these analysis are 
summarised in Figure 3.3B. A significant OPLS-DA model was obtained comparing 
metabolic profiles of autistic and non-autistic models at baseline (Q2Y = 0.07; P < 0.05; 
Figure 3.4C-I). Supernatants from the autistic models contained greater amounts of ethanol, 
glycine, tyrosine, tyramine, 5-aminopentoanate, acetate, 4-aminobutyrate and betaine, 
compared to the non-autistic models and lower amounts of butyrate. B-GOS 
supplementation was found to modulate metabolic profile of the autistic models (Q2Y = 
0.08; P < 0.05) increasing ethanol, lactate, acetate and butyrate and decreasing propionate 
and trimethylamine (Figure 3.4B-I). Increased butyrate and acetate production was also 
observed in the non-autistic models following the addition of B-GOS (Q2Y = 0.12; P < 0.01; 
Figure 3.4B-II). Comparing metabolic profiles of the autistic and non-autistic models after 
B-GOS feeding (Q2Y = 0.17; P < 0.01) revealed that metabolic variation was reduced 
(Figure 3.4C-II). There was no longer variation in 4-aminobutyrate between the models, 
however the difference in ethanol and acetate between autistic and non-autistic models was 
increased being higher in the autistic models.  
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Figure 3.3: 1H-NMR data analysis. (A) PCA score plot show a separation between models inoculated with stool samples of non-ASD and ASD children after administration 
of B-GOS. Dark and light blue dots represent replicates of samples from gut models inoculated with faecal samples of autistic children, before (SS1) and after (SS2) treatment 
respectively. Yellow and red dots represent replicates of samples from gut models inoculated with faecal samples of non-autistic children, before (SS1) and after (SS2) 
treatment respectively. (B) Correlation coefficients indicating the associations of identified metabolites with autism and their alteration upon B-GOS administration. SS1: before 
treatment; SS2: after treatment. White cells represent no significant correlations. 
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Figure 3.4: (B-C) OPLS-DA model constructed from NMR spectra of the culture broth recovered from each 
vessel (V1, V2 and V3) of the colonic model discriminating between before (SS1) and after (SS2) the daily 
administration of B-GOS (1g/daily GOS) in autistic and non-autistic model models. B shows the comparison 
between before and after treatment in autistic (I) and non-autistic children (II). C shows the comparison 
between the combined data of autistic and non-autistic models before (I) and after (II) B-GOS supplementation. 
Compounds identified: Acetate, butyrate, propionate, lactate, ethanol, glycine, betaine, 5-aminopentoanate, 4-
aminobutyrate, tyrosine, tyramine, trimethylamine (TMA). 
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3.4 Discussion 
Recent studies have focused on influences of pre/probiotics on the gut-brain axis (Liu 
2015). This study investigated B-GOS on a small scale, in vitro, gut model system 
inoculated with faeces from autistic and non-autistic children. The results showed a positive 
modulation of bacterial populations, using an automated FISH method combined with flow 
cytometry. We also assessed metabolic profiles and key metabolites in both test groups.  
Lower concentrations of SCFAs have previously been found in ASD children by 
Adams et al. suggesting reduced fermentation capacity by the ASD microbiota. It was 
hypothesised that this was due to a compromised microbiota characterised by lower numbers 
of bifidobacteria, consistent with microbial signatures observed here (Adams 2011). 
Concomitant with these population changes, functional alterations were also observed in 
both autistic and non-autistic models with acetate and butyrate being increased.  
Recent studies have focused on SCFAs and their effect on the CNS. These 
fermentation products can cross the blood-brain barrier and might influence early brain 
development. Synthesis of neuroactive compounds such as dopamine and serotonin can be 
modulated by SCFA and they are able to produce reversible psychological and physiological 
changes in rats similar to those found in ASDs (Wang 2011). Experimental evidence using 
intraventricular infusion in rats indicates that propionic acid can produce brain and 
behavioural changes similar to ASD (MacFabe 2008).  
Recent ASD studies have shown increase in numbers of Sutterella spp. and decrease 
in Veillonellaceae group. In this study, results did not show any significant differences 
between ASD and non-ASD group. However, a general decrease in those bacterial groups 
after treatment was highlighted, suggesting that B-GOS administration might have an impact 
on the growth of ASD-associated bacteria.  
Following B-GOS feeding, the microbiota of autistic children produced greater 
amounts of ethanol and lactate while the amount of amino acids and the SCFA propionate, 
present in the model, was reduced. These metabolic alterations were not observed when the 
faecal microbiota of non-autistic individuals were fed B-GOS. In a healthy colon, lactate 
production is generally low due to its conversion to other organic acids by many bacteria and 
because lactate can be used as a substrate for dissimilation of sulphate (e.g. by Desulfovibrio 
spp.) (Flint 2014;  Marquet 2009;  Fite 2004). In ASD children, presence of lactate is 
interesting because its accumulation has been associated with neurological problems, in 
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particular studies show the effect of lactate infusion on anxiety and panic disorders (Dillon 
1987;  Cowley 1987). Cowley and colleagues, in their findings, showed that lactate infusion 
in patients suffering from panic disorder, provoked higher panic symptom reactions 
compared to controls (Dillon 1987). Dillon et al. have showed similar results in in vivo, 
where panic and anxiety reaction has been measured using Acute Panic Inventory (API) 
scores. After lactate infusions scores were much higher in patients with panic and anxiety 
disorders compared to normal controls (Cowley 1987). 
The lysine degradation product, 5-aminopentanoic acid, was also higher in the 
autistic compared to the non-autistic models. This metabolite can be produced both 
endogenously or through the bacterial catabolism of lysine. It is believed to act as a 
methylene homologue of γ-aminobutyric acid (GABA) and functions as a weak GABA 
agonist (Callery 1985). Interestingly, GABA was also higher in the autistic models 
compared to the non-autistic models pre-treatment, but these differences were not evident 
following B-GOS treatment. Certain bacteria, such as lactobacilli, are able to produce 
molecules that acts as neurotransmitters and directly affect the brain (Wall 2014). Here, its 
reduction might be due to changes in gut microbiota composition.  
Ethanol was found in higher amount in ASD children comparing to non-ASD. The 
vast majority of bacteria form ethanol from acetyl-CoA and the glycolytic pathway 
(Macfarlane 2003). Microorganisms are able to oxidase ethanol and the impact of bacterial 
overgrowth on ethanol production has previously been studied (Baraona 1986). Metabolism 
of ethanol can lead to the production of toxic end-products such as acetaldehyde, which may 
affect the gastrointestinal mucosa. The role of acetaldehyde in ASD has been recently 
evaluated in particular in oxidative stress and DNA damage. Under healthy conditions, 
ethanol is converted into acetic acid in the liver by a two-step process involving alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Mutation of the ALDH gene 
has been shown to increase the accumulation of acetaldehyde and result in cancers within 
different regions of the gastrointestinal tract and Alzheimer’s disease (Jurnak 2015). The 
potential role of this toxic compound in neurological disorders, including autism, warrants 
further exploration.  
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3.5 Conclusions 
This in vitro study showed promising and positive results in that supplementing the 
microbiota of ASD children with 65%B-GOS may manipulate gut bacterial populations and 
alter metabolic activity towards a configuration that might represent a health benefit to the 
host. However, further work will be required to assess such changes in an in vivo human 
intervention study. 
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Abstract 
Evidence suggests that diet has a strong impact on the gut microbiota and its metabolic 
activity. Gluten- and casein-free diets are the most common dietary approaches in autism 
but, to date, it is not clear how and whether they can actually modulate autistic features, 
such as behavioural traits and/or GI problems. In this study, we recruited 30 autistic 
children, with formal diagnosis of ASD, who were following different diets: gluten-, 
casein- and dairy-free diet or un-restricted diet. We assessed the effect of these dietary 
habits on gut microbiota composition and metabolic profiles. In addition, we asked 
parents to fill in GI symptom diaries and 4-days food diaries in order to investigate 
nutrient intake and potential differences in GI issues. Results showed ASD children 
under gluten and casein-free diet to have significant reduction in abdominal pain and 
bowel movement and higher fibre intake, compared to the un-restricted dietary group. In 
addition, the exclusion diet group had reduced abundance of Bifidobacterium spp. and 
Veillonellaceae family, and increased F. prausnitzii and Bacteroides spp. In both groups, 
no significant differences were found in the urine metabolome, but significant 
correlations were found between bacterial populations and amino acids in faeces. Taken 
together, our findings indicate that exclusion diets impact gut microbiota composition 
and GI symptoms in ASD children but not enough to support their validity as treatment. 
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4.1 Introduction 
 Autism is a neurodevelopmental disorder characterized by impaired social 
interaction, verbal and non-verbal communication, and repetitive behaviour. In addition 
to cognitive aspects, ASD individuals might suffer from gastrointestinal (GI) problems 
(Kral et al. 2013).  
 Dietary interventions, including use of supplements, or exclusion diets have been 
suggested in ASD in order to reduce these issues. Gluten and casein-free (GFCF) diets 
are common within autistic individuals even though there is a lack of strong empirical 
evidence. Alterations in intestinal function have been often attributed to children who are 
on the autism spectrum (White 2003). It has been reported that autistic individuals might 
have increased gut permeability that could lead the passage of molecules, such as 
peptides from metabolism of gluten and/or casein, that could interact with central 
nervous system (CNS) and cause typical autistic traits (De Magistris et al. 2010). 
Observational studies reported how GFCF diets seem to alleviate GI problems and/or 
improve behavioural traits, according to parents/guardians reports, but association 
between the restricted diet and symptoms was not always apparent (Harris & Card 2012; 
Patel & Curtis 2007; Pennesi & Klein 2012). Some confounding outcomes have been 
seen in intervention studies, where only mood and behavioural aspects were evaluated. 
Some showed significant improvements in behavioural traits (Nazni 2008; Whiteley et 
al. 2010), while others reported no differences after treatment (Elder et al. 2006; Seung 
2007; Johnson 2011). More recent randomised trials, showed that ASD individuals 
tolerated gluten and casein introduction in their diet but limitations in these studies, such 
as participant number and/or short treatment period, lead to careful consideration of these 
findings (Pusponegoro et al. 2015; Hyman 2016).  
 It is well known that the diet influences bacterial community and its role in health 
and well being of the host (Salonen & De Vos 2014). Differences in food intake have 
been reported to modify the gut microbiota since early life, depending on breast or 
formula feeding (Liu et al. 2016), and later on in life according to food intake, lifestyle 
(De Filippis et al. 2014), allergies and diseases (Girbovan 2017).  
   To date, little is understood about the relationship between the exclusion diets 
and the gut microbiome in the context of autism. Many of these diets focus on 
carbohydrate, because ASD individuals appear to be defective in intestinal digestive 
enzymes responsible for carbohydrate digestion (Williams et al. 2011), but evidence is 
still relatively weak and sometimes inconsistent, as in the case with GFCF diets. Further 
 81 
studies on modified diets and food supplementation are needed not only to assess the 
efficacy of these diets, but also their impact on the gut microbiome and how its 
manipulation might influence autistic traits. 
Therefore the aim of this study was to investigate the impact of gluten, casein and 
dairy-free diets on gut bacterial composition and metabolite production in autistic 
children who were following these restricted diets and in comparison to those on un-
restricted diet.  
 
4.2 Materials and Methods 
4.2.1 Subjects 
Thirty volunteers (8 female and 22 male; mean age 7.7 years-old; range 4-11 
years) were included in the study. All participants had a formal diagnosis of ASD (Table 
4.1) and previous history of antibiotic treatment in early life. None of the volunteers had 
been treated with antibiotics, prebiotics or probiotics within 4 weeks before sample 
collection. The study was approved by the University of Reading Research Ethics 
Committee (UREC15/41; Registration number: NCT02720900) prior to the start of the 
study and informed consent was obtained from the volunteers’ parents. 
 
Table 4.1: Diagnosis reported from parents by medical assessment (*). ASD: Autism Spectrum 
Disorders; ADHD: Attention Deficit Hyperactivity Disorder; PDD: Pervasive Development Disorder 
Diagnosis* ASD ADHD Asperger PDD 
Volunteers (n) 30/30 5/30 2/30 1/30 
 
4.2.2 Dietary intervention and assessments 
Food diary records were kept for 4 consecutive days (Appendix 4.1) and subjects 
were divided in 2 groups according to the diet they were following: 12 children were on 
an exclusion diet (gluten, casein and dairy free diet) and 18 children were on an un-
restricted diet. At the front of the diary, detailed information on how to record food and 
beverages consumed using common household measures were provided. Food diaries 
were analysed using Diet-plan7 software (Forestfield Software Ltd.) 
 
4.2.3 GI symptoms 
Parents/guardians of child volunteers were asked to fill in daily questionnaires for 
GI function and symptoms (Appendix 4.2). The Bristol stool chart was used to assess 
faecal samples’ type and consistency, together with the number of bowel movements, 
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abdominal pain, intestinal bloating and flatulence (none, present but well tolerated, 
present and interfering with but not preventing normal daily activities, preventing normal 
daily activities; Lewis & Heaton 1997). Concomitant medication, adverse events, 
changes in diet and behaviour were also recorded throughout the study, on a separate 
sample submission forms (Appendix 4.3). 
 
4.2.4 Faecal sample collection and preparation 
Faecal samples were collected once a week for 3 weeks using faecal collection kit 
(FC2040, Laboratories Ltd, UK), and volunteers were asked to keep them at -20°C until 
the visit day, when they were transferred to the laboratory and processed. Samples for 
DNA extraction and 1H-NMR were weighed (~ 250 mg) and stored at -80°C until needed 
for analysis. 
 
4.2.5 Urine sample collection and preparation 
 Urine samples were collected using sterile tubes (Mid-Stream Urine Specimen 
Collector; Pennine Healthcare, UK) or sterile pads (Sterisets Urine Collection Kit; 
MediBargains, UK) and stored at -20°C until a visit day when they were processed. 
Samples were transferred to 15 ml falcon tubes, centrifuged for 10 min at 1136 x g, 
supernatant transferred to 1.5ml Eppendorf tube (duplicate) and stored at -80°C. 
 
4.2.6 DNA extraction and PCR 
Total microbial DNA was extracted from faeces using the DNA stool mini kit 
(Qiagen, UK) by introducing three 1-min steps at 50 movements/s using TyssueLyser LT 
(Qiagen, UK) with 5-min incubation in ice between treatments as previously described 
by Candela et al. 2016. Briefly thermal disruption of the samples was performed by 
incubation at 95°C for 15 min, then centrifuged for 5 min at 4°C to pellet stool particles. 
260 μl of 10 M ammonium acetate was added to the supernatant, incubated in ice for 5 
min and centrifuged at full speed for 10 min at 4°C. Supernatants were collected and one 
volume of isopropanol added and samples incubated in ice for 30 min. The samples were 
centrifuged for 15 min at 4°C and the pellet washed with 70% (v/v) ethanol. They were 
re-suspended in 100 μl of TE buffer (10 mM Tris-Cl, pH 7.5; 1 mM EDTA, pH 8.0) and 
treated with 2 μl of DNase-free RNase (10 mg/ml, Sigma-Aldrich) at 37°C for 15 min. 
Proteins were removed by adding 15 μl of proteinase K (DNA stool mini kit; Qiagen, 
UK) and DNA was subsequently purified following the manufacturer’s instructions. 
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DNA recovery was evaluated using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies). 
 
4.2.7 16S rRNA gene amplification via next generation sequencing (NGS) and 
bioinformatics analysis 
For each sample, the V3–V4 region of the 16S rRNA gene was PCR-amplified in 
25 μl volumes containing 12.5 ng of microbial DNA, 2× KAPA HiFi HotStart ReadyMix 
(Kapa Biosystems, USA) and 200 nmol/l of S-D-Bact-0341-b-192 S-17/ S-D-Bact-0785-
a-A-21 primers carrying Illumina overhang adapter sequences (Bio-Fab Research). 
Thermal cycling consisted of an initial denaturation at 95°C for 3 min, 25 cycles of 
denaturation at 95°C for 30 s, annealing at 55°C for 30 s, extension at 72°C for 30 s and 
a final extension step at 72°C for 5 min. Amplicons of 440 bp were purified with a 
magnetic bead-based clean-up system (Agencourt AMPure XP; Beckman Coulter) and 
sequenced on Illumina MiSeq platform using a 2×300 bp paired end protocol, according 
to the manufacturer’s instructions (Illumina, San Diego, CA). Libraries were pooled at 
equimolar concentrations, denatured and diluted to 4 nmol/l. Pair-ended amplicon reads 
(with corresponding quality scores) were trimmed, merged, clustered (operational 
taxonomic units [OTU] with 97% similarity), filtered from chimeric sequences using 
UPARSE (Edgar 2013), and taxonomically assigned using the GreenGenes database 
(version 12.10; McDonald et al. 2012). For downstream analysis, the OTU-table was 
normalised with cumulative sum scaling (CSS; Paulson et al. 2013) using the Qiime 
toolbox (v1.9; Caporaso et al. 2010). Beta-diversity was assessed through Bray-Curtis 
and Soresen distance and the factor-treatment analysed with redundancy analysis (RDA; 
Oksanen et al. 2015). 
 
4.2.8 Metabolic analysis by 1H-NMR 
400 μL of urine samples were combined with 200 μL of phosphate buffer [0.2 M 
(pH 7.4) in D2O plus 0.001% TSP (3-(trimethylsilyl)-[2,2,3,3,−2H4]-propionic acid, δ 
0.00)], mixed by vortexing, centrifuged at 1136 x g for 10 minutes, and then 550 μL was 
transferred into 5 mm NMR tubes for analysis. Faecal samples were pre-weighed (250 
mg) and 700 μL of phosphate buffer and 2 glass beads were added in order to perform a 
bead-beating 5 min step at 25 movements/s using TyssueLyser LT (Qiagen, UK). Then, 
500 μL was transferred into 5 mm NMR tubes for analysis. 
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All NMR spectra were acquired on a Bruker Avance DRX 500 MHz NMR 
spectrometer (Bruker Biopsin, Rheinstetten, Germany) operating at 500 MHz. They were 
acquired using a standard one-dimensional (1D) pulse sequence [recycle delay (RD)-90°-
t1-90°-tm-90°-acquire free induction decay (FID)] with water suppression applied during 
RD of 2 s, a mixing time Tm of 100 ms and a 90 pulse set at 7.70 μs. For each spectrum, 
a total of 128 scans were accumulated into 64 k data points with a spectral width of 
12.001 ppm. The FIDs were multiplied by an exponential function corresponding to 0.5 
Hz line broadening. 
 
4.2.9 Data Preprocessing and Analysis  
All spectra were manually phased, baseline corrected and calibrated to the 
chemical shift of TSP using TopSpin (Bruker Biopsin, Rheinstetten, Germany). Spectra 
were digitised using an in-house MATLAB (version R2014a, The Mathworks, Inc.; 
Natwick, MA) and median fold normalisation was performed. The spectral region 
containing the water resonance was removed to minimise distortions in the baseline 
arising from imperfect water saturation. Principal components analysis (PCA) using 
mean-centred data was applied and orthogonal projection to latent structure discriminant 
analysis (OPLS-DA) models were constructed using for pairwise comparisons of the 
different experimental groups and time points. Colour represents the significance of 
correlation (r) for each metabolite to class membership. Predictive strength (Q2Y) of the 
models was obtained using a 7-fold cross-validation method, and these were validated 
using permutation testing (number of permutations = 1000). 
 
4.2.10 Statistical analysis 
 Statistical tests for food intake and GI symptoms were performed using Graphad 
Prism (version 5.0; Graph-Pad Software, 188 LaJolla, CA, USA). Normality test was 
used to assess whether the data were parametric or not parametric and unpaired Student’s 
t test and Mann-Whitney tests were performed respectively on the data set.  
 
4.3 Results  
4.3.1 Dietary intake and bowel habit  
Food diaries were analysed by comparing daily macronutrient and micronutrient 
intake according to different diets that the children were following (exclusion and un-
restricted diet) and significant differences were seen only in Vitamin D intake (Table 
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4.2). ASD children who were not on the exclusion diet had significantly lower Vitamin D 
intake compared to ASD children on exclusion diet (P<0.01). In addition, Vitamin D 
intake seemed to be much lower, for both groups, than daily UK government 
recommendations (10 μg/day). 
Vitamin C and B12, total sugar and protein intake was higher in both ASD groups 
compared to the nutrient intake requirements for typically developing children.  
 
Table 4.2: Energy and nutrient intake in children on exclusion and un-restricted diets and 
comparison with the UK government recommendations for typically developing children. Mean: 
average of 4 consecutive days; SD: standard deviation. **: P<0.01 
Exclusion diet            Un-restricted Diet Typically developing 
children 
Daily dietary composition             Mean        SD             Mean SD                Adequate intake    
Energy Intake Kcal 1579.18 394.19 1478 578.70 1430-1920 
Protein Intake g 56.93 17.30 55.01 15.68 19.7-42.1 
Carbohydrate g 183.58 35.20 187.26 74.99 191-333 
Total sugars g 63.32 27.58 81.46 36.44 19-33 
Fibres g 17.19 5.60 15.36 9.26 17.5-25 
Saturated fatty 
acid 
g 
22.22 12.26 22.28 12.25 
 
17.5-31 
PUFA g 12.41 6.39 9.88 7.97 10.5-18 
MUFA g 22.88 18.19 19.39 16.76 20.5-36 
Vitamin C mg 73.64 44.46 70.94 68.00 30-35 
Vitamin D μg 2.72 1.40 1.21** 1.18 10 
Vitamin B1 mg 1.38 0.49 1.38 0.66 0.6-1 
Vitamin B2 mg 1.44 0.56 1.41 0.64 0.8-1.2 
Vitamin B6 mg 1.15 0.33 1.13 0.53 0.9-1.2 
Vitamin B12 μg 3.04 1.84 3.82 2.56 0.8-1.2 
Iron mg 10.37 4.30 8.04 2.99 6.1-11.3 
Calcium mg 536.00 247.89 697.17 357.52 450-1000 
 
 
Scores extracted from GI symptoms diaries showed that exclusion diet had a significant 
impact on gastrointestinal problems (Figure 4.1). Significant reduction in abdominal pain 
(P<0.05) and bowel movement (P<0.001) has been reported in children following gluten, 
casein and dairy free diet. 
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Figure 4.1: GI symptom assessment during 3 weeks data collection.   
S: exclusion diets; N: un-restricted diet; *: P<0.05; ***: P<0.001.  
 
4.3.2 Bacterial analysis 
 Beta-diversity was analysed in faecal samples of ASD children during the 3-
weeks of sample collection. Soresen principal coordinate analysis (PCoA, Figure 4.2A) 
showed good separation between volunteers on exclusion diet (red dots) and un-restricted 
diet (green dots) considering presence or absence of particular bacterial species; 
separation that is lost in Bray-curtis PCoA (Figure 4.2B) when abundances were 
analysed. 
A)           B)  
Figure 4.2: Comparison of the gut microbiota composition between ASD children following 
exclusion diet and ASD children following un-restricted diet. A) Sorensen PCoA; B) Bray-Curtis 
PCoA. Red dots: exclusion diet; green dots: un-restricted diet. 
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In order to assess the impact of the diets on the total gut microbiota composition, 
a RDA model was built. A 3% variance in the dataset was significant (P<0.004) and 
different bacterial groups were associated with the separation (Figure 4.3). 
 
Figure 4.3: Microbial genera involved in the separation in the RDA plot. Blue dots: exclusion 
diet; pink dots: un-restricted diet. 
 
Bacteroides spp. (Bacteroidaceae), Rikenellaceae, Roseburia spp. 
(Lachnospiraceae), F. prausnitzii (Ruminococcaceae) and Clostridiaceae were associated 
with the exclusion diet group, whereas Eggerthella lenta, Bifidobacterium spp. 
(Coriobaceriaceae), B. fragilis (Bacteroidaceae), Akkermansia muciphila 
(Verrucomicrobiacea), Streptococcus anginosus, Lactococcus spp. (Streptococcaceae), 
Dehalobacterium spp. (Dehalobacteriaceae) were associated with the un-restricted diet. 
In addition, our results showed bifidobacteria in lower abundances (3.5%) in the 
exclusion diet group compared to the un-restricted diet group (4.5%) and a reduction in 
the Veillonellaceae family.  
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4.3.3 1H-NMR analysis 
  Comparison of spectra profiles from urine samples did not show any significant 
differences in the general metabolism of ASD children when considering the different 
diets (Q2Y= -0.0199). A significant OPLS-DA model was obtained by analysing faecal 
samples (Q2Y=0.185, P <0.001), where changes in metabolic profile were driven by the 
diet. The PCA (Principal component analysis) score plot showed partial separation 
between the two groups; in particular for the exclusion diet, indicating its influences 
upon variation in data sets (Figure 4.4). 
 
 
Figure 4.4: PCA score plot. PCA plot shows partial separation between children following exclusion 
diets and those whose diet was not restricted. Blue dots: exclusion diet; green dots: un-restricted diet. 
 
Figure 4.5A and B summarises correlations between bacterial changes and 
metabolic variation in faecal samples of children following an exclusion diet and those 
on an un-restricted diet, respectively. During the exclusion diet (Figure 4.5A), 
Bacteroides spp. (OTU005 and OTU007) had a strong correlation with glycerol and 
propionate (black arrows), whereas Clostridiaceae (OTU013) were positively correlated 
with valine, 2-hydroxy-2-methilbutyrate, glucose and lactate (green arrows). The latter 
(red arrow) was also positively associated with Roseburia spp. (OTU015). In faecal 
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samples from children on the un-restricted diet (Figure 4.5B) positive correlations were 
identified for Eggerthella lenta (OTU004) and Streptococcus anginosus (OTU011) with 
lactate, tyrosine, 2-hydroxy-2-methilbutyrate, isoleucine, leucine, alanine and valine 
(black arrows); for Clostridiaceae (OTU012) and bifidobacteria (OTU001 and OTU002) 
with valine (orange arrow) and alanine (red arrow), respectively; and for Lactococcus 
spp. (OTU010) and Coprobacillus spp. (OTU017) with 2-hydroxy-2-methilbutyrate and 
propionate (green arrows). 
 
A)  
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B)  
Figure 4.5: Summary of the correlation between bacterial changes and metabolic variation in faecal 
samples of children following exclusion diet (A) and those in un-restricted diet (B). OUTs: bacterial 
groups. Arrows: metabolites identified; Squares: bacteria involved in the metabolic pathway. 
OTU001: Bifidobacterium spp.; OUT002: Bifidobacterium longum; OTU003: Coriobacteriaceae; OTU004: 
Eggerthella lenta; OTU005: Bacteroides spp.; OTU006: B. fragilis; OTU007: B. ovatus; OTU008: B. 
uniformis; OTU009: Rikenellaceae spp.; OTU010: Lactococcus spp.; OTU011: Streptococcus arginosus; 
OTU012: Clostridiales; OUT013: Clostridiaceae; OTU014: Dehalobacterium spp.; OTU015: Roseburia 
spp., OTU016: F. prausnitzii; OTU017: Coprobacillus spp.; OTU018: Akkermansia muciphila.  
 
 
4.4 Discussion 
The effect of restricted diet in ASD children was investigated in this study. Diet 
has been previously seen to have a strong impact on the gut environment (De Angelis 
2017), therefore we aimed to understand if and how it could impact on composition of gut 
microbiota and metabolic profile. The results showed significant differences in gut 
bacterial populations and faecal metabolome between the 2 diet groups (children 
following gluten and casein free diet and those whose diet was not restricted), but not in 
urine samples, indicating that diet has a strong effect on gut ecosystem but not on the 
general metabolism of ASD individuals. 
Previous studies in ASD have mainly focused on the GFCF diet and the impact 
on GI symptoms or behaviour, showing inconsistent results (Mulloy et al. 2010). In our 
study, ASD children following gluten, casein and dairy-free diets had significant 
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reductions in abdominal pain and bowel movements, supporting the hypothesis that 
exclusion diets might alleviate these GI issues. 
Lower abundances of bifidobacteria and Veillonellaceae were found in healthy 
volunteers following a gluten-free diet in a recent human intervention study by Bonder 
and colleagues (Bonder et al. 2016). These findings are reflected in our results, 
suggesting that dietary restriction might have bigger impact on the growth of these 
bacterial groups, than the type of disorder (eg autistic features). Veillonellaceae is 
considered to be a pro-inflammatory family of bacteria and reduction in its abundance 
could be considered a beneficial effect of this restricted diet. Reduction in 
Bifidobacterium spp. abundance was also confirmed by De Palma et al., who associated 
the decrease of this bacterial group to the lower fibre intake in healthy participants during 
a one month gluten-free diet (De Palma et al. 2009). Our results are contrary to this 
suggestion since dietary records of ASD children in our study showed that those 
following GFCF diet had higher fibre intakes compared with autistic ones who were on 
un-restricted diet.  
Similar outcomes were reported in a recent study conducted in Spain where 
researchers enrolled 105 ASD volunteers and 495 typically developing peers. Even 
though the autistic group consumed fewer carbohydrates (reported also in our study) they 
ate more legumes and vegetables. This could be an explanation for the higher fibre intake 
potentially derived from different sources (Marí-Bauset et al. 2016). The same research 
group obtained similar results, focusing only on the nutritional impact of GFCF in ASD 
individuals; their results showed higher fibre intake and, in addition, deficiency in 
Vitamin D intake, also supporting our findings (Marí-Bauset et al. 2015). Vitamin D is 
considered a neurosteroid that is active during brain development and its deficiency has 
been taken into consideration as potential environmental risk factor for ASD (Kocovska 
et al. 2012, Vinkhuyzen et al. 2017, Cannell  et al. 2017). Our results reinforced this 
hypothesis, therefore the association between ASD and Vitamin D deficiency is worth to 
be further investigated. 
Our metabolomic analysis showed amino acid (AA) and glucose as main 
metabolites present in the faecal samples in both dietary groups, as previously reported 
by De Angelis and colleagues (De Angelis 2015). It could be due to malassimilation of 
nutrients since results obtained from the food diaries showed increase in protein and total 
sugar intake. These results support the hypothesis that exclusion diet alone might not  be 
enough to improve gut health. 
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Bacterial groups such Clostridium spp., Bacillus spp., Lactobacillus spp., 
Streptococcus spp., and proteobacteria have been associated with AA metabolism (Neis 
2015) and this was confirmed by our results. Clostridiaceae and Streptococcus anginosus 
were positively correlated to alanine, tyrosine, isoleucine, leucine and phenylalanine. It is 
known that amino acids are precursors for neurotransmitters, such as tryptophan for 
serotonin or tyrosine for catecholamines, but little is known on the impact of the gut 
microbiota in these pathways and how the diet might modulate them (Tuohy et al. 2015). 
Alteration in AA metabolism has been seen in the urine of ASD children (Ming et al. 
2012) and in vitro studies investigating the AA transporters in fibroblasts from skin 
biopsies of autistic individuals. Alterations were found for tryptophan, alanine and 
tyrosine that might lead to modifications in the neurotransmitter pathway (Fernell et al. 
2007; Johansson et al. 2011).  
Since AA are important for brain development and cognitive functions, Fernell 
and colleagues focused on the hypothesis that autistic individuals might have altered 
tyrosine and alanine transport mechanisms (L- and A-systems). They demonstrated that 
ASD children have aberrant AA transport systems and this might cause changes in levels 
of tyrosine in the brain, and therefore in dopamine synthesis (Fernell et al. 2007). 
Johansson et al., focused not only on the tyrosine and tryptophan transporters, but also 
investigated the competition between alanine and tyrosine for transport across the brain-
blood barrier (BBB). Their results showed a decrease in tryptophan transport into the 
brain, which might lead to a reduction of serotonin synthesis and a higher level of 
alanine. Synthesis of neurotransmitters do not require the presence of alanine, but the 
authors speculated that the high level might cause a reduction in essential amino acids 
important for brain activity (Johansson et al. 2011). 
SCFAs have also been proven to have an effect on the CNS. In particular, 
injection of propionate in mice has been seen to cause autistic like behaviour (MacFabe 
et al. 2008). Our results showed strong correlations between Bacteroides spp. and 
propionate in faecal samples of ASD children on exclusion diets, confirming the role of 
the gut microbiota in metabolite production that might be associated with autistic traits. 
However, recently this hypothesis has been questioned since children with inborn 
propionic acidemia do not show typical autistic behaviour (Goof 2014). Also, the 
presence of lactate has been previously associated with psychological comorbidities 
(Dillon et al. 1987; Cowley et al. 1987) and its detection in both groups confirms in vitro 
results (Chapter 3, Grimaldi et al. 2017) and its potential role in ASD.  
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4.5 Conclusion 
 In summary, the results of this study give an insight on the impact of exclusion 
diets on gut microbiota composition and metabolic activity in ASD.  
Apart from the improvement in GI symptoms in children following exclusion diets, our 
results suggested that dietary approach overall does not alter the general metabolism in 
ASD children, as reported by urine metabolome analysis. 
We confirmed that gluten and casein-free diets modulated the gut microbiota 
revealing different bacterial populations associated with the two respective groups. In 
addition, faecal metabolic profiles showed amino acids as main metabolites identified, 
suggesting potential gut inflammation that might lead to malabsoption. 
 In conclusion, our results showed not only that exclusion diet might not be 
enough to improve gut health, but also that it is able to manipulate the gut environment 
and potentially be a factor that might interfere with other therapeutical approaches. 
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Abstract 
The main hypothesis of this study was to investigate the effect of B-GOS (83% GOS 
content) after 6 weeks treatment period on the gut microbiota composition and metabolic 
signature in autistic children. Furthermore, we also aimed to evaluate effect of B-GOS 
administration on GI dysfunction, mood, behaviour and sleep. We did not observe strong 
impact on GI issues after B-GOS intervention, but there were improvements in sleep 
habits. Our results also showed that anti-social behaviour varied over time depending on 
both exclusion diet (gluten and casein free diet) and treatment. 16S rRNA sequencing 
showed that B-GOS had a bifidogenic effect, confirming its prebiotic effect, as well as 
modulation of Lachnospiraceae family, in ASD children following un-restricted diets. 
The effect of B-GOS was significant also on the metabolome of this group. Butyrate and 
valerate were the main SFCAs produced and reduced amino acid excretion was detected 
in faecal samples of the intervention group. Urine samples were dominated by citrate, 
creatine, creatinine, DMA, DMG, malonate, carnitine, TMAO, and α-hydroxybutyrate in 
ASD children taking B-GOS, whereas PAG, phenylalanine and β-hydroxybutyrate were 
detected in the control group. To our knowledge, this is the first study where a prebiotic 
intervention has been evaluated in autism and the results are promising. Administration 
of B-GOS to autistic children may be useful in positively affecting the microbiota, 
metabolic profile and some traits associated with autism. 
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5.1 Introduction 
 Autism is a spectrum of disorders diagnosed in early life and interferes with the 
normal course of social, communicative, and cognitive development. Autistic Spectrum 
Disoder (ASD) individuals might also sufferer GI problems. The causes are still 
unknown but there are hypotheses behind these issues such as (1) dysbiosis in gut 
microbiota composition, in particular reduced number of bifidobacteria and increased 
Clostridium spp., Desulfovibrio spp., Sutterella spp. and/or Veillonellaceae; (2) altered 
dietary intake and (3) increased gut permeability. Dysfunction of the intestinal barrier 
might lead to the translocation of bacteria and/or metabolites that may have an impact on 
systemic metabolome, immune and nervous systems (Ding et al. 2016).  
Previous studies have reported alterations in gut barrier function in ASD 
individuals (White 2003) and in order to reduce these problems, exclusion diets are often 
suggested. It was previously shown (as reported in chapter 4) that exclusion diet was able 
to modulate gut bacterial populations and reduce GI discomfort, but partial changes in 
the metabolomics analysis, such as the presence of amino acids in faecal samples, lead us 
to think that diet alone does not have an effect on problems with nutrient absorption, and 
potentially, on gut inflammation. Patel and Curtis (2007) reported improvement in 10 
ASD children after 6 months of multiple behavioural, language and nutritional therapies 
in a controlled environment, speculating that multiple interventions might have greater 
potential in improving ASD symptoms.  
Manipulation of the gut microbiota using pre- and probiotics has shown 
beneficial effects on human health (Holmes et al. 2012) but, to date, there are only a few 
studies that have focused on the impact of these food supplements in autism. Parracho et 
al. reported improvement behavioural changes after Lactobacillus plantarum WCSF1 
administration in ASD children (Parracho et al. 2010). Adam and colleagues noticed a 
strong correlation between GI symptoms and severity of autism (Adams et al. 2011). 
Furthermore, they showed significant differences in SCFA levels in ASD individuals 
taking probiotics. Kaluzna-Czaplinska, after 2 months of oral supplementation with 
Lactobacillus acidophilus, found significant modifications in the level of D-arabinitol 
(DA) and the ratio of D-/L-arabinitol (DA/LA) in ASD children, and an improvement in 
concentration (Kaluzna-Czaplińska and Błaszczyk 2012). Recently, Tomova and 
colleagues confirmed the correlation of autism severity with GI dysfunction and showed 
that 4 months of mixed probiotic administration was able to modulate gut microbiota 
populations in ASD children (Tomova et al. 2015). Furthermore, probiotic therapy has 
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been demonstrated to reduce inflammation, as assessed by myeloperoxidase-MPO and 
copper in autistic children compared to non-autistic controls (Russo 2015). 
To date, data on the effect of prebiotics in ASD are scarce. B-GOS is a galacto-
oligosaccharide mixture that has been widely tested in vitro and in vivo studies, showing 
improvements in several aspects of human physiology (Vulevic et al. 2008) (Depeint et 
al. 2008) (Silk et al. 2009) (Vulevic et al. 2015) (Drakoularakou et al. 2009). It was 
previously shown that B-GOS has an impact on the faecal gut microbiota composition 
and metabolic profile of autistic children using an in vitro fermentation system 
mimicking conditions of the colon (Chapter 3). 
 Considering these promising results, the main hypothesis of this study was to 
investigate the effect of B-GOS after 6-weeks treatment period on gut microbiota 
composition and metabolic signature in autistic children. Furthermore, we also aimed to 
evaluate the effect of B-GOS administration on GI dysfunction, mood, behaviour and 
sleep. 
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5.2 Materials and Methods 
5.2.1 Study design 
A randomised, double-blind, placebo-controlled (Maltodextrin), parallel-
designed prebiotic GOS mixture (B-GOS; Bimuno®) feeding study was conducted in 
children diagnosed with ASD (Figure 5.1). Both treatments were provided in powder 
form and supplied by Clasado Biosciences Ltd. (Reading, United Kingdom).  
 
 
Figure 5.1: Study design and nutritional information on the treatments administrated 
throughout the study. Each treatment was pre-weighed and delivered in individual containers. 
Volunteers’ parents were asked to mix the powder with drinks that children usually consume. 
 
The study was conducted according to the guidelines of the Declaration of 
Helsinki, and the University of Reading Research Ethics Committee (UREC15/41; 
Registration number: NCT02720900) approved all procedures involving human 
subjects (questionnaires, volunteer forms, diaries and advertising documents 
Appendices 5.1 - 5.9). 
Recruited subjects were divided into two groups A and B, according to dietary 
habits assessed by 4-day food diaries (as previously discussed in Chapter 4), children 
whose diet was not restricted and on restricted diet (mainly gluten, casein and dairy 
free) respectively. Within these two groups, children were randomly assigned to two 
feeding groups using a random number system. Group-I received placebo and Group-
II received B-GOS during the 6 weeks feeding period. Volunteers were required to 
visit the University of Reading or the researcher visited the volunteers at home on five 
separate occasions during the study period in order to provide faecal (weekly 
collection) and urine samples.  
Screening Run-in  Treatment  B-GOS or Placebo Follow-up 
-2                        0                    2                            5                        8              10 weeks 
                       Visit 1                  Visit 2                   Visit 3                Visit 4                      Visit 5  
Treatments:  - 1.8 g B-GOS (83.7% w/w galacto-oligosaccharide, 10.7% lactose, 4.2% glucose and 0.46% galactose 
    - 1.8 g Maltodextrin   
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5.2.2 Subjects  
The study was powered using Hedwig Harvard Software and the calculation was 
based on changes in bifidobacterial number from a previous intervention study in human 
volunteers using B-GOS (Vulevic et al. 2008). A total of 41 autistic children (31 male 
and 10 female) with formal diagnosis of ASD were enrolled in the study in order to have 
a 95% probability that the study would detect, at a two-sided 5% significance level, an 
effect on the colonic bifidobacterial population.  
Of these 41, 11 subjects withdrew from the study during the baseline period, 
largely due to difficulties and/or inconveniences associated with collecting samples. The 
remaining 30 volunteers were divided into group A (un-restricted diet; n=18) and B 
(exclusion diet; n=12) and each group randomly distributed between groups I and II (A-I: 
n=9, A-II: n= 9 and B-I: n=6, B-II: n=6). However, 4 subjects subsequently dropped out 
before the end of the first feeding arm. One left the study without giving a reason, two 
were withdrawn due to protocol violation, and one withdrew due to an adverse event 
(strong diarrhoea and abdominal pain observed after 2 days of treatment feeding).  
In total, 26 volunteers completed the 10 weeks study (A-I: n=7, A-II: n= 7 and B-
I: n=6, B-II: n=6; Table 5.1) providing 80% statistical power to the study. 
 
Table 5.1: Diagnosis reported from parents by medical assessment (*). 
ASD: Autism Spectrum Disorders; ADHD: Attention Deficit Hyperactivity 
Disorder; PDD: Pervasive Development Disorder 
Diagnosis* ASD ADHD Asperger PDD 
Volunteers (n) 26/26 5/26 1/26 1/26 
Exclusion diet  
B-GOS (B-II) 
6/6   1/6 
Exclusion diet  
Placebo (B-I) 
6/6 3/6 1/6  
Un-restricted 
diet B-GOS (A-
II) 
7/7 1/7   
Un-restricted 
diet Placebo 
(A-I) 
7/7 1/7   
 
Volunteers were assessed before the start of the trial and were selected according to 
certain exclusion and inclusion criteria. Inclusion criteria for participation in the study 
were signed consent form from volunteers’ parents or guardians, age of 4-11 y inclusive, 
formal diagnosis of ASD. Volunteers taking probiotics, prebiotics, antibiotics or other 
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dietary supplement drugs that could affect the luminal microenvironment of the intestine 
within 4 weeks before the study were also excluded. Volunteers were instructed not to 
consume such products during the study and not to alter their usual diet or fluid intake.  
 
5.2.3 Faecal sample collection and preparation 
Faecal samples were collected weekly using faecal collection kit (FC2040, 
Laboratories Ltd, UK) and volunteers were asked to keep them at -20°C until the visit 
day when they were transferred to the laboratory for all the analysis. Samples for 
fluorescence in situ hybridisation (FISH) were stored in glycerol until the visit day and 
diluted 1 in 10 (wt:wt) in phosphate-buffered saline (1X PBS, 0.1 mol/L, pH 7.0; Oxoid, 
UK) and homogenised in a Stomacher 400 (Seward, Norfolk, United Kingdom) for 2 min 
at normal speed. Samples for DNA extraction and 1H-NMR were weighed (250 mg) and 
stored at-80°C. 
 
5.2.4 Urine sample collection and preparation 
 Urine samples were collected using sterile tubes (Mid-Stream Urine Specimen 
Collector; Pennine Healthcare, UK) or sterile pad (Sterisets Urine Collection Kit; 
MediBargains, UK) and stored at -20°C until visit day when they were processed. 
Samples were transferred to 15ml falcon tubes and centrifuged for 10 min at 1136 x g. 
The supernatants were transferred to 1.5ml Eppendorf tube (in duplicate) and stored at -
80°C. 
 
5.2.5 Fluorescence in situ hybridisation (FISH) 
Synthetic oligonucleotide probes targeting specific regions of the 16S rRNA 
labelled with the fluorescent dye Cy3, as previously described in Chapter 2 were used for 
bacterial enumeration assessed by FISH analysis. Briefly, faecal homogenate samples 
were fixed for at least 4 hours (4 °C) in 4% (wt:vol) paraformaldehyde. Fixed cells were 
centrifuged at 1136 x g for 5 min at 25 °C and washed twice in 1 mL filtered PBS (0.1 
mol/L, pH 7.0; Oxoid, UK). The washed cells were resuspended in 150 μL PBS/EtOH 
(1:1) and stored at -20 °C. The probes used (Eurofins Genomics, UK) were Bif164 for 
Bifidobacterium genus (Langendijk et al. 1995) and EUB 338 I-II-II for total bacteria 
(Daims et al. 1999).  
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5.2.6 DNA extraction and PCR 
Total microbial DNA was extracted from faeces using the DNA stool mini kit 
(Qiagen, UK) by introducing three 1-min steps at 50 movements/s using TyssueLyser LT 
(Qiagen, UK) with 5-min incubation in ice between treatments as previously described 
by Candela et al. 2016. Thermal disruption of the samples was performed by incubation 
at 95°C for 15 min, then centrifuged for 5 min (1136 x g) at 4°C to pellet stool particles. 
Two hundred-sixty μl of 10 M ammonium acetate was added to the supernatant, 
incubated in ice for 5 min and centrifuged at full speed for 10 min at 4°C. The 
supernatants were collected, one volume of isopropanol added and the samples incubated 
on ice for 30 min. Samples were centrifuged (1136 x g) for 15 min at 4°C and the pellet 
washed with 70% (v/v) ethanol. They were resuspended in 100 μl of TE buffer (10 mM 
Tris-Cl, pH 7.5; 1 mM EDTA, pH 8.0) and treated with 2 μl of DNase-free RNase (10 
mg/ml, Sigma-Aldrich) at 37°C for 15 min. Proteins were removed by adding 15 μl of 
proteinase K (DNA stool mini kit; Qiagen, UK) and DNA was subsequently purified 
following the manufacturer’s instructions. DNA recovery was evaluated using the 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). 
 
5.2.7 16S rRNA gene amplification via next generation sequencing (NGS) and 
bioinformatics analysis 
For each sample, the V3–V4 region of the 16S rRNA gene was PCR-amplified in 
25-μl volumes containing 12·5 ng of microbial DNA, 2× KAPA HiFi HotStart 
ReadyMix (Kapa Biosystems, USA) and 200 nmol/l of S-D-Bact-0341-b-192 S-17/ S-D-
Bact-0785-a-A-21 primers carrying Illumina overhang adapter sequences (Bio-Fab 
Research). Thermal cycle consisted of an initial denaturation at 95°C for 3 min, twenty-
five cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, extension at 72°C 
for 30 s and a final extension step at 72°C for 5 min. Amplicons of about 440 bp were 
purified with a magnetic bead-based clean-up system (Agencourt AMPure XP; Beckman 
Coulter) and sequenced on Illumina MiSeq platform using a 2×300 bp paired end 
protocol, according to the manufacturer’s instructions (Illumina, San Diego, CA). 
Libraries were pooled at equimolar concentrations, denatured and diluted to 4 nmol/l. 
Pair-ended amplicon reads (with corresponding quality scores) were trimmed, merged 
clustered (operational taxonomic units [OTU] with 97% similarity), filtered from 
chimeric sequences using UPARSE (Edgar 2013), and taxonomically assigned using the 
GreenGenes database (version 12.10; McDonald et al. 2012). For downstream analysis, 
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the OTU-table was normalised with cumulative sum scaling (CSS; Paulson et al. 2013) 
using the Qiime toolbox (v1.9; Caporaso et al. 2010). Beta-diversity was assessed 
through Bray-Curtis and Soresen distance and the factor-treatment analysed with 
redundancy analysis (RDA; Oksanen et al. 2015). Alpha-diversity was measured and 
expressed as observed species (97% similarity OTUs) and computed with 10 rarefied 
OTU tables. Comparison of Alpha-diversities was made through nonparametric 𝑡-test 
method (Monte Carlo, 999 permutations). 
 
5.2.8 Metabolic analysis by 1H-NMR 
Four hundred μL of urine samples were combined with 200 μL of phosphate 
buffer [0.2 M (pH 7.4) in D2O plus 0.001% TSP), mixed by vortexing, centrifuged at 
1136 x g for 10 minutes and then 550 μL was transferred into 5 mm NMR tubes for 
analysis. Faecal samples were pre-weight (250 mg) and 700 μL of phosphate buffer and 
2 glass beads were added in order to perform a bead-beating 5-min step at 25 
movements/s using TyssueLyser LT (Qiagen, UK). Then, 500 μL was transferred into 5 
mm NMR tubes for analysis. All NMR spectra were acquired on a Bruker Avance DRX 
500 MHz NMR spectrometer (Bruker Biopsin, Rheinstetten, Germany) operating at 500 
MHz. They were acquired using a standard one-dimensional (1D) pulse sequence 
[recycle delay (RD)-90°-t1-90°-tm-90°-acquire free induction decay (FID)] with water 
suppression applied during RD of 2 s, a mixing time Tm of 100 ms and a 90 pulse set at 
7.70 μs. For each spectrum, a total of 128 scans was accumulated into 64 k data points 
with a spectral width of 12.001 ppm. The FIDs were multiplied by an exponential 
function corresponding to 0.5 Hz line broadening. 
 
5.2.9 Data Preprocessing and Analysis 
All spectra were manually phased, baseline corrected and calibrated to the 
chemical shift of TSP using TopSpin (Bruker Biopsin, Rheinstetten, Germany). Spectral 
features were picked using in-house MATLAB (version R2014a, The Mathworks, Inc.; 
Natwick, MA) script and median fold normalization was performed. The spectral region, 
containing the water resonance, was removed to minimise distortions in the baseline 
arising from imperfect water saturation. Principal components analysis (PCA) using 
mean-centred data was applied and orthogonal projection to latent structure discriminant 
analysis (OPLS-DA) models were constructed for pairwise comparisons of the different 
experimental groups and time points. Colour represents the significance of correlation 
 107 
(R2) for each metabolite to class membership. Predictive strength (Q2Y) of the models 
was obtained using a 7-fold cross-validation method and these were validated using 
permutation testing (number of permutations =1000). 
 
5.2.10 GI symptom diaries 
Parents/guardians of children volunteers were asked to fill in daily questionnaires 
for GI function and symptoms. The Bristol stool chart was used to assess faecal sample 
type and consistency, together with number of bowel movements, abdominal pain, 
intestinal bloating and flatulence (i.e. low, present but well tolerated, present and 
interfering with but not preventing normal daily activities, preventing normal daily 
activities; Lewis & Heaton 1997). Concomitant medication, adverse events, changes in 
diet and behaviour were also recorded throughout the study, on a separate sample 
submission forms. 
 
5.2.11 Behavioural and sleep assessment 
Autism Treatment Evaluation Checklist (ATEC) was used to evaluate the 
effectiveness of treatment. In addition, parents/guardians were asked to complete 5-day 
sleep diaries before and after interventions in order to understand the qualitative impact 
of B-GOS supplementation on sleep disorder, if present. 
 
5.2.12 Statistical analysis 
 Behavioural assessments and GI symptoms were analysed using SPSS software 
(SPSS Inc., Chicago, IL, USA). Mood and behavioural questionnaire analysis were 
performed considering the 4 ATEC scale scores (Communication, anti-sociability, 
Sensory and Behaviour) and the total ATEC score, for each time point (before T1, after 
treatment T2 and follow-up T3). One-way ANCOVA was used in order to test whether 
T2 scores differed between treatment groups, adjusting for baseline T1 scores as 
covariate. GLM 2x3 RMANOVAs were used to test whether there were any treatments 
by time interaction across time points. Each of those RMANOVAs was followed by a 
2x2 RMANCOVA to test for any treatment by time interactions across T2 and T3 
adjusting for baseline (T1) differences.  This test was used in order to assess whether any 
treatment effect was consistent to follow-up.  
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GI symptoms were analysed using a linear mixed model. The fixed terms 
assessed in this model were diet, treatment, time (pre-treatment, during treatment, 
follow-up), weeks, diet x time, treatment x time and volunteer scores as a random effect. 
 Statistical test for bacterial composition results was performed using Graphad 
Prism (version 5.0; Graph-Pad Software, 188 La Jolla, CA, USA). One-way ANOVA 
tests and unpaired Student’s t tests, including post hoc tests appropriate for individual 
data sets (Tukey post-test with significance set at P< 0·05), were used. 
 
5.3 Results 
5.3.1 GI symptoms and sleep diaries 
 GI symptoms were quantitatively evaluated each day, by recording abdominal 
pain, intestinal bloating and flatulence, stool form and bowel movement. A general trend 
of reduction in GI symptoms was reported, but differences between treatments were not 
significant.  The significant effect was observed for the interaction between the diet and 
time, for bowel movements (P<0.01) and flatulence (P<0.05).  
Qualitative analysis was performed on sleep habits and 3 volunteers (23% of 
participants) benefited from B-GOS intervention. Parents reported that their children 
slept one hour longer than usual and one of them also noticed that the child had less 
problems falling asleep. 
 
5.3.2 Mood and behaviour questionnaires 
 Mood and behaviour questionnaires were analysed taking into account age, diet 
and intervention. ASD children following exclusion diet, showed a significant reduction 
in the “anti-social behaviour” score after B-GOS intervention. The results from the 
ATEC questionnaire showed that anti-sociability varied over time depending on both 
exclusion diet and treatment (P<0.05; Figure 5.2). 
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Figure 5.2: ATEC questionnaire. Results showed consistent reduction in anti-sociability score 
in children on exclusion diet and B-GOS intervention. Results were reported in mean ± standard 
error. Placebo: Maltodextrin. *: P <0.05. 
 
 
5.3.3 Bacterial composition by FISH analysis 
 FISH analysis was performed on total bacteria and bifidobacteria of the faecal 
samples collected at baseline, after 6 weeks intervention and follow-up (Figure 5.3A and 
B). Despite an increase in number of Bifidobacterium spp. after B-GOS intervention 
(Figure 5.3A), FISH results did not show any significance considering treatment and the 
interaction between treatments versus diet. 
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B) 
 
Figure 5.3: FISH analysis. Bifidobacteria (A) and total bacteria (B) numbers measured as Log10 CFU/g 
faeces before, after treatment and follow up in ASD children. Data were analysed considering treatment and 
interaction treatment/diet. B-GOS (n=13); Placebo (n=13); B-GOS_Exclusion Diet (n=6); 
Placebo_Exclusion Diet (n=6); B-GOS_Un-restricted Diet (n=7); Pacebo_Un-restricted Diet (n=7). 
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5.3.4 Metagenomics analysis 
 Beta-diversity of faecal samples collected at baseline (W0-W1-W2), last 3 weeks 
of treatment period (W6-W7-W8) and follow-up (W9-W10) were analysed. The only 
significant model was identified comparing bacterial populations in faecal samples from 
ASD children under un-restricted diet, before (baseline) and after B-GOS administration. 
Soresen and Bray-curtis principal coordinate analysis (PCoA) did not show any 
separation between the 2 groups (Figure 5.4A and B). Introducing the treatment as 
variable in RDA model, a 4% variance was significant (P<0.038). Figure 5.5 shows PCA 
(principal component analysis) score plot reporting bacterial populations positively 
associated with the separation after B-GOS supplementation in ASD children under un-
restricted.  
 
A)   B)  
Figure 5.4: Comparison of the gut microbiota composition between baseline and after B-GOS 
administration in ASD children under un-restricted diet. A) Sorensen PCoA B) Bray-Curtis PCoA. 
Red dots: samples before B-GOS treatment; green dots: samples after B-GOS intervention 
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Figure 5.5: Microbial genera involved in the separation in the RDA plot after B-GOS 
treatment. Blue dots: after B-GOS intervention; pink dots: before B-GOS intervention. 
 
B-GOS supplementation positively modulated some bacterial groups such as 
Bifidobacterium spp., Ruminococcus spp., Lachnospiraceae family (Coprococcus spp., 
Dorea formicigenerans, Oribacterium spp.), Eubacterium dolchum, TM7-3 family and 
Mogibacteriaceae.  
In addition, rarefaction curves showed that B-GOS supplementation increased the 
diversity in gut microbial composition of ASD children in un-restricted diet, but the 
increase was not significant (Figure 5.6). 
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Figure 5.6: Comparison of bacterial richness and diversity before and after B-GOS treatment in 
ASD children following un-restricted diet. Rarefaction curves and box plots showed that B-GOS 
supplementation increased the diversity in gut microbial composition of ASD children in un-restricted diet. 
 
 
5.3.5 1H-NMR analysis 
Comparison of the spectra profiles from urine samples did not show any 
significant differences at baseline. Significance was identified in ASD children following 
un-restricted diet after B-GOS intervention, indicating that B-GOS supplementation 
contributed to the metabolic variation. A significant OPLS-DA model was obtained 
comparing metabolic profiles of ASD children taking placebo and those taking B-GOS, 
after 6 weeks intervention (Q2Y=0.065; P<0.01; Figure 5.7). Urine spectra of autistic 
volunteers receiving B-GOS treatment contained greater amounts of creatinine, creatine, 
dimethylglycine (DMG), dimethylalanine (DMA), carnitine, malonate, citrate, adipate, 
trimethylamine-N-oxide (TMAO) and α-hydroxybutyrate compared to the autistic one 
taking maltodextrin. In addition, B-GOS supplementation seemed to reduce amount of 
phenylacetylglycine (PAG), phenylalanine and β-hydroxybutyrate in the intervention 
group. 
Before B-GOS intervention 
After B-GOS intervention 
After B-
GOS 
intervention 
Before B-GOS 
intervention 
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Figure 5.7: OPLS-DA obtained comparing the metabolic profile in urine samples of ASD children in 
un-restricted diet taking B-GOS to those taking placebo (control group). Compounds identified: 
Dimethylglycine (DMG); Dimenthylalanine (DMA); Creatinine; Creatine; PAG (Phenylacetilglycine); 
Cartine; Malonate; TMAO (Trimethylamine-N-oxide); Citrate; Adipate; Alpha-hydroxybutyrate; Beta-
hydroxybutyrate; Phenylalanine. 
 
Changes in metabolic profile were also seen after B-GOS intervention in faecal 
samples. At the baseline, a negative Q2Y was associated with ASD children in un-
restricted diet (Q2Y= -0.3632), but after B-GOS supplementation, a significant OPLS-
DA model was obtained (Q2Y=0.2997, P <0.001). Ethanol, DMG and SCFAs were 
positively correlated with B-GOS intake, in particular butyrate and valerate. In addition, 
lower levels of amino acids and lactate were detected in the B-GOS group, compared to 
the control (Figure 5.8). 
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Figure 5.8: OPLS-DA obtained comparing the metabolic profile in faecal samples of ASD children in 
un-restricted diet taking B-GOS to those taking placebo (control group). Compounds identified: 
Dimethylglycine (DMG); glutamate; butyrate; valerate; ethanol; alanine; lactate; isoleucine; leucine; 
valine; uracil; phenylalanine; tyrosine. 
 
 
5.4 Discussion 
It has been suggested that pre- and probiotics have potential effects on the gut-
brain axis (Li et al. 2017), therefore they have been considered a potential novel 
therapeutic approach for improvement of behavioural traits and GI discomforts 
associated with some ASD children. This study was designed to understand if a well-
known prebiotic B-GOS was able to modulate the gut bacterial population and metabolic 
profile of ASD individuals and if it was able to impact other autistic traits, such as mood, 
behaviour and sleep.   
Overall, our data did not show a strong impact on GI symptoms, sleep, mood and 
behaviour. The reason for this might in part be due to various difficulties reported by the 
parents in evaluating these aspects and related to impediments in communication skills 
typical of ASD children. Slight improvements were recorded on sleep diaries and, 
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combining B-GOS treatment with the restriction diet showed a significant reduction in 
anti-sociability scores, supporting the hypothesis that multiple intervention therapies 
might have a better impact on such psychological traits. 
To date, metagenomic analyses in autism mainly focused on identifying potential 
biomarker in the gut bacterial composition, usually comparing faecal samples from 
autistic individuals with siblings and non-autistic controls. Finegold and colleagues 
found significant differences in Firmicutes and Bacteroidetes phyla, with the latter more 
abundant in the ASD individuals, and they identified some genera present in all the 
autistic participants, such as Bacteroides, Clostridium, Faecalibacterium, Eubacterium, 
Ruminococcus, Roseburia, Dorea, Hespellia, Tucibacter (Finegold et al. 2010). These 
genera have been also detected in our analysis but unfortunately we did not have a non-
autistic control for comparison. Other studies showed reduced Prevotella, that may be 
explained by a low carbohydrate intake (Kang et al. 2013, Strati et al. 2017), whereas 
others focused on lower bifidobacterial numbers in ASD groups, compared to the 
typically developing children and significant effects of probiotics on lactobacilli (Adams 
et al. 2011b). All these results support the hypothesis that other bacterial populations 
might be involved in autism rather than only the clostridial group (Toh and Allen-Vercoe 
2015), as it was initially suggested (Bolte 1998).   
To our knowledge, this is the first study where 16S rRNA next generation 
sequencing has been used to better understand the impact of prebiotic intervention on gut 
microbiota in autism. Our results showed that B-GOS was able to modulate the gut 
microbiota composition in autistic children under un-restricted diets, exhibiting 
bifidogenic effects as well as changes in other bacterial groups, such as Lachnospiraceae 
family, known to be butyrate-producing bacteria. Mego and colleagues reported the same 
results in a recent human intervention study where regular consumption of GOS 
treatment induced changes in microbiota, and its modulation was correlated with 
reduction of gas production (Mego et al. 2017).  
We supported our metagenomics results by 1H-NMR, detecting butyrate and 
valerate as main SCFAs produced and matching previous in vitro data, where B-GOS 
supplementation modulated bacterial and metabolic changes in ASD (Grimaldi et al. 
2017; chapter 3). It has been shown, in cell culture studies, that butyrate seems to 
regulate tyrosine hydroxylase (TH) mRNA levels and consequently it might regulate 
catecholamine pathway in the brain (DeCastro 2005; Shah 2006; Parab 2007; Nankova 
2003; Patel 2005) thus, potentially positively impacting ASD (Nankova et al. 2014). 
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Therefore, showing that B-GOS was able to stimulate butyrate production in ASD in 
vitro and in vivo, suggests that it could have an effect indirectly on the CNS through the 
modulation of the gut bacterial populations. 
B-GOS seemed able to modulate presence of glutamate in the intervention group. 
Glutamate is the precursor of GABA, neurotransmitters in the brain, and its alteration 
might influence the CNS of autistic individuals (Mazzoli and Pessione 2016). 
Intestinally, reduction of amino acids in faecal samples of ASD children taking B-GOS 
occurred. A presence of these compounds in stool samples has been associated with 
disorders related to gut inflammation, such as Inflammatory Bowel Disease (Marchesi et 
al. 2007), therefore our results suggest that B-GOS supplementation could help to 
improve gut health. In addition, our results could be associated with butyrate production, 
detected after B-GOS intervention, since improvements in barrier functions have been 
previously detected in vitro with sodium butyrate (Wang et al. 2012c). 
Some confounding factors might impact on the analysis of urine samples, such as 
medication, diet and lifestyle. They are difficult to control especially when the sample 
size is small; this might explain our results, even though diet and medication intake were 
recorded during the trial. Strong correlations were identified in ASD children under un-
restricted diets between citrate, creatine, creatinine and B-GOS. These metabolites were 
previously identified by Yap and colleagues who did not find any significant correlation 
with autism (Yap et al. 2010); in other studies, inconsistent levels of creatinine have been 
detected in ASD individuals and considered potential biomarkers for creatine deficiency 
syndrome (CDS), a metabolic disorder with similar features to autism (Wang et al. 
2011a). In addition, they have been considered as biomarkers for other brain disorders 
such as Alzheimer’s disease (Fukuhara et al. 2013) and schizophrenia (Cai et al. 2012), 
so it would be interesting to have a deeper understanding of their implications for ASD. 
Malonate, α- and β-hydroxybutyrate were also previously correlated to other mental 
diseases (An and Gao 2016) but there is not much evidence on how the same metabolic 
pathways may be altered in different psychological disorders. 
Urinary NMR spectra were also dominated by dietary and microbial-derived 
metabolites such as dimethylamine (DMA), trimethylamine N-oxide (TMAO) in the B-
GOS group and phenylacetylglutamine (PAG) in the control group. Elevated levels of 
DMA have been identified in urine of ASD children (Yap et al. 2010), however the data 
could not be correlated with our findings due to the absence of a non-autistic control. 
TMAO and PAG were reduced after antibiotic treatment (Wang et al. 2011b) (Yap et al. 
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2008) proving an impact of the gut microbiota on metabolic pathways. B-GOS was able 
to modulate the gut bacterial populations; therefore it might have an effect their 
production. 
 
5.5 Conclusion 
 In the present study, we demonstrated that B-GOS intervention might have an 
effect on the microbiome and metabolome in ASD children. Interestingly, we showed 
that 6 weeks supplementation had a significant effect, in particular, in children on un-
restricted diets. These results strengthen our previous assumption that exclusion diet, 
such as gluten- and casein-free diets, have modulatory effects on the gut environment, 
therefore further studies testing longer treatment administration should be carried out in 
order to show functionality effect also in children already following different therapeutic 
approaches. Other limitations such as lack of typically developing children as a control 
group, dose of the treatment and small sample size should also be considered. Regardless 
of all these issues, to date this is the first study that attempted to understand if and how 
prebiotic supplementation might impact various aspects of autism.  
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CHAPTER 6 
 
6.1 General discussion  
In the last few years, prevalence rates of autism have increased, partly due to 
improvements in medical assessment and public awareness. Generally, it is considered as 
a childhood condition, but it does have influences throughout life (Lyall 2017). Studies 
that focus on more intervention to improve life course outcomes are required. The results 
presented in this thesis have highlighted the potential for B-GOS to be considered as a 
dietary approach in Autistic Spectrum Disorders (ASDs). 
Recently, B-GOS has been seen to have an effect on cognitive function, via the 
gut-brain axis, in mice and healthy human studies (Williams et al. 2016) (Savignac et al. 
2016) (Savignac et al. 2013) (Schmidt et al. 2015), supporting the hypothesis that 
modulation of the intestinal microbiota might help not only to improve GI symptoms 
associated with ASD, but potentially also impact on the central nervous system and 
typical autistic traits. Despite studies focusing on the impact of different food 
supplements in ASD individuals, there is not much information on the effect of 
prebiotics in autism. 
Initially, prebiotic activity of purified B-GOS (65%GOS content) was investigated 
in faecal samples of healthy volunteers, compared to commercial B-GOS (52%GOS 
content), using a batch culture fermentation system. FISH was used to assess faecal 
microbiota composition and metabolic activities were analysed by GC and 1H-NMR. 
65%B-GOS was shown to selectivity enhance beneficial bacteria, confirming that 
reduction in impurities, such as sugars, is important to study activity and functional 
properties of prebiotics in in vitro systems (Chapter 2). In addition, reducing the presence 
of sugars, such as lactose, in prebiotic products is an important goal to achieve for in vivo 
application; in particular considering lactose intolerance, previously correlated with 
gastrointestinal and behavioural problems in ASD (Lucarelli et al. 1995). 
Although batch cultures are considered acceptable models for preliminary studies 
of gut microbial fermentations, they have several limitations compared to in vivo 
conditions. These systems do not enable long fermentation periods since it is not possible 
to add extra nutrients or remove waste from the culture; therefore, bacteria will enter the 
stationary phase, terminating the fermentation. Furthermore, batch cultures only 
modelling one area of the colon.  
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It was therefore investigated whether purified B-GOS could modulate faecal 
microbiome and metabolome of autistic and non-autistic children using a more complex 
fermentation model. A three-stage continuous system was used in order to better simulate 
different conditions in the entire colon, through gradients of pH, substrate concentration 
and residence time (Chapter 3). B-GOS was able to significantly increase bifidobacteria 
in all vessels, representing different regions of the colon; and modulate other bacterial 
groups such as Clostridium spp., Roseburia spp., Bacteroides spp., Atopobium spp., 
Sutterella spp., F. prausnitzii and Veillonellaceae. Furthermore, in parallel with these 
population changes, functional alterations were also observed in both autistic and non-
autistic models with the organic acids acetate and butyrate being increased, as well as 
ethanol.  
Results from the in vitro work showed positive effects of B-GOS on faecal 
bacterial populations and metabolic activity; for this reason a parallel, double-blind, 
randomised human intervention study was designed in order to assess the effect of B-
GOS in vivo. Exclusion diets, such as gluten, casein and dairy free diets, are often 
suggested for ASD individuals in order to reduce GI problems, but to date there are no 
studies investigating the impact of these restriction diets on gut microbiota and 
metabolism in autism. Diet has a huge impact on the gut microbiota and it provides the 
main substrates for bacterial composition and metabolism (Steegenga 2016, Proctor 
2017). 
Therefore, in Chapter 4 the effect of restricted diets was investigated in order to 
understand whether they could influence GI issues and if they impact on the general 
physiology of ASD children. Results highlighted that children following exclusion diets 
had significant reductions in abdominal pain and bowel movement, but presence of amino 
acids in faecal samples, previously associated with nutrient absorption and gut 
inflammation (Marchesi et al. 2007), proved that restricted diets might not be able to 
impact gut health.  
In addition, significant differences in gut bacterial populations were reported at 
baseline. The gut microbiota of ASD children following special diets showed reduced 
bifidobacteria and Veillonellaceae, confirming previous studies in healthy volunteers 
(Bonder 2016) and reiterating the key research hypothesis that diet has a strong impact on 
the gut microbiota. 
This was an important outcome that underlines diet as a potential confounding 
factor that might indirectly “compete” with other intervention approaches, such as 
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prebiotics; concept that was also confirmed in Chapter 5. Results showed that 6 weeks B-
GOS administration had a significant impact on children whose diet was not restricted, 
increasing bifidobacteria, stimulating other bacterial groups such as Lachnospira family 
and modulating the metabolome. In this group, metabolic differences were detected in 
urine with increased DMA, DMG, creatine, creatinine, TMAO, citrate and alpha-
hydroxybutyrate after prebiotic intervention, compared to the control group, showing that 
B-GOS was driving changes in the general metabolism. In addition, B-GOS was also able 
to modulate faecal metabolome, after 6 weeks intervention, stimulating butyrate 
production and reducing amino acids in faecal samples of ASD children taking the 
prebiotic, supporting the assumption that B-GOS intervention might help to improve gut 
health modulating the gut microbiome and metabolome. The in vitro (Chapter 3) in in 
vivo (Chapter 5) sections of this thesis back up cellular studies where a positive impact of 
butyrate was reported on gut barrier function (Wang et al. 2012, Miao et al. 2016). 
Even though no big changes were detected in microbiome and metabolome in 
children following exclusion diets and taking B-GOS, significant improvements were 
seen in social behaviour, confirming the hypothesis that multiple therapies could have a 
stronger impact on psychological aspects. 
Overall, the results from this project showed that B-GOS could be considered as 
potentially useful approach for ASD individuals but improvements in the study protocol 
could help to obtain stronger impacts, perhaps in combination with other dietary 
interventions. 
6.2 Limitations 
Despite relevant findings, the study protocol has limitations that should be taken 
into consideration for future studies.  
The length of time was one example. Results supported the idea that a longer 
prebiotic intervention period is probably required in order to see a stronger effect, 
especially in individuals that are already following different therapeutic approaches, such 
as exclusion diets. 
Lack of normally developing children as control group was another limitation. 
This was from the viewpoint of not only understanding differences between the ASD and 
non-ASD groups at baseline, but also to identify potential pathways through which 
prebiotics could impact in these groups.  
Other limitations are the sample size and diagnosis confirmation through updated 
questionnaires.  
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6.3 Future work 
Future work should focus on the importance of study protocol in relation to the 
specific considerations of this subject population, with a high dropout rate 
(predominantly during the baseline period) and relatively high inter-individual 
variability.  
A parallel study is suitable for this subject population but additional logistics 
involved might have affected the completion rate, such as weekly sample collection and 
daily completion of detailed questionnaires and diaries across the whole study. Key 
questionnaires and diaries should be used in order to help a more direct interpretation of 
the impact of the prebiotic intervention on behaviour and sleep. In addition, identification 
of key time points for sample collection is also crucial in order to reduce stress in 
children that already suffer routine changes.  
In addition to the human intervention study, a deeper insight into the mechanistic 
effect of butyrate in ASD is worth investigating. Recent mouse studies suggested 
potential correlation between altered gut barrier functions in ASD and IBD and how 
probiotics may impact on systemic immunity (Hsiao et al. 2013) (Lim et al. 2017), 
therefore it would be interesting to better understand how prebiotic modulates gut health 
in ASD. An animal study, using an autistic mouse model, could be carried out in order to 
understand how alteration of the gut microbiota by B-GOS influences butyrate 
production; and to understand the mechanistic effect of this SCFA on gut inflammation, 
permeability and catecholamine pathway.  
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APPENDIX 4.1 
 
 
 
PLEASE READ THROUGH THESE PAGES BEFORE STARTING YOUR DIARY 
WE WOULD LIKE YOU TO KEEP THIS DIARY AND RECORD EVERYTHING THE CHILD 
EATS AND DRINKS OVER 4 DAYS (including one day during the weekend). Please include all 
food and drinks consumed at home and outside the home e.g. school, restaurants. It is very 
important that the child does not change what he/she normally eats and drinks just because you are 
keeping this record. Food diaries are very important part of the study because they help us to 
interpret the information we get from the child’s study visits. The more details you add to the 
descriptions the more accurate our analysis will be and the better the feedback we can give you.  
PLEASE KEEP THE CHILD’S USUAL FOOD HABITS 
Please return the completed diary at your next visit at the University 
We have given you 2 pages for each of the 4 days; please see below the empty sheets after 
some important guidelines and a useful example. Please write down the date, and indicate the 
next study visit. Use as many pages as you need for each day.  
 
 
 
 
 
 
 
  
                                                
School of Food Biosciences 
Food Microbial Sciences Unit 
 
VOLUNTEER 4 DAYS FOOD AND DRINK DIARY  
Issued on: 
   day      month             year 
  (in letters) 
Date of next visit: 
   day      month             year 
  (in letters) 
Bi2muno®   Screening No. 
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When should I complete the diary? 
• You can choose which days to complete, but ideally it must be 4 consecutive days (one of 
the days must be during the weekend, the other three must be during Monday-Friday). 
You will need to record on the same days of the week for each diet diary.  
• Do not record on the day before the intervention visits (i.e. the day when the child eats a 
standard evening meal and fast).  
• Try to write down what the child eats at the time the child eats it rather than from 
memory at a later date. Each diary day covers a 24 hours period, so please include any food 
or drinks that the child may have had during the night. Remember to include foods and 
drinks between meals (snacks or nibbles, no matter how small the amount) including water. 
 
How should I complete it?  
• A portion size guide has been included to help you (please write down which photo you 
are referring to by each portion of food) but you may also weigh child’s food portion if you 
prefer. 
• Take a notebook with you if you eat out and try to include as much detail as possible (you 
could use the labels on food to help you or any details provided in the menu).  
• Keep the labels of ready meals or unusual foods if they are clean and put in the back of 
the record book. 
• Be as specific as possible, for example, Kellogg’s cornflakes is better than cornflakes, 
Tesco’s value baked beans etc. Use brand names and include details about food types such 
as semi-skimmed or full-fat milk. 
• For items that are rehydrated, e.g. pasta, rice, noodles and couscous, it is important to 
state whether you are recording dry or cooked weight, if you do choose to weigh it out. The 
same applies to foods such as meat, and vegetables (i.e. raw or cooked weight). 
• Record any supplements taken during diary recording days. 
• For items that are eaten and drunk on a very regular basis such as tea, record as much detail 
as possible the first time i.e. amount of water, amount of milk, type of milk, the amount of 
sugar or sweetener, brand of tea bag and then record ‘as usual’ for these items in future. 
• For any meals cooked from a recipe (home made dishes), complete the recipe sheet 
provided (please also see the example below). State how much the child ate as a proportion, 
e.g. one quarter, or half and remember to add this item to the main food diary too, e.g. 
‘Recipe 1:’. 
• Record how you cooked the child’s food (boiled, steamed, fried, grilled, etc.). If you 
fried the food, don’t forget to record what you fried it in (olive oil; butter; lard, beef 
dripping, etc.). 
• Remember to include any fats/oils (butter, spread, oils etc.), condiments/sauces (ketchup, 
mayonnaise, gravy salad dressing etc) added to food.  
• If the child spills anything or doesn’t finish a plate of food, add this to the remarks section 
and include how much was spilt or left uneaten.  
• State whether the food was fresh, frozen, dried, canned, etc.  
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• For takeaway dishes from a restaurant or a friend’s house, please record as much detail 
about the ingredients (and the portion size) as you can e.g. vegetable curry containing 
chickpeas, aubergine, onion and tomato. Also record any other food or drink when the 
child eats away from home (e.g. egg and cress sandwich from Marks and Spencer). Brand 
name or name of the restaurant will be very helpful.  
• Break down foods like salads, sandwiches and pasta dishes into individual ingredients and 
add each on a separate line in the diary. Include the amount of each ingredient (weight or 
size).  
• For butter, please specify whether it is spreadable or block, salted or unsalted.  
• Please specify if the child is having a heaped or level tablespoon/teaspoon. 
• If the weight is on the packaging of the food item, record that, noting down the individual 
ingredients and amounts. Write the weight of the portion that the child actually ate on your 
food recording sheets.  
• An example of a record sheet is shown below. 
• A table with some useful words to describe items is also included. 
 
REMEMBER TO ALWAYS SPECIFY THE BRAND, INCLUDING SUPERMARKET BRANDS 
(E.G. SAINBURY’S BASIC OR SAINSBURY’S TASTE THE DIFFERENCE) 
 
The table below lists common foods and drinks and gives examples of the words that you can use to 
describe these items.  (Note: You may wish to use other relevant words that are not on this list) 
Food / Drink Examples of Descriptions 
Soft drinks No added sugar, diet, diluted / undiluted volume. If measured in a pub: pint / half-pint. 
Biscuits Varieties: shortbread / digestive / rich tea / custard cream / etc. With / without chocolate / cream-filled.  
Bread 
Wholemeal / brown / white / 50:50 / seeded / granary / fruit.  
Not pre-sliced, medium / thick slice, small loaf, toasted.  
Crusty / soft, baguette / French stick, bagel, pitta.  
Breakfast Cereals Include details about milk and sugar (type & quantity). Porridge: instant / homemade, quantity of raw oats, toppings. 
Butter Hard / spreadable, salted / unsalted  Check butter & not buttery spreads like I Can’t Believe It’s Not Butter 
Cakes & Buns Type: Victoria / chocolate / fruit / carrot, muffin / sponge / etc. Filling: frosting / royal icing / marzipan / buttercream / jam. 
Cheese 
Variety: Cheddar (extra mature / mature / mild) / parmesan / brie / etc. 
Hard / soft / cream / cottage / processed / triangle. 
Half-fat / light. 
Cream Double / clotted / single / sour / long-life / spray / crème fraiche. Half-fat / light. 
Tea 
Include details about milk and sugar / sweetener (type & quantity). 
Cup / mug. 
Fruit / herbal / green. 
Filter / instant / decaffeinated / cappuccino / espresso. 
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Eggs 
Medium / large. 
Scrambled (include details for milk & butter) / boiled / fried (include details for 
oil). 
Fish & Shellfish 
Type: salmon, cod, sardines, king prawns, etc. 
Fresh / canned (oil, brine or water) / frozen. 
Breadcrumbs / batter / cakes / fingers.  
Fruit, Vegetables & 
Fruit Juice 
Varieties: e.g. apples - brae burn, cox, gala, etc. 
State If peeled and add the weight of the peeled item, e.g. apples, potatoes, 
kiwi, banana. 
Canned (juice or syrup) / fresh / stewed / dried / frozen. 
Fruit juice: freshly squeezed / fresh (e.g. from chilled section) / from 
concentrate (e.g. long-life). 
Gravies & Sauces Instant / sachet / jar / fresh. With meat juices / milk (type & amount), thick / thin. 
Meat & Poultry 
Type: pork, chicken, beef, lamb, etc. 
With / without fat or skin, well-done / medium / rare. 
Cut: chop / steak / leg / drumstick / mince (lean) / sausages (pork or beef, thick 
or thin, low-fat) / bacon (streaky or back). 
Milk Skimmed / 1% fat / semi-skimmed / whole (or full-fat). UHT / soya / rice / flavoured / condensed. 
Nuts & Seeds Salted / unsalted / honey roasted / dry. Please state type of nuts & seeds, e.g. walnuts, peanuts, sesame seeds. 
Oils Varieties: olive oil / extra-virgin olive oil / vegetable oil / sunflower oil / rapeseed oil / sesame oil. 
Pasta, Rice, 
Noodles & 
Couscous 
Wholemeal / brown / white / pilaf / egg-fried. 
It is important to state whether weight is for the dried or cooked ingredient. 
Pies & Quiches 
Short crust / puff pastry / suet. 
Individual / family-sized / party-sized. 
Provide details on filling, e.g. steak and kidney. 
Pizza Size: 8” / 10” / 12”.  Takeaway / chilled / frozen.   Thick / thin / stuffed crust.  List toppings. 
Potatoes 
Chips: frozen / fresh, oven-baked / fried, thick-cut / crinkle cut / French fries. 
Mash: remember to include butter, milk, cheese, etc. 
Roast: remember to include type & amount of fat used.  
New & Baked: with / without skin, butter. 
Sandwiches Spread / no spread / mayonnaise. List all fillings.  
Spreads 
Varieties: buttery (e.g. I can’t believe it’s not butter, Clover), olive oil-spread 
(e.g. Bertolli), vegetable oil spread (e.g. Flora), sunflower spread, soya spread. 
Low fat / full-fat. 
Yoghurts Creamy / full-fat / low fat / fat-free. Natural / Greek / fruit / toffee / fromage frais 
 
 
 
 
 
 
 
 
 133 
Recipes 
What to do if you make a dish containing more than one portion, e.g. lasagne, casserole, meat pie, stir fry, 
(please see the attached example). 
In the Recipe sheet: 
o Date of when the meal was cooked and then eaten 
o Name of dish 
o Cooking method 
o Ingredients  
▪ List all ingredients – using brand names and amounts (if you are able to weigh things, 
that would be very useful) 
▪ It is important to include cooking oils/fats to your ingredients 
In the main diary (Food intake sheet): 
o Record the recipe name, e.g. Lasagne – recipe and served portion. 
 
Figure: Food portion sizes 
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Figure: Food portion sizes 
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Common used spoons, cups and glasses sizes 
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Food intake sheet - EXAMPLE Page 1 out of 2 
Volunteer Code:          Day: Mo    Tu    We    Th    Fr    Sa    Su   (please circle)       Date: __/__/20_ 
 
TIME 
 
BRAND NAME 
FOOD/DRINK 
(description; how cooked; where bought; 
brand and any comments) 
AMOUNT SERVED  LEFT OVER  
08.00 Alpen Original Muesli  Small bowl (A)  
 Tesco Milk (semi-skimmed) ~100mL  
 Tesco White toast (fresh baked large) bloomer 1 thick slice  
 Anchor Butter, spreadable, unsalted 1 teaspoon  
 Robertson’s Marmalade orange (thick cut) 1 tablespoon  
10.30  Coffee (from machine), milk (semi-skimmed), no sugar small cup (190ml) teaspoon 
13.00 Allison’s Bread: Wholemeal thick 2 slices   
 Cathedral city Extra mature cheddar cheese match box sized (B)   
 Utterly Butterly Spread, original 1 tablespoon  
  Orange large Peel & pips  
 Tesco Diet Coca Cola 1 can (330ml)  
15.30 PG Tips Tea - see recipe sheets medium mug (220ml)  
  Twix bar 1 regular   
18.00  Chilli con carne – see recipe, page 2 medium portion 300g (B - stew)  
  Cauliflower, boiled in salted water small portion (about 70g) (A – boiled potatoes)  
  Potatoes, roasted in vegetable oil small portion (about 70g) (A)  
 Ski Low fat Strawberry yoghurt  1 small yoghurt  
20.00 Blossom hill Red Wine – Italian Shiraz 1 small glass (175ml)  
22.15  Tap water Half pint  
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Recipe sheet – EXAMPLE Page 2 out of 2 
Please use this sheet for any recipes that you use whilst recording the child’s intake for us. In the “portion 
served” box tell us how much of the recipe the child actually ate. Use this sheet also to tell us how the child 
would usually take tea on a regular basis. 
INTERVENTION DIARY         
Volunteer Code:                      Day: Mo   Tu   We    Th    Fr    Sa    Su (please circle)          Date: __/__/20_ 
 
NAME of RECIPE AND 
INGREDIENTS 
(description, cooking method etc) 
BRAND NAME AMOUNT IN RECIPE (g) PROPORTION 
SERVED 
Tea (medium cup)   220mL 
water  200mL  
semi skimmed milk Tesco 30mL  
Tea bag  PG Tips strong infusion  
    
Chilli con carne   ¼ of the recipe 
Lean minced beef  Tesco 440 g  
1 large onion, diced   Large white onion  
6 cloves of garlic, finely chopped   6 fat cloves  
tin of tomato puree  Tesco small tin  
tin chopped tomatoes  Napoli Large can (440g)  
tin red kidney beans, drained and 
washed  
Tesco Large can (440g)  
Plain flour  ASDA’s smart price Heaped tablespoon  
beef stock  cube OXO  1 cube  
1 large red pepper, deseeded and 
chopped  
 1 large pepper  
MILD CHILLI POWDER – ASDA smart price 1 heaped teaspoon   
Salt and pepper to season   Pinch of  
Dried mixed herbs  Schwartz’s 1 level teaspoon  
A little vegetable oil -  
(enough to cover the bottom of 
the casserole dish) 
Waitrose 2 tablespoons  
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General questions about the child’s food/ drink in the last 4 days 
Special diet 
1. Does the child follow a special diet e.g. gluten free, casein free, vegetarian, cholesterol 
lowering, weight reducing? 
 
No 
 
Yes           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If yes, please give details? 
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INTERVENTION DIARY                                                                                       (Page 1 of the 1st day of completion) 
                                                                    FOOD INTAKE SHEET 
 
Volunteer Code: .............Day: Mo    Tu    We    Th    Fr    Sa    Su   (please circle) Date: __/__/20_   Visit.....  
 
TIME 
 
BRAND NAME 
FOOD/DRINK 
(description; how cooked; where bought; brand 
and any comments) 
AMOUNT SERVED  LEFT OVER  
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Recipe Sheet                                                                                             (Page 2 of the 1st day of completion) 
Use this page only for recipes and then state the amount the child consumed on the previous page 
       
Volunteer Code:                      Day: Mo   Tu   We    Th    Fr    Sa    Su (please circle)          Date: __/__/1_ 
 
NAME of RECIPE AND INGREDIENTS 
(description, brand etc) 
BRAND NAME AMOUNT IN 
RECIPE (g) 
PORTION SERVED 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
GI symptoms diary Card  141 
Issued on: 
   Randomisation No. 
   day      month             year 
  (in letters) 
 
 
 
 
 
 
APPENDIX 4.2 
 
 
GI SYMPTOMS DIARY CARD 
Bi2muno® 
                                                
School of Food Biosciences 
Food Microbial Sciences Unit 
 
GI symptoms diary Card  142 
The Bristol Stool Form Scale: to be used for the evaluation 
of patient stools! 
 
 
 
7Watery, no solid pieces. Result of very
fast transit
6Fluffy pieces with ragged edges, a
mushy stool
5Soft blobs with clear cut edges
(easy to pass)
4Like a sausage or snake-smooth and
soft
3Like a sausage but with cracks on its
surface
2Sausage-shaped but lumpy
1Separate hard lumps, like nuts (hard to
pass). Result of slow transit
TypeAppearanceStool form
GI symptoms diary Card  143 
 
                                                                                                                                                             Week … 
                                        
                                                                                 Date of first day of the week: 
 
Please complete one row each day.  
Day No. of bowel 
movements 
Stool form 
(average daily score) 
Abdominal pain Bloating Flatulence Product 
intake 
 
0=None 
1=One 
2=Two 
3=Three 
>3=More than 
three 
 
1=Separate hard lumps, like nuts 
2=Sausage-shaped but lumpy 
3=Like a sausage or snake but with cracks on its 
surface 
4=Like a sausage or snake, smooth and soft 
5=Soft blobs with clear cut edges 
6=Fluffy pieces with ragged edges, a mushy stool 
7=Watery, no solid pieces 
 
0=None 
1=Present but well tolerated 
2=Present and interfering with but not preventing normal daily activities 
(like work or sleep) 
3=Preventing normal daily activities 
 
 
E
xa
m
pl
e       
 
1 
 
      
 
2 
 
      
 
3 
 
      
 
4 
 
      
 
5 
 
      
 
6 
 
      
 
7 
 
      
   day      month             year 
  Randomisation No. 
 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3 
 
0 1 2 3 
 0 1 2 3  x x x x x 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3 
 0 1 2 3  
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3 
 0 1 2 3  
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3  0 1 2 3  
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3  0 1 2 3  
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3  
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3  
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
5 6 7 0 1 2 3  0 1 2 3  
0 1 2 3 
 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
x 
Bi2muno® 
GI symptoms diary Card  144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the end of Week … please answer: 
 
Over the past week, do you consider that your child has felt better than in the previous week?                                                   
 yes  no 
 
 
Over the past week, do you consider that your child has slept better than in the previous week?                                                     
 yes  no 
   
 
Over the past week, do you consider that your child was less stressed than in the previous week?                                           
 yes  no 
 
 
Over the past week, do you consider that your child was more alert than in the previous week?                                                 
 yes  no 
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APPENDIX 4.3 
 
Sample submission form 
Screening No…….……………………………  
Date………….………………………………… 
All participants  
It is important that this section is filled out for all participants of the study when 
samples are submitted. The aims of this section are to understand the symptoms, 
health, treatments and diet of the participant at the time at which the samples were 
taken. 
1. Symptoms, health and treatments 
a) Please tick any of the following symptoms or state any other bowel symptoms that 
have occurred in the week prior to sample collection. 
 
 
Bi2muno® 
 
 
 
 
 
 
 
 
Week … 
Please complete the row if there are any changes in GI 
symptoms 
 
Day No. of bowel 
movements 
Stool 
consistency 
Abdominal 
pain 
Bloating Flatulence Product 
intake 
. 
  
 
1=Hard 
2=Formed 
3=Loose 
4=Watery 
 
 
0=None 
1=Present but well tolerated 
2=Present and interfering with but not preventing 
normal daily activities (like work or sleep) 
3=Preventing normal daily activities 
 
 
 
E
xa
m
pl
e 
      
 
1 
 
     
 
 
2 
 
     
 
 
3 
 
     
 
 
 
4 
 
     
 
5 
 
 
     
 
6 
 
 
     
 
7 
 
 
     
 
Randomisation No. 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 >3 1 2 3 4 
 
0 1 2 3 
 
0 1 2 3 
 
0 1 2 3 
 x x x x x 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
yes no 
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2. DIET 
 
1. Has the child changed the diet during sample collection in the week …?  
 
 
No                 Yes                  
 
If yes, please give more details below 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
DAY 
 
DIET KIND OF 
SAMPLE 
COLLECTED 
 
REASON FOR THE CHANGE 
Urine Saliva Stool 
 
1 
 
 
   
 
 
2 
 
 
   
 
 
3 
 
     
 
4 
 
     
 
5 
 
     
 
6 
 
     
 
7 
 
     
  
 147 
 
3. Behaviour  
 
a) If bowel symptoms (section 1) and/or diet issues (section 2) were evident during 
the week … when the samples were taken, were these associated with worsened 
behaviour that is associated with ASD: 
 
 bowel symptoms?  Yes   ☐ No   ☐ 
 
 diet issues?   Yes   ☐ No   ☐ 
 
 
b) If yes to either or both, please provide details: 
 
When did it happen?  
Please specify the which day of the week and which sample you were 
collecting 
 
…………………………………………………………………………………. 
 
How long ago did this occur? 
 
 ………………………………………………………………………………….. 
  
 How long did this last? 
 
 …………………………………………………………….................................. 
  
 What aspects of behaviour changed? 
 
 ………………………………………………………………………………….. 
 
 ………………………………………………………………………………….. 
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 4. Concomitant medications 
 
 
 
 
 
Is the child taking any concomitant medication, 
 including dietary supplement?         
 
If YES, please fill in the concomitant medication section below 
Concomitant medication log  
Enter all medications taken during the week ... 
MEDICATION 
NAME 
TYPE 
(capsule, tablet, 
suppository, enema, 
syrup, etc.) 
DOSAGE FREQUENCY 
(once only, once a day, 
twice a day, once 
weekly, etc.) 
START DATE 
(day, month, year) 
END DATE 
(day, month, year) 
REASON FOR 
MEDICATION 
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Thank you very much for completing the sample submission form as part of the study. 
If you have any questions or comments regarding the study, please do not hesitate to 
contact the study investigators.  
 
Thank you very much for your time and effort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If#so,#would#you#and#your#child#be#willing#to#
par7cipate#in#our#prebio7c#feeding#study?#
For$further$informa.on$please$contact$
$Roberta#Grimaldi#
on$r.grimaldi@pgr.reading.ac.uk$or$
07538209801$
$
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APPENDIX 5.2 
 
Volunteer Information Leaflet  
 
 
Title: Effect of a prebiotic (B-GOS) supplementation on microbiota and 
gastrointestinal (GI) symptoms in children with autism spectrum disorders 
(ASD) 
 
My name is Roberta Grimaldi, I am a research student working at the University of Reading 
studying the role of the gut bacteria in children with autism spectrum disorders (ASD), 
especially in relation to gut symptoms. My supervisors are Prof. Glenn R Gibson and Dr. 
Adele Costabile, who specialise in gut microbiology.  
 
You and your child have been invited to take part in a volunteer research study at the 
University of Reading. 
 
Before you decide, it is important that you understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully and discuss 
it with others if you wish (friends, relatives or your GP, for example).  Ask if there is anything 
that is not clear or if you would like more information.  Take time to decide whether or not 
you wish to take part.  Thank you for reading this. 
 
What is the purpose of the study? 
 
 
Please read the following inclusion/exclusion criteria to identify if your child is able to 
participate in the trial. 
 
Exclusion Criteria - If the following applies to him/her, he/she will not be able to 
participate in the trial: 
 
                                               
School of Chemistry, Food 
Biosciences and Pharmacy 
Food Microbial Sciences Unit 
 
The aim of this study is to investigate the effect of a dietary prebiotic food supplement (B-
GOS, Bimuno - Clasado UK) on composition of the gut bacteria and their products in the 
gut of children with autism. We aim to recruit 42 children with autism into this study.  
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• Use of antibiotics, prebiotics or probiotics (in food products or as supplements) in the 
last 4 weeks prior to, or during the study period. 
• Regular use of certain medications (see section 3.4). 
• Children who have received bowel preparation for investigative procedures in the 4 
weeks prior to the study. 
• Children who have undergone surgical resection of any part of the bowel. 
 
Inclusion Criteria – If the following applies to your child, he/she is suitable for the trial: 
 
• Children aged 5-10 years with formal ASD diagnosis.  
• Children’s parent or guardian has given written informed consent to participate and is 
willing to participate in the entire study. 
 
Why is this study being carried out? 
 
It has been known for a long time that bacteria in the lower gut (bowel) can influence health. 
Some bad bacteria produce unhealthy substances that harm the gut. However, not all bacteria 
are harmful and most in the gut are actually positive. These produce beneficial substances 
that the human body can use.  
 
In individuals with ASD, parents and health professionals have commonly recognised a 
higher incidence of dietary and/or bowel problems. It has been postulated that imbalances in 
the gut bacteria and/or metabolites present in the gut may be a contributing factor to these 
symptoms, with potentially bad (toxin-producing) bacteria colonising the gut. Studies to 
investigate such possibilities have led to inconsistent results and no studies have yet linked 
imbalances in the gut microbiota with imbalances of gut microbiota products.  
 
Certain carbohydrates (so-called ‘prebiotics’) are not digested by the human gut and they 
provide food for beneficial bacteria and thus they improve the composition by preventing the 
growth of bad bacteria. Individuals could therefore benefit from these safe and effective 
dietary interventions to maintain the healthy gut bacteria and overall health. 
 
This study is being carried out to establish the effect of one such prebiotic, called 
galactooligosaccharide (B-GOS) on the relative balance of gut bacteria and metabolites.  
 
What will I be asked to do? 
 
As the parent or guardian, we would like for you to discuss with your child (where 
appropriate), the potential participant, the purpose of the research study and what would be 
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involved for them. Where appropriate, it is important that you decide together whether you 
would like to participate.  
 
The study will last 10 weeks and it will include 2 weeks baseline (before the treatment), 6 
weeks treatment and 2 weeks fellow up. 
 
Screening: If you decide to participate, we will ask you to give a brief medical history of 
your child, to fill in a 4-days food diary and to provide few personal details in order to 
determine his/her inclusion in this study. This is to provide some background information 
such as age and gender and will also provide some information on the recent diet and gut 
health of the participant to the study investigators.  
Samples: If your child meets the inclusion criteria, you will be asked to provide your child’s 
following samples: 20g of stool sample (weekly), 10ml of urine sample and 2ml of saliva 
sample (daily – or as often as possible). These will be used to screen some parameters that 
we are interested in (composition of gut bacteria and metabolites).  
 
Treatment: We would like to form a group of volunteers that meet all the inclusion criteria 
that will then be randomly assigned a volunteer number and placed in one of two groups 
(one of which will start with B-GOS and the other Placebo). A placebo is a dummy 
treatment, which looks like the real thing but is not. It contains no active ingredient. To 
minimise any outside influence, neither you nor the investigator will know whether you are 
taking GOS or Placebo. Details about each stage of the research are provided in a table at the 
end of this document. 
These products will be supplied to you in sachets of powder (1.8g - app. 1 teaspoon) and you 
will be asked to reconstitute them with water or other drinks or sprinkle them over your 
child’s bowl of cereal. You will be provided with enough sachets to last until your next visit. 
You will be asked to give to your child one sachet each day. It may be easier to remember if 
you do that at the same time each day, e.g. in the morning, with their normal breakfast.  
 
Gut symptoms and concomitant medication: During the 10 weeks you will be required to 
fill in a diary recording the number of faecal samples and gut symptoms your child 
experiences each day. The diary system works using a scale of severity requiring a tick in the 
appropriate box or a yes/no answer. In addition, any medication your child is taking or has 
during the study will also have to be recorded, including the type and dosage of the 
medication and the start and end date. 
 
Behavioural assessment: Before and after the treatment period you will be asked to 
complete four mood and behaviour questionnaires (AQ, ATEC, EQ-SQ and SCAS-P) and 5-
days sleep diary. They will give us additional information about the effect of the treatment 
related to social and communication difficulties. 
 
Your child and/or you will either be asked to visit the Department of Food and Nutritional 
Sciences, University of Reading or the investigator will visit your home on 5 different 
occasions over the course of the 10 weeks study. At each visit, you will be asked to provide 
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your child’s stool, saliva and urine sample. Specific containers and all relevant instructions 
will be provided for sample collection. Additionally, you will also be asked to fill in some 
questionnaires related to your child’s sleep, mood and behaviour.  
 
Are there any risks? 
 
B-GOS has been widely used in a number of different feeding trials with various groups of 
volunteers and was well tolerated by all. Participation in this study does not pose any 
significant risk.  
 
However, some people who have taken other similar prebiotics have reported an increase in 
gas production, with slight bloating feelings, some flatulence and mild diarrhoea. Cases of 
this are very rare. Occasionally, people have experienced gut cramping. 
 
 
Confidentiality 
 
Children’s records will be kept strictly confidential. Children’s study results will be recorded 
in a case record form for the study investigator but their name will not appear in this or on 
any report/publication of the results. Children’s records will be kept by the investigators for 
five years. However, these records will only contain an identification code while information 
matching volunteer names with identification codes will be kept separately from these files 
by a departmental secretary. The only time data will be matched with volunteer names is for 
those volunteers that request to have their personal results discussed with them.  
 
General  
 
• This study has been subject to ethical review by the Southampton Research Ethics 
Committee and has been given a favourable ethical opinion for conduct. 
• The travel expenses (with maximum £15 per visit) to the University will be covered 
upon receipt of train or bus tickets or at the rate of £0.45 per mile.  
• The participation in this study is purely voluntary. Your children may leave the study 
at any time without giving a reason. You are free to ask the investigator for more 
information about this study before you give consent for your child to take part or 
once you have agreed to take part in the study. 
• The general results from the study and those relating to children’s individual samples 
may be obtained from Miss Roberta Grimaldi once the study is finished and all 
statistical analysis has been completed. No information relating to any other 
volunteer will be given. The information collected during this study and the overall 
results are still only experimental and although they will give us new information 
about how the bacteria in the human gut work and what they do, the results can not 
be used to tell the difference between health and ill-health. 
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What happens next? 
 
If you would like to take part in this study, or have any questions then please contact the 
principal investigator Roberta Grimaldi, using the details below. Alternatively, if you are 
satisfied and happy to participate, then sign the consent forms and fill pre-trial 
questionnaires and send back to Roberta using the stamped/addressed envelope. Following 
Roberta will contact you and make arrangement for a visit. 
 
 
 
 
 
 
 
Investigator 
Miss Roberta Grimaldi  
  
Department of Food and Nutritional 
Sciences 
Telephone: +44 7538209801 
University of Reading, P.O. Box 226,  
Reading RG6 6AP 
E-mail: r.grimaldi@pgr.reading.ac.uk  
  
 
 
Sponsor 
Clasado Biosciences Ltd.  
2-6 Church Street,  
St Helier,  
Jersey,  
JE2 3NN 
Telephone: 01534 715 100  
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Trial Day Stage of the study Procedures 
 
-2 weeks 
 
Screening period 
Contact the Department of Food and Nutritional Sciences or arrange for an induction session 
during which you will be asked questions to determine inclusion criteria and you will get the 
chance to find out details on the study from the investigator.  
Once you consent to your child’s participation in the study, you will be asked to fill in 4-day 
food diary during this period.  
 
2weeks 
 
Run-in Period 
 
• You will be asked to fill in daily GI symptom diary, 5-day sleep diary and 4 
questionnaires related to mood and behaviour of your child.  
• You will also be asked to collect daily (or as often as possible) urine (10ml) and saliva 
(2ml) samples and weekly stool samples (20g).  You will be provided with instructions 
and home kits. You will have a choice of either storing samples and bringing them to the 
University at arranged visits or telephoning the study investigator and requesting 
collection of the samples.  
• Weekly telephone calls from the member of the research team will allow you to clarify 
any questions or concerns and for the research team to assess the compliance with sample 
collection, storage (where applicable), diary and questionnaires. 
 
   
6 weeks 
 
 
Intervention study 
 
• The child will be requested to take 1 sachet of 1.8g prebiotic or placebo food supplement 
daily. Please reconstitute it with water and make your child take the sachet at the same 
time each day.  
• You will be asked to fill in daily GI symptom diary  
• You will be asked to collect daily (or as often as possible) urine (10ml) and saliva (2ml) 
samples and weekly stool samples (20g).  You will be provided with instructions and 
home kits. You will have a choice of either storing samples and bringing them to the 
University at arranged visits or telephoning the study investigator and requesting 
collection of the samples.  
• Weekly telephone calls from the member of the research team will allow you to clarify 
any questions or concerns and for the research team to assess the compliance with sample 
collection, storage (where applicable), diary and questionnaires.  
• At the end of the treatment period, you will be asked to fill in 5-day sleep diary and 4 
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questionnaires related to your child’ behaviour and mood. 
 
 
2weeks  
 
 
Follow-up Period 
• You will be asked to fill in daily GI symptom diary  
• You will be asked to collect daily (or as often as possible) urine (10ml) and saliva (2ml) 
samples and weekly stool samples (20g).  You will be provided with instructions and 
home kits. You will have a choice of either storing samples and bringing them to the 
University at arranged visits or telephoning the study investigator and requesting 
collection of the samples.  
• Weekly telephone calls from the member of the research team will allow you to clarify 
any questions or concerns and for the research team to assess the compliance with sample 
collection, storage (where applicable), diary and questionnaires.  
• At the end of the follow-up period, you will be asked to fill in 4 questionnaires related to 
your child’s behaviour and mood. 
Trial Day Stage of the study Procedures 
Visit 1  2 weeks before the 
start of the 
treatment period 
At visit 1 (this could either be investigator visiting your home or you visiting the University 
of Reading), you will be provided with: 
• Home kits for collection of stool, urine and saliva samples and given instructions on 
how to use these kits and store samples.  
• You will also be provided with GI symptom and sleep diaries.  
• The regularity of sample collection, storage or any other concerns that you may have 
with trial procedures will be discussed. 
• Height and weight measurements will be taken either by the investigator or by you. 
• You will be asked to provide your child’s stool sample on this visit from either that 
day or any 3 days after visit 1.  
• Visit will not take longer than an hour. 
 
Visit 2 
 
Start of the 
intervention period 
(2weeks) 
At visit 2 (this could either be investigator visiting your home or you visiting the University 
of Reading) all remaining samples and diaries from the run-in period will be collected. You 
will be asked: 
• To fill in 4 questionnaires related to your child’s behaviour and mood during this 
visit.  
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• You will be provided with correct number of sachets for the first 3 weeks of 
treatment, home kits for collection of stool, urine and saliva samples, GI symptom 
diary and given all relevant instructions. 
• Weight of the child will be recorded either by the investigator or by you.  
• Concomitant medication will be checked and any changes to child’s diet, GI 
symptoms or behaviour will be discussed with you. Any other concerns that you may 
have in relation to the study procedures will also be discussed (it will take about 30 
minutes). 
• You will also be asked to provide your child’s stool sample on this visit from either 
that day or any 3 days prior or after visit 2.  
• Weekly telephone calls from the member of the research team will be maintained 
during this period too.  
• Visit will take about 1 and half hours. 
 
Visit 3  
 
3 weeks after the 
start of the 
intervention period 
At visit 3 (this could either be investigator visiting your home or you visiting the University 
of Reading) all remaining samples and diary from the first 3 weeks of the intervention 
period will be collected. You will be provided with: 
• Correct number of sachets for the remaining 3 weeks of treatment, home kits for 
collection of stool, urine and saliva samples, GI symptom and sleep diaries and given 
all relevant instructions. 
• Concomitant medication will be checked and any changes to the child’s diet, GI 
symptoms or behaviour will be discussed with you. Any other concerns that you may 
have in relation to the study procedures will also be discussed (it will take about 30 
minutes). 
• You will also be asked to provide your child’s stool sample on this visit from either 
that day or any 3 days prior or after visit 3.  
• Weekly telephone calls from the member of the research team will be maintained 
during this period too.  
• Visit will take about 30-45 minutes. 
  At visit 4 (this could either be investigator visiting your home or you visiting the University 
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Visit 4 End of the 
intervention period 
(3weeks) 
of Reading) all remaining samples and diaries from the intervention period will be collected. 
• You will be asked to fill in 4 questionnaires related to your child’s mood and 
behaviour during this visit.  
• You will be provided with home kits for collection of stool, urine and saliva samples, 
GI symptom diary and given all relevant instructions (it will take about 30 minutes). 
• Weight of your child will be recorded either by the investigator or by you.  
• Concomitant medication will be checked and any changes to your child’s diet, GI 
symptoms or behaviour will be discussed with you. Any other concerns that you may 
have in relation to the study procedures will also be discussed (it will take about 30 
minutes). 
• You will also be asked to provide your child’s stool sample on this visit from either 
that day or any 3 days prior or after visit 4.  
• Weekly telephone calls from the member of the research team will be maintained 
during this period too.  
• Visit will take about 1 and half hours. 
 
Visit 5 
 
End of the trial 
(2weeks) 
At visit 5 (this could either be investigator visiting your home or you visiting the University 
of Reading) all remaining samples and diary from the follow-up period will be collected.  
• You will be asked to fill in 4 questionnaires related to your child’s behaviour and mod 
during this visit.  
• Weight of your child will be recorded either by the investigator or by you.  
• Concomitant medication will be checked and any changes to the child’s diet, GI 
symptoms or behaviour will be discussed with you. 
• You will be asked to provide your child’s stool sample on this visit from either that 
day or any 3 days prior or after visit 5.  
• Visit will take about 1 and half hours. 
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APPENDIX 5.3 
 
Volunteer Information Leaflet (Primary aged School children) 
 
 
Would you like to help me answer  
a tricky question? 
 
                 
 
Please read the sheet carefully and talk to your mum and dad to  
see if you can take part. If you have any questions please ask me. 
 
 
 
                                               
School of Chemistry, Food 
Biosciences and Pharmacy 
Food Microbial Sciences Unit 
 
Hello my name is Roberta and I need your help!  
I would like to understand is whether  
eating a sugar can help  
to stop your tummy problems. 
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These ‘unfriendly’ bacteria may cause the tummy problems.  
Eating this sugar could help to stop your tummy pain increasing  
the ‘friendly’ bacteria and reducing the ‘unfriendly’ bacteria. 
 
                                
 
What will I have to do? 
 
You will need to do: 
                                                                     
 
 
 
 
 
 
What is the research about? 
 
Some children have tummy problems, 
for example pain and toilet problems. 
Lots and lots of bacteria live in the tummy. 
Some of them are ‘friendly’ and  
some are ‘unfriendly’. 
 
 
1) Take a prebiotic powder every day for 6 
weeks with your Breakfast 
(It does not have any smell or taste) 
2) Give Roberta 10 poo samples, 
so she can analyse your tummy bacteria 
and urine and saliva samples as often  
as possible. Your mum and dad will help you 
in using the kit to collect the sample. 
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Talk to your mum and dad, they will help you decide.  
You can also talk to me and ask me as many questions as you want.  
 
 
 
Miss Roberta Grimaldi 
 
  
Department of Food and 
Nutritional Sciences 
Telephone: +44 7538209801 
University of Reading, P.O. Box 
226,  
Reading RG6 6AP 
E-mail: r.grimaldi@pgr.reading.ac.uk  
 
3) Help your mum in completing 
diaries after the sample collection  
and how your tummy feels 
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School of Chemistry, Food and Pharmacy               
University of Reading 
Whiteknights 
PO Box 266, Reading RG6 6AP, UK 
 
 
APPENDIX 5.4 
 
Consent Form – Parent/Guardian consent 
 
 
If the individual who will be providing the samples for the study are under 16 years of 
age and do not wish to consent for themselves or if they are unable to understand fully 
the study outlined in the information sheet, the parent/guardian is asked to provide 
consent for their children in the study. 
 
 
1. I confirm that I am the parent/guardian of……………………….. (Please 
initial) 
 
 
 
2. I have read and had explained to me by ………………….. the accompanying 
information sheet relating to the project entitled “Effect of a prebiotic (B-GOS) 
supplementation on microbiota and gastrointestinal (GI) symptoms in children 
with autism spectrum disorders (ASD)”. (Please initial) 
 
 
3. As the parent/guardian of the child involved in the study, I have had explained 
to me the purposes of the project and what will be required of my child and 
any questions I had, have been answered to my satisfaction. I agree to the 
arrangements described in the information sheet in so far as they relate to my 
participation. (Please initial) 
 
 
4. As the parent/guardian of the child involved in the study, I understand that 
participation is entirely voluntary and that my child has the right to withdraw 
from the study at any time without giving reason, and that this will be without 
detriment to any care or services they may be receiving or may receive in the 
future. (Please initial) 
 
 
5. As the parent/guardian of the child involved in the study, I authorise the 
Investigator to consult the General Practitioner of my child and I authorise 
their General Practitioner to disclose any information which may be relevant to 
my proposed participation in the project. (Please initial) 
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6. This project has been subjected to ethical review, according to the procedures 
specified by the University Research Ethics Committee, and has been given a 
favourable ethical opinion for conduct. (Please initial) 
 
 
7. As the parent/guardian of the child involved in the study, I have received a 
copy of this consent form and of the accompanying information sheet.  
(Please initial) 
 
 
8. As the parent/guardian of the child involved in the study, I consent to my child 
providing urine and saliva sample daily and one faecal sample weekly. (Please 
initial) 
 
 
9. As the parent/guardian of the child involved in the study, I wish to receive a 
summary of the results once the study is complete and analysed statistically. 
(Please initial as appropriate) 
 
 
            Yes                           No 
 
 
 
10. As the parent/guardian of the child involved in the study, I have had explained 
to me that my child and my contact details and personal information are kept 
strictly confidential and only the investigator can have access to them. My 
child and me will be matched to an identification code and my child and my 
personal details will be kept separately from this file. (Please initial)  
 
                             
 
 
11. As the parent/guardian of the child involved in the study, I have had 
explained to me that consent for my contact details and personal information to 
be added to the Nutrition Unit Volunteer Database is entirely voluntary. 
Accordingly I consent as indicated below: 
 
I consent to my contact details being stored on the Nutrition Unit Volunteer 
Database. (Please initial as appropriate) 
 
Yes                            No  
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I consent to the information that I provided in the pre-study questionnaire 
being stored on the Nutrition Unit Volunteer Database. (Please initial as 
appropriate) 
 
Yes                            No  
 
 
 
 
Name  ………………………………… 
 
Signed  ………………………………… 
 
Date             ………………………………… 
 
 
I consent to the GP of my child being informed of their participation in the study 
and of my screening results and give his/her contact details below. 
 
 
Name  ………………………………… 
 
Address    ……………………………………………...………………………… 
 
………………………………………………………………………….………… 
 
Telephone …………………………………. 
 
 
 
Witnessed by 
 
Name  ………………………………………. 
 
Signed  ………………………………………. 
 
Date  …………………………………….…
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Assent Form – Children 
 
WOULD YOU LIKE TO HELP ROBERTA? 
 
 
 
 
 
1. My name is……………………… 
(Please colour the box) 
 
 
 
2. I talked to my mum and dad about Roberta’s study 
(Please colour the box) 
 
 
 
 
3. I am happy to help Roberta in her study                                       
(Please colour the box) 
 
 
 
 
 
 
SIGNATURE ……………………………….. 
 
DATE……………………. 
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Head of Department 
Professor Bob Rastall 
Department of Food and Nutritional Sciences 
Food Microbial Sciences Unit 
 
Whiteknights 
Reading RG6 6AP 
 
Phone +44 7538209801 
Email r.grimaldi@pgr.reading.ac.uk 
Web www.food.rdg.ac.uk/ 
 
  - 
APPENDIX 5.6 
 
Dear Dr. 
Your patient [name] has been enrolled into a trial conducted by the University of 
Reading, on behalf of Clasado Biosciences Ltd., St Helier, Jersey. 
Details of the trial procedure can be obtained from the Department of Food and 
Nutritional Sciences at the University of Reading, at the address given above. Briefly, 
your patient was asked to take a new food supplement, Bi2muno®, which is a prebiotic. 
 
GI bacteria secrete detrimental as well as beneficial compounds and overgrowth of 
certain species or imbalances (i.e. increases in less beneficial and decreases in beneficial 
bacteria) in the gut microbiota have been associated with ASD. Certain carbohydrates 
(so-called ‘prebiotics’) are not digested by the human gut and they provide food for 
beneficial bacteria and thus they improve the composition by preventing the growth of 
bad bacteria. Individuals could therefore benefit from these safe and effective dietary 
interventions. 
 
We have provided the parents of your patient with an information leaflet, giving details 
about Bi2muno® and the trial procedures. The parents of your patient were asked to sign 
an informed consent and the patient has undergone screening before his/her inclusion 
into the study. Your patient is now receiving daily dose of either Bi2muno® or placebo 
and will continue to receive the treatment, in this parallel study, for the duration of 10 
weeks. No other change to diet or lifestyle is required. At the end of the study, it will be 
possible for the parents of your patient to find out when the patient was receiving active 
or placebo product.  
 
Should you require any further information, please do not hesitate to contact me. 
 
Yours sincerely, 
 
 
 
Roberta Grimaldi 
 date 
 
Randomisation number: Date: 
APPENDIX 5.7  ATEC Questionnaire 
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APPENDIX 5.8 
 
 
 
You can choose which days to complete, but it must be 5 consecutive days.  
 
Please return the completed diary at your next visit at the University 
We have given you 1 page for each of the 5 days; please see below the empty sheets. 
Please write down the date, and indicate the next study visit.                
  
                                                School of Food Biosciences 
Food Microbial Sciences Unit  
Bi2muno®   Screening No. 
VOLUNTEER 5 DAYS SLEEP DIARY  
Issued on: 
   day      month             year 
  (in letters) 
Date of next visit: 
   day      month             year 
  (in letters) 
170  
 
Starting Day: Mo    Tu    We    Th    Fr    Sa    Su   (please circle) Date: __/__/20__ 
 
DAY 1 
 
Morning questions 
 
Answer the following questions about your child’s sleep last night 
 
1.     What time did your child go to bed last night? ___________________ 
2.     What time did your child fall asleep last night? ___________________ 
3.     Did your child wake up during the night last night?  
 
YES NO (circle one) 
 
a)    If YES, how many times ____________________ 
b)   If YES, how much time were they awake__________________ 
 
4.     Last night, did your child take anything to help them sleep? 
 
YES NO (circle one) 
 
a)    If YES, what did they take ____________________ 
b)   If YES, what time did they take it__________________ 
  
5.     What time did your child get up for the day today? __________________ 
6.     About how many hours did your child sleep last night? __________________ 
  
  
Bedtime question: 
 
Answer this question about your child’s day before they go to bed 
 
7.     Did your child take any naps during the day or evening today?  
 
YES NO (circle one) 
 
a)    If YES, how much time total did your child sleep during the day and evening today 
____________________ 
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APPENDIX 5.9 
 
Instructions to collect stool and urine samples 
 
 
Stool and urine samples are biologically active and hence, safe handling is essential. 
Please read these instructions before you collect a stool or urine sample from your child. 
These guidelines are to aid you in sample collection as easily and safely as possible 
using the sample collection kit provided for collecting stool and urine samples.  
 
The sample collection kit comprises of the following: 
 
• two stool collection pots 
• a paper loop to fit over the toilet seat 
• a urine collection container (specimen jar) 
• two polythene bags to insert the sampling tubes for freezing (one for stools and 
one for urine) 
• 2 larger protective plastic tubes 
 
 
Step-by-step instructions for stool sample collection (Pictures below)  
 
 
 
1. Open the envelope and insert the paper loop over the toilet seat (step 1-2).  
2. Ask your child to provide a stool sample onto the paper loop. 
3. Use the spatula inside the inner (smaller) sampling pot to scoop a portion 
(approximately four peas worth) of stool sample from the middle of the stool 
sample. Please try to minimise the urine getting into the stool sampling tube (step 
5). 
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 Stool sample pot 
 
4. Insert the spatula with the stool sample into the inner (smaller) sampling pot and 
tightly seal. 
5. Repeat this with the second tube, so that we have a replicate sample. 
6. Place both tubes with the samples into the larger protective plastic tubes provided 
and ensure that the protective tube is tightly sealed. 
7. Place the protective tubes into the polythene bag provided and seal the bag, 
folding twice around the strap fixed and then folding the side straps into the bag.  
8. Freeze the samples immediately. It is essential that this is performed within ten 
minutes of the sample being collected. 
9. Dispose of the rest of the sample and the paper loop down the toilet. 
10. Please contact the study investigators as soon as possible once the sample has 
been collected from the child and stored in the freezer and they will arrange for 
the sample to be collected within two weeks. 
 
 
Step-by-step instructions for urine sample collection  
 
1. Ask your child the parents to provide a urine sample from their child into the 
urine collection container (specimen jar). 
 
  
 
2. Wash your hands 
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3. Peel open the pack 
4. A) help the child to pass a SMALL QUANTITY of urine into the toilet and stop 
B) help the child to pass a FURTHER QUANTITY of urine directly into the 
container and stop 
C) Finish helping the child to pass urine directly into the toilet 
            D) detach the funnel from the container 
            E) discard the funnel 
            F) FASTEN THE LID SECURELY 
5. Wash your hands and write your child’s ID number on the label provided. 
6. Place the protective tubes into the polythene bag provided and seal the bag, 
folding   twice around the strap fixed and then folding the side straps into the bag.  
7. Freeze the samples immediately. It is essential that this is performed within ten 
minutes of the sample being collected. 
8. Please contact the study investigators as soon as possible once the sample has 
been collected and stored in the freezer and they will arrange for the sample to be 
collected within two weeks. 
 
 
 
If you have any questions regarding these guide lines please do not hesitate to contact 
the study investigators.  
 
